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Abstract 
Use of Topical (Intra-articular) Tranexamic Acid to Minimise 
Blood Loss and Transfusion in Total Knee Replacement 
Surgery 
 
Introduction 
Total knee replacement (TKR) is a common orthopaedic procedure, with 20-
70% of patients needing 1-3 units of blood, although allogeneic transfusion is 
not risk free. Tranexamic acid (TXA) is a synthetic antifibrinolytic agent used in-
travenously to stop bleeding in TKR and other surgical procedures.  
  
Objectives 
To determine whether intra-articular TXA is effective, safe and cost-effective in 
reducing blood loss and subsequent blood transfusion after TKR.  
 
Design 
This thesis describes three research projects to address the objectives: 
1. A systematic review and meta-analysis of the use of intravenous (IV) 
TXA in TKR. 
2. A randomised controlled trial of the topical (intra-articular) use TXA in 
TKR. 
3. A biomechanical study of the effect of local TXA on TKR materials.  
 
Outcome measures 
The primary aim of intra-articular TXA was to reduce the blood transfusion rate. 
Secondary outcomes included reduced blood loss, length of stay, complications 
and cost and improved functional outcome measures. To explore whether TXA 
degrades TKR materials, tensile properties, wear rate and surface topographic 
profile were biomechanically tested. 
 
7 
 
 
Results 
The systematic review found that IV TXA reduced blood loss and transfusion 
significantly but there was significant heterogeneity between trials. A first trial of 
topical (intra-articular) TXA in TKR found TXA to be effective and safe in reduc-
ing blood loss and transfusion. Thirteen patients (16.7%) were transfused in the 
placebo group versus 1 (1.3%) patient in the TXA group (2; P=0.001). Blood 
loss was reduced from 465 ml in the placebo group to 297 ml in the TXA group 
(t-test; P=0.00025). TXA use resulted in a net cost saving of £333 per patient 
(P=0.044). There was no adverse effect of TXA on the biomechanical properties 
of the joint materials. 
  
Conclusion 
Topically Applied TXA in TKR is effective, safe and cost-effective in reducing 
blood loss and transfusion in TKR, and avoiding the potential complications of 
intravenous administration. 
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Background to the thesis 
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1.1 Introduction 
Work reported in this thesis addresses the topical (intra-articular) use of 
Tranexamic acid (an antifibrinolytic agent) as means to reduce blood loss and 
subsequent blood transfusion associated with artificial total knee joint replace-
ment (TKR). To set the context for the research, it is useful to summarise cur-
rent techniques in TKR. This introduction is structured to cover the following 
topics: 
 
 A brief history of total joint replacement. 
 The surgical technique of total knee replacement. 
 Blood loss in joint replacement and its consequences. 
 Haemostasis (The natural process of our body to stop bleeding): 
o Vasospasm 
o Platelet plug formation 
o Coagulation and the fibrinolysis system 
o Antifibrinolytics 
 Overview of current techniques of blood conservation in elective ortho-
paedic surgery: 
o Pre-operative assessment and optimisation. 
o Intra-operative blood conservation and cell salvage. 
o Post-operative conservation techniques, including indications for 
transfusion, and postoperative cell salvage. 
 
1.2 A Brief History of Total Joint Replacement 
Arthritic joint failure is a common and crippling disease causing severe pain and 
significant disability. Although medical treatment such as pain killers and local 
injections can be successful in the early stages, they are less effective in the 
advanced stages of the disease. Worldwide, scientists and surgeons have 
worked together to find a lasting, safe and effective way to treat this condition. 
Artificial joints have been introduced and become one of the most effective 
ways to treat advanced arthritis.  
 
Historically, because of its greater disability, arthritis of the hip has been of more 
interest to orthopaedic surgeons than arthritis of the knee. The hip has a more 
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complex range of movement and function than the knee joint. Sufferers usually 
have difficulty in walking, sitting, bending and even turning in bed. Hence, new 
surgical treatments and techniques to treat hip joint arthritis have preceded 
those for knee arthritis. Treatment and techniques for hip arthritis have been 
subsequently adapted to treat knee arthritis. Therefore we need to understand 
how hip replacement developed to properly summarise modern knee replace-
ment.   
 
Initial attempts to treat arthritic hips and knees surgically were varied and 
ranged from arthrodesis (fusion of the joint) to excision of the joint. Fusion of the 
joint can be a very successful operation to alleviate pain but it sacrifices move-
ment. Alternatively, excision of the joint (excisional arthroplasty), although re-
taining some movement, can be a very disabling operation, particularly in a big, 
weight bearing joint such as the hip or the knee. Other surgical modalities such 
as osteotomy, joint debridement and nerve division have been practised with 
variable success. The goal of bony osteotomy is to realign the joint so that the 
weight load is distributed evenly across the joint surface. Joint debridement in-
volves removing arthritic spurs, calcium deposits, and irregular cartilage in an 
attempt to smooth the surfaces of the joint. Although, nerve division can be 
helpful in improving symptoms, it accelerates the rate of joint wear and destruc-
tion. Furthermore, it is also not always possible, being dependent on the anat-
omy of that particular nerve and other structures it supplies. 
 
There has been a long history of research for a material which could be utilized 
to resurface or even replace the hip and the knee joints. Materials considered 
included muscle, fat, chromatised pig bladder, gold, magnesium and zinc, all 
without success. The problem was to find a material which was biocompatible 
with the body, and yet strong enough to withstand the tremendous forces 
placed on the hip joint.  
 
In 1925, an American surgeon, Dr Smith-Petersen, moulded a piece of glass 
into the shape of a hollow hemisphere. This fitted over the ball of the hip joint 
and provided a new smooth surface for movement. While proving biocompati-
ble, the glass could not withstand the stress of walking and quickly failed [1].  
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A dramatic advance came in 1936 when scientists developed a cobalt-
chromium alloy which was almost immediately applied to orthopaedics. This 
new alloy was both very strong and resistant to corrosion, and has continued to 
be employed in various prostheses since that time. During the 1940s, mould ar-
throplasty was the gold standard for severe joint arthritis. 
 
In 1938, Dr. Jean Judet and his brother, Dr. Robert Judet, of Paris, attempted to 
use an acrylic material to replace arthritic hip surfaces. This acrylic provided a 
smooth surface, but unfortunately tended to come loose.  
 
In England, Sir John Charnley worked on the ongoing problem of hip repair, 
looking for a way to replace both the femoral head and acetabulum of the hip 
with different materials [1]. He tried using stainless steel to replace the femoral 
head and he replaced the eroded arthritic socket with a Teflon implant. He 
hoped this would allow for a smooth joint surface to articulate with the metal ball 
component. This approach failed as the Teflon debris created a harmful body 
reaction. Undaunted, he went on to try polyethylene which worked well because 
it has a better biomechanical and wear properties than Teflon and wear debris 
caused much less harmful reactions. In order to fix the polyethylene socket as 
well as the femoral implant to the bone, Charnley used polymethylmethacrylate 
as used by dentists. This substance, known as bone cement, was mixed during 
the operation then used as a strong grouting agent to firmly secure the artificial 
joint to the bone. Charnley closely followed-up each patient and after their 
death, he retrieved the hip to see how it had performed. He questioned his 
ideas and designs and continually worked on improving them. He was knighted 
in 1977. 
 
With regard to knee replacement, Themistocles Gluck became the first surgeon 
to implant an artificial knee in 1890. He devised a hinge linked to ivory stems 
that could be attached to bone. All Gluck‟s joint replacements became infected 
due to the lack of antisepsis and antibiotics. This was a major factor in slowing 
down the development of modern artificial total knee replacement [1]. In the 
modern era, another attempt came at the end of 1950 when Guepar used a 
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prosthesis which was really a hinge fixed to the bones with stems into the me-
dullary canals of the adjacent bones. These hinges provided good short term 
pain relief but function was not always great due to the limitations of motion. Af-
ter a few short years, this prosthesis showed severe problems with loosening 
and infection and was abandoned.  
 
Some surgeons tried to treat arthritis of the knee with a metal spacer which was 
placed between the bones of the knee to eliminate the rubbing of irregular sur-
faces against each other. These implants, the McKeever (1957) and MacIntosh 
(1958), achieved some success but were not predictable, and many patients 
continued to experience significant symptoms.  
 
The introduction of polyethylene as an artificial bearing surface in 1963 and the 
approval of methylmethacrylate for general use in the United States in 1971 set 
the stage for the development of alternatives to hinged knee replacement  for 
the treatment of severe knee arthritis. During the late 1960s, a Canadian ortho-
paedic surgeon, Frank Gunston, from Sir John Charnley's Hip Centre, devel-
oped a metal on plastic knee replacement secured to the bone with cement 
marking the beginning of era of total knee arthroplasty. In 1972, Dr John Insall, 
designed what has become the prototype for current total knee replacements. It 
was called the TC knee (Total Condylar knee). This was a prosthesis made of 
three components which would resurface all three surfaces of the knee - the 
femur, tibia and patella (kneecap). They were each fixed with bone cement and 
the results were a significant advance [2].  
 
Current research in TKR is aimed at refining the design to improve patient func-
tion. The aim is to achieve greater knee range of motion and permanence. 
 
Today, TKR has become one of the commonest operations in orthopaedic prac-
tice. The sixth annual report of the National Joint Registry [3] showed that there 
were around 65 979 primary TKRs performed in England and Wales during 
2008. Fifty seven percent were in female and 43% were in male patients. In 
97% of patients, advanced osteoarthritis was the condition underlying the indi-
cation for surgery. Interestingly, there has been steady increase of the number 
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of TKRs performed in England and Wales surpassing total hip replacement 
(THR) as shown in figure 1.1. 
 
Figure 1.1 The trend in joint arthroplasty in England and Wales 
0
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Source: the 6th and 7th annual reports of the national joint registry [3, 4]. 
 
1.3 Surgical Technique of Total Knee Replacement 
There follows a brief description of the surgical technique of modern TKR, spe-
cifically, the P.F.C Sigma total knee replacement as recommended by the 
manufacturer DePuy International Ltd [5]. This is by far the commonest type 
used in our centre and in the UK [3].  
 
The operation is performed under spinal (SA) or general anaesthetic (GA). The 
patient is positioned supine on the operating table. A tourniquet is applied 
around the thigh and after preparation and draping it is inflated to 350 mm Hg to 
ensure a bloodless surgical field. 
 
The standard approach is used by making a longitudinal midline incision cen-
tred over the patella and extending from the middle of the thigh to the tibial tu-
bercle. The joint is entered through a medial parapatellar capsular approach as 
in figure 1.2.  
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Figure 1.2 The surgical incision and approach of TKR 
 
Reproduced by permission of DePuy International Ltd. 
 
Menisci, anterior cruciate ligament and fat are excised to expose the end of 
bones. Femoral, tibial and patellar articular surfaces are then excised using 
specifically designed jigs to accommodate the artificial prosthetic components. 
The femoral end is shaped with three different cuts as shown by figure 1.3. 
 
Figure 1.3 The femoral articular surface cuts 
 
Reproduced by permission of DePuy International Ltd. 
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The tibial articular surface is cut almost perpendicular to the main axis of the 
tibia (figure 1.4). The patellar articular surface is excised using a special jig (fig-
ure 1.5). Some surgeons do not replace the patella. 
 
Figure 1.4 the tibial articular surface cut and preparation 
 
Reproduced by kind permission of DePuy International Ltd. 
 
 
Figure 1.5 the patellar articular surface cut using a patellar jig 
 
Reproduced by permission of DePuy International Ltd. 
Trial implants are used to confirm sizes and check stability and range of move-
ment. Then the permanent components are fixed to the bone using bone ce-
ment (Methylmethacrylate). The joint is then washed out thoroughly. Two drains 
are inserted on each side of the new joint. The wound is closed in layers using 
absorbable sutures. The skin is usually closed using skin clips. The wound is 
dressed with a dry dressing and a doubled layer of soft band and crepe ban-
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dage, commonly known as a pressure bandage.  Then the tourniquet is de-
flated. Typically, the operation lasts about 60 minutes. 
 
Figure 1.6 Cementing the three components of TKR  
(tibial, femoral and patellar components) 
 
Reproduced by kind permission of DePuy International Ltd. 
 
Vacuum type drains are used. In our centre, they are released after applying a 
doubled layer pressure bandage. They are usually removed after 48 hours 
unless there is excessive bleeding in which case they are left longer. In other 
centres, the practice may vary. Some do not use drains at all; others leave the 
drains clamped for a variable length of time from 15 to 60 minutes.  
25 
 
 
1.4 Blood Loss in Joint Replacement 
Blood loss is common after joint replacement. A patient who is undergoing TKR 
can lose up to 2300 ml of blood, which is almost one third of the total circulating 
blood volume [6]. This carries significant general and local risk. An aging popu-
lation has meant an increase in the number of major orthopaedic surgical inter-
ventions in the elderly. Older patients have a low tolerance to blood loss and its 
consequences because of their low physiological reserve and associated co-
morbidities such as ischaemic heart disease and lung disease. Blood transfu-
sion is routine for significant blood loss and it is estimated that 20-70% of pa-
tients undergoing TKR need 1-3 units (around 300 to 1000 ml) of blood [7-9]. 
 
Although safer than ever, allogeneic blood transfusion is still associated with 
risks for the recipient: fluid overload, autoimmune haemolysis, infection, immu-
nosuppression and transfusion-related acute lung injury (TRALI, see Table1.1) 
[10]. Moreover, the cost of allogeneic blood products is expected to rise be-
cause of the high cost of screening; safety management and the increasing im-
balance between blood donation and use [11]. To control both inherent risks 
and increasing costs, allogeneic transfusion should be minimized during surgi-
cal procedures.  
 
Total knee replacement is performed with an occlusive tourniquet. As a result, 
TKR is associated with minimal intra-operative blood loss; however, patients 
lose a lot of blood in the postoperative period. Consequently, TKR is ideally 
suited to pharmacological manipulation of the coagulation and fibrinolysis sys-
tems. 
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Table 1.1 Incidence of adverse events associated 
 with allogeneic blood transfusions 
Adverse event Incidence per transfused units 
Infectious 
Viral infection 
Hepatitis A  
Hepatitis B  
Hepatitis C  
HIV  
HTLV I/II 
 
Bacterial contamination  
Parasitic infection  
Prion disease  
 
Non infectious 
Febrile non haemolytic reaction  
Urticarial reaction  
Anaphylactic reaction  
Haemolytic transfusion reaction  
Transfusion-related acute lung injury (TRALI) 
Transfusion-associated circulatory overload  
Post-transfusion purpura  
 
 
1:2 000 000 
1:31 000 to 1:81 000 
1:1 935 000 to 1:3 100 000 
1:2 135 000 to 1:4 700 000 
1:1 900 000 
 
1:14 000 to 1:28 000 
1:4 000 000 
Rare 
 
 
1:500 
1:50 to 1:100 
1:23 000 
1:9 000 
1:1 300 to 1:5 000 
1:17 000 
1:143 000 
 
1.5 Haemostasis, Coagulation and Fibrinolysis System 
The prevention of bleeding depends upon maintaining the integrity of the blood 
vessel walls; ensuring that any breaches are rapidly sealed by deposition of 
platelets and fibrin. This process is divided into 3 stages[12]: 
 
1.5.1 Vasospasm 
Damage to the blood vessel wall results in immediate vasoconstriction of the 
injured and adjacent vessels resulting in a transient reduction of the blood flow 
to the affected area. This has a dual effect. It reduces blood loss and allows 
more time for blood components to seal the breach. 
Diseases may weaken the blood vessel wall and may cause rash, skin bruises 
or frank bleeding. Hereditary haemorrhagic telangiectasia, Ehler Danlos syn-
drome and Marfan syndrome are known to cause bleeding by weakening of the 
blood vessel wall. 
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1.5.2 Platelet plugs formation 
The body contains about 300,000 platelets/dl of the circulating blood. Platelets 
are complex highly specialised cells within the blood with a lifespan of about 10 
days. They are capable of responding quickly to a variety of stimuli. Damage to 
the blood vessels can activate platelets inducing morphological (change from 
discoid into spherical) and physiological changes. They become adherent to the 
vessel wall and to each other forming a plug to seal the breach. These platelets 
also release chemical factors which cause further vasospasm (namely serotonin 
and Thrombxane A2) and activate the coagulation system. 
 
However, the optimum number of the platelets is vital to their function. Increase 
or decrease of the platelets in the blood can cause bleeding. There are several 
pathological conditions that can affect the number or functions of the platelets. 
Idiopathic Thrombocytopenic Purpura (ITP) and thrombocytosis are two medical 
conditions in which platelets numbers are low or high respectively. Both condi-
tions are associated with bleeding tendency. Von Willebrand Disease is another 
medical condition in which the count of platelets is normal but the function is 
abnormal making the sufferers prone to bleeding. 
 
The plug-forming stage can be modified pharmacologically to achieve desired 
effects. For example, aspirin is widely used to reduce the incidence of heart at-
tack and stroke by impairing platelet function and reducing thrombosis. Clopi-
dogrel and dipyridamole are another two drugs that affect platelet function 
through different mechanisms and can cause bleeding. 
 
1.5.3 Coagulation and fibrinolysis 
Coagulation involves a series of complex enzymatic reactions among different 
coagulation factors leading to the conversion of soluble plasma fibrinogen to an 
insoluble fibrin clot which further stabilises the platelet plug.  
 
The conversion of fibrinogen to fibrin is catalysed by thrombin. This is a serine 
protease formed from its circulating precursor, pro-thrombin by action of the ac-
tivated factor X. Factor X activation occurs through either the intrinsic or extrin-
sic system. Factor X activation through the intrinsic system occurs when the 
28 
 
 
blood is exposed to the collagen fibres underlying the endothelium in the blood 
vessels. Factor X is activated through the extrinsic system by the release of 
thromboplastin (a protein-phospholipids mixture) from damaged tissues[13]. 
The following diagram summarises these two coagulation systems [14, 15]. 
 
Figure 1.7 Coagulation pathways 
X            V
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Extrinsic System
Damaged Tissues
Intrinsic System
Vessel Wall Damage
Fibrin
Tissue factor
VII
XII, XI
VIII,IX
Ca, Phospholipid
Fibrinogen
ThrombinProthrombin
Final Common Path
 
The preservation of an intact vascular system requires not only that blood be 
capable of coagulating but also that the products of coagulation can be proc-
essed when they have served their purpose of stopping a vascular leak. This is 
the function of the fibrinolysis system. In this system, a plasma protein called 
Plasminogen is activated and converted to Plasmin. The latter is a serine prote-
ase which breaks down the fibrinogen and fibrin into several fragments known 
as fibrinogen (fibrin) degradation products (FDP). Plasmin is also capable of 
breaking down other coagulation factors such as factor V and VIII [15] 
 
 The fibrinolysis system is activated by the presence of fibrin in the blood. Like 
the coagulation system this can occur through either an extrinsic or intrinsic sys-
tem. There are several Plasminogen activators. The most potent one is tissue 
Plasminogen activator (t-PA) which is derived from the vascular endothelium 
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(extrinsic activation).  Intrinsic Plasminogen activators such as factor XII and 
Kallikrein are of minor physiological importance. 
 
Inactivators of Plasmin (such as α2 antiplasmin) are also present in the plasma 
and contribute to the regulation of the fibrinolysis figure 1.8. 
 
Figure 1.8 Fibrinolysis system 
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Coagulation and fibrinolysis systems can also malfunction. Congenital deficien-
cies of different factors are well known and some of them are common. Haemo-
philia is a disorder caused by deficiency of factor VIII while Christmas disease is 
caused by deficiency of factor IX. Nutritional deficiency of Vitamin K can lead to 
serious bleeding because it is important for the synthesis of factors (X, IX, VII 
and II). Table 1.2 summarises the common diseases that affect the blood 
haemostasis. 
 
With advancing medicine, these interacting coagulation and fibrinolysis systems 
can be manipulated to produce a favourable state of bleeding depending on the 
clinical need.  For example, patients with deep venous thrombosis or pulmonary 
embolism can be treated with Warfarin. This interferes with the metabolism of 
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vitamin K in the liver, inhibiting the synthesis of the factor (X, IX, VII and II), 
hence there is less clotting. Patients with heart attack, if they present early, can 
be treated with Alteplase. Alteplase is a potent tissue Plasminogen activator 
produced by recombinant technology. It binds strongly to Fibrin and is capable 
of dissolving the clots that caused the attack.  
 
Conversely, antifibrinolytic agents such as Tranexamic acid (TXA), Aprotinin 
and Epsilon Aminocaproic acid (EACA) inhibit the fibrinolysis system, prevent-
ing premature clot dissolution and excessive bleeding. 
 
Table 1.2 Common faults of haemostasis that lead to bleeding tendency 
Blood vessels  
(Vasospasm) 
Platelets Coagulation factors 
 
1. Vasculitis 
2. Senile purpura 
3. Henoch Schonlin Pur-
pura 
4. Hereditary Haemorrhagic  
Telangiectasia 
5. Ehler Danlos Syndrome 
6. Aneurysms 
 
1. Thrombocytopenia  
(Reduced in number).  
i. Idiopathic 
ii. Drug induced 
iii. Bone marrow failure 
 
2. Thrombocytosis  
(Increased in number) 
i. Reactive 
ii. Essential thrombocyto-
sis 
iii. Myelofibrosis 
iv. Leukaemia 
 
3. Thrombosthenia  
(Abnormal function). 
i. Bernard-Soulier Syn-
drome 
ii. Dense granule defi-
ciency 
iii. Drug induced. 
 
1. Factor I deficiency  
(Afibrogenemia) 
2. Factor II deficiency  
(Hypoprothrombinaemia) 
3. Factor V deficiency  
(Para haemophilia) 
4. Factor VII  
(Hypoconvertinemia) 
5. Factor VIII deficiency 
(Haemophilia) 
6. Factor IX deficiency  
(Christmas Disease) 
7. Factor X deficiency  
(Stuart-Prower Disease) 
8. Factor XII deficiency  
(Hageman trait) 
 
 
1.6 Antifibrinolytics and Tranexamic Acid 
Antifibrinolytic agents interfere and inhibit the fibrinolysis system preventing 
premature clot lyses and preventing excessive bleeding. They have been ex-
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tensively used in clinical practice. They have been successfully used to stop 
bleeding after dental treatment, removal of tonsils, prostate surgery, heavy 
menstrual bleeding, eye injuries and in patients with Haemophilia [16-21]. There 
are three commonly used agents; these are Aprotinin, Tranexamic acid (TXA) 
and Epsilon Amino Caproic Acid (EACA). 
 
1.6.1 Aprotinin 
Aprotinin is a naturally occurring inhibitor of Plasmin (obtained from bovine lung) 
which has been used for the treatment of life threatening haemorrhage. 
Aprotinin is a non-specific, serine protease inhibitor, with antifibrinolytic proper-
ties. It inhibits several serine proteases, including trypsin, Plasmin, plasma Kal-
likrein and tissue Kallikrein. During open heart surgery the negatively charged 
surface of the cardiopulmonary bypass circuit activates factor XII, converting 
prekallikrein to Kallikrein which further activates factor XII. This positive feed-
back loop acts to intensify the intrinsic coagulation cascade. By inhibiting 
plasma Kallikrein, Aprotinin minimises derangements in coagulation and fibri-
nolysis [22]. There is also evidence that Aprotinin exerts an indirect preservative 
effect on platelet function during extracorporeal circulation [23]. In many coun-
tries Aprotinin is specifically indicated for the reduction of blood loss during car-
diopulmonary bypass. 
 
1.6.2 Tranexamic acid 
Tranexamic acid was first used in Sweden in 1969.  Its chemical name is trans-
4- (aminomethyl) cyclohexanecarboxylic acid. The empirical formula is 
C8H15NO2. The structural formula is shown in figure 1.9. Molecular weight is 
157.2. 
 
Figure 1.9 The structural formula of Tranexamic acid 
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It is a synthetic lysine analogue that acts as an effective inhibitor of fibrinolysis. 
TXA acts principally by blocking the lysine binding sites on Plasminogen mole-
cules, inhibiting the formation of Plasmin and therefore inhibiting fibrinolysis. 
Tranexamic acid is about ten times more potent than EACA and binds much 
more strongly to both the strong and weak sites of the Plasminogen molecule 
than EACA [24]. Tranexamic acid undergoes negligible metabolism in the body 
and is eliminated unchanged in the urine.  
 
1.6.3 Epsilon Aminocaproic Acid (EACA) 
It is chemically related to TXA. EACA is a derivative and analogue of the amino 
acid lysine. It has the same mechanism of action of TXA by blocking the lysine 
binding sites on Plasminogen molecules inhibiting the formation of Plasmin and 
therefore inhibiting fibrinolysis. In TXA, the 4-carbon chain of EACA is substi-
tuted by a cyclohexane molecule enhancing potency by 7-10 times. It has a 
similar safety profile to the TXA. For these reasons, EACA is now seldom used 
and is no longer registered for clinical use in many countries [25].  
 
1.7 Blood Conservation in Elective Orthopaedic Surgery 
Responding to the issue of blood loss and its consequences for patients, the 
British Orthopaedic Association (BOA) introduced the concept of blood conser-
vation surgery and produced guidelines in elective orthopaedic surgery [26]. It is 
accepted that blood conservation in orthopaedic surgery goes hand-in-hand 
with good orthopaedic surgical practice. Surgical procedures should be done 
with the minimum of blood loss and, if possible, lost blood should be returned to 
the patient.  
 
The guidance covers three stages in the patient journey where a variety of 
techniques can be utilised to reduce blood loss and / or the need for allogeneic 
blood transfusion: 
 Pre-operative assessment and optimisation. 
 Intra-operative blood conservation and cell salvage. 
 Post-operative conservation techniques, including indications for transfu-
sion, and postoperative cell salvage. 
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A successful blood conservation programme addresses all three areas. Table 
1.3 summarises these techniques and the following sections review the ration-
ale and the evidence for each technique. 
 
Table 1.3 Preoperative, intra operative and postoperative  
blood conservation techniques  
Preoperative 
Iron therapy 
Erythropoietin (EPO) 
Preoperative autologous blood donation (PAD) 
Acute normovolemic haemodilution (ANH) 
Acute hypervolemic haemodilution (AHH) 
 
Intra-operative 
Surgical technique 
Anaesthetic technique 
Intra-operative cell salvage 
Pharmacological agents 
Artificial blood substitute 
 
Postoperative 
Iron therapy 
Transfusion trigger 
Postoperative cell salvage 
 
1.7.1 Pre-Operative Assessment and Optimisation 
Artificial joint replacement is regarded as a grade 4 (major +) surgery by the Na-
tional Institute of Clinical Excellence (NICE) [27]  reflecting the potential risk this 
surgery poses to patients. Patients undergoing this type of surgery require thor-
ough assessment and investigation to establish their fitness for surgery and op-
timise their physiological reserve to withstand its effects.  
 
One important aspect of preoperative assessment is to identify patients who are 
likely to bleed excessively, such as patients with bleeding disorders (see table 
1.2) and those who take warfarin, Clopidogrel and Aspirin. Anticoagulants 
medications intended to prevent blood clotting and may cause serious bleeding; 
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ideally they should be stopped for few days before surgery. Alternatives with a 
lower tendency to cause bleeding are available and can be used [28]. 
 
Patients with a low pre-operative haemoglobin level (less than 12 g/dl) have an 
increased risk of needing a blood transfusion [29]. Iron deficiency anaemia is 
probably the commonest cause of preoperative low haemoglobin in patients un-
dergoing artificial joint replacement. Iron therapy is indicated to increase red 
blood cell and haemoglobin production. Some evidence suggests that ferrous 
sulphate, given for four weeks preoperatively to all patients undergoing elective 
orthopaedic surgery, leads to improved post-operative haemoglobin [30, 31]. 
 
An alternative and increasingly popular treatment for low preoperative haemo-
globin is the use of Erythropoietin (EPO): a natural hormone produced by the 
kidney that promotes the formation of red blood cells in the bone marrow. Using 
recombinant DNA technology, EPO has been synthetically produced for use by 
patients with certain types of anaemia. It is particularly effective in the manage-
ment of mild to moderate anaemia prior to surgery (Hb 10-13g/dl). EPO is safe, 
with relatively few side effects. However, it works only when iron stores are 
adequate [32].  
 
Another technique is preoperative autologous blood donation (PAD). Using 
autologous (self donated) rather than allogeneic blood reduces the risk of 
transmitting infection and immunological reactions, but it introduces other risks 
such as mismatched transfusion (giving the patient the wrong blood) and bacte-
rial contamination. During PAD, autologous blood is collected weekly in the 4-6 
weeks preceding surgery. The number of PAD units needed is calculated de-
pending on the type of surgery, the likelihood of requiring a transfusion, and the 
interval between the collection time and the date of surgical procedure. It is 
used for those procedures likely to have large blood loss. PAD is contraindi-
cated in patients with ischaemic heart disease, heart failure and it is not ac-
cepted by Jehovah Witnesses.  
 
Two other preoperative techniques are called acute normovolemic haemodilu-
tion (ANH) and acute hypervolemic haemodilution (AHH). During haemorrhage, 
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haemodiluted patients lose fewer red blood cells than normal. In ANH, blood is 
exchanged with a similar volume of a cell-free crystalloid (3: 1 exchange) or col-
loid solution (1: 1 exchange) directly prior to surgery. Depending on the target 
haematocrit (Hct), a variable amount of fresh autologous whole blood, including 
platelets and coagulation factors, is withdrawn from the patient. In clinical prac-
tice, ANH is targeted to an Hct of 20% in healthy patients and an Hct of 30% in 
patients suffering from mild cardiac co morbidity. ANH blood has to be stored in 
theatre and is therefore immediately available in case of intra-operative bleed-
ing. 
 
Similarly, AHH dilutes the circulating blood reducing the number of lost red cells 
of intra-operative blood loss. However, in contrast to ANH, this objective is 
achieved by the additional infusion of crystalloid and colloidal solutions, i.e. 
without the simultaneous withdrawal of whole blood. During AHH, the patient‟s 
intravascular volume is significantly increased. Hence the technique is recom-
mended only for patients without cardiac co-morbidity.  
 
PAD, AHH and ANH are equipotent in terms of their allogeneic blood-sparing 
effect when blood loss is around 1000 ml [33-35]. However, ANH and AHH are 
less expensive and allow for flexible surgery schedules. 
 
1.7.2 Intra-Operative Blood Conservation and Cell Salvage 
Bleeding is an inevitable part of surgery; however, the amount of blood loss is 
partially controllable. It is well known that the surgeon plays a major role in con-
trolling surgical haemorrhage. Good surgical technique is important in keeping 
haemorrhage to the minimum during surgery. 
 
In practice, the surgical site is positioned at or even above heart level (e.g. 20° 
Trendelenburg or bending the knee) to reduce hydrostatic blood vessel en-
gorgement. The use of an appropriately sized and fitted tourniquet is a very ef-
fective way in achieving a bloodless surgical field. The tourniquet should be in-
flated to the appropriate pressure necessary to occlude the arterial blood flow to 
the limb. Good surgical technique also includes rapid and careful soft tissue 
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handling using the right tools as well as rigorous haemostasis at the time of ex-
posure using electric diathermy to lower blood loss.  
 
Tissue adhesives derived from human proteins (sealants) or animal proteins 
(glues) may have a useful place in blood management during spinal surgery, 
revision arthroplasty or bilateral knee replacement. They have also been shown 
to reduce blood loss in primary hip and knee arthroplasty, but further work is 
needed to establish their cost-effectiveness [36]. 
 
Minimally invasive surgical techniques have been promoted as another way to 
reduce overall blood loss, however, these remain controversial and may not be 
appropriate for all patients. 
 
With advancing techniques, the anaesthetist‟s role has become increasingly im-
portant in reducing blood loss and transfusion. Blood loss varies with the type of 
anaesthesia. Blood loss may be less in patients having regional anaesthesia 
than general anaesthesia. Similarly patients with general anaesthesia with 
spontaneous ventilation may experience less blood loss than with general an-
aesthesia combined with positive pressure ventilation. If general anaesthesia is 
indispensable, total intravenous anaesthesia is preferable to balanced anaes-
thesia with inhalation anaesthetics to better control vasodilatation [37]. 
 
The use of hypotensive anaesthesia significantly and safely reduces blood loss 
safely, provided patients are selected and monitored appropriately [38, 39]. De-
liberate hypotension is induced pharmacologically with the use of inhaled an-
aesthetics, nitro-glycerine, urapidil or epidural anaesthesia to decrease the sys-
tolic arterial pressure to 80 mmHg or the mean arterial pressure to 50 mmHg. 
Patients with restricted auto-regulation of organ perfusion (peripheral and coro-
nary artery disease, hypertension, cerebrovascular insufficiency, hypovolemia, 
anaemia) are excluded from deliberate hypotension, as are patients suffering 
from renal and/or hepatic insufficiency. 
 
Maintenance of normal temperature reduces blood loss. Some steps in the co-
agulation cascade as well as platelet function are temperature-dependent. Mild 
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hypothermia (35.0 ± 0.5°C) increases intra-operative blood loss and transfusion 
need. Suitable fluid warming and forced air warming devices are essential for 
major surgical cases. [40-42].  
 
The type of intravenous fluid administered may influence coagulation. Balanced 
salt solutions (e.g. Hartmann‟s), gelatine based colloids and medium molecular 
weight starches (e.g. Voluven) cause fewer coagulation problems than Dextrans 
and other Starches. 
 
Intra-operative red cell salvage is one of major advances in blood conservation 
surgery which greatly reduces the need for allogeneic blood transfusion and can 
be life-saving [43]. Intra-operative blood salvage involves aspirating the blood 
directly from surgical wound then removing any clots or debris. Subsequently 
the collected blood is washed re-transfused back to the patient. The technique 
produces autologous red blood cell units with Hct values ranging from 60% to 
70% and is suitable for surgical interventions with an estimated blood loss of 
800 to 1000 ml. 
  
Potential bacterial contamination of the collected wound blood represents an 
absolute contraindication to auto-transfusion in patients undergoing joint re-
placement surgery. In tumour surgery, auto-transfusion is possible if the proc-
essed red blood cell concentrate is gamma-irradiated (50 Gray) [44]. Jehovah‟s 
Witnesses accept auto-transfusion as long as the patient, collection system, 
processing unit and final blood bag form a closed system. 
 
Newly introduced cell salvage devices (e.g. „Orthopat‟), which allow both intra-
operative and post-operative collection, may become cost effective in primary 
total hip and total knee arthroplasty. 
 
Pharmacological agents have gained more popularity as a means of reducing 
blood transfusion and its inherent risks. There are three main groups of such 
pharmacological agents: antifibrinolytics (see 1.6), Desmopressin and Recom-
binant activated factor VII. Desmopressin is a synthetic vasopressin (a naturally 
present hormonal polypeptide) analogue. It is more active than the vasopressin 
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and has a wide range of activities. Desmopressin is known to release platelets 
from the bone marrow and increase plasma concentrations of factor VIII and 
von Willebrand cofactor (after 4–12 hours). Hence, it is used to treat mild hae-
mophilia. There is evidence to support the use of Desmopressin in patients with 
pre-existing coagulation disorders. Potential indications for Desmopressin to re-
duce perioperative blood losses are urgent surgery in patients under pharma-
cologic platelet inhibition; urgent surgery in patients dependent on haemodialy-
sis; and on-pump cardiac surgery [45]. It is not recommended for routine use to 
reduce blood loss in elective surgery. 
 
Recombinant activated factor VII is a coagulation factor concentrate that is 
newly licensed to use in patients with haemophilia and other bleeding disorders. 
Factor VII forms complexes with tissue factors and activates factor X, particu-
larly at the site of injured vessels and damaged tissue. A recent Cochrane re-
view [46] assessed the effectiveness of recombinant activated factor VII in 
stopping bleeding in patients without haemophilia and concluded that its value 
was uncertain. In some cases of extreme blood loss after trauma or during sur-
gery, recombinant activated factor VII has been successfully administered as 
the final therapeutic option and saved lives. High cost and the lack of evidence 
prohibit its routine use in high blood loss surgery [47, 48]. 
 
Artificial blood substitutes such as Perfluorocarbons and haemoglobin solutions 
are being assessed and may have a role to play in reducing the need for al-
logeneic blood transfusion but minimal data is available in the field of orthopae-
dic surgery and they are not yet licensed for general use. 
 
1.7.3 Post-Operative Conservation Techniques 
Post-operative techniques are not unique but rather draw on techniques from 
the earlier stages of surgery. Postoperative red cell salvage involves the contin-
ued collection of drain blood loss, washing and re-transfusion of autologous 
blood. The method has been shown to be safe and has been used repeatedly 
over the last 10 years with few reported problems [49]. 
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Restrictive transfusion triggers have been proven to be of great value in stan-
dardising blood transfusion practice in the field of orthopaedics and have re-
duced unnecessary blood transfusion. The following restrictive transfusion trig-
gers are recommended by the BOA, Blood Transfusion Task Force and British 
Committee on Haematology Standard [50-52]: 
 Patients should not normally be transfused if the haemoglobin concentra-
tion is above 10g/dl. 
 A strong indication for transfusion is a haemoglobin concentration below 
7 g/dl. 
 A haemoglobin concentration between 8 and 10 g/dl is a safe level, even 
for those patients with significant cardio-respiratory disease. 
 Symptomatic patients should be transfused. 
 
Intra-operative transfusion triggers should be decided on an individual patient 
basis; near patient testing (e.g. using the „Haemocue‟ device) can be used to 
closely monitor haemoglobin level. 
Post-operative iron therapy is widely used in orthopaedic practice; however, 
there is little evidence that the use of oral iron therapy in the immediate post-
operative phase hastens the recovery of the patient‟s haemoglobin. 
 
1.8 Summary of the background to the thesis 
Artificial joint replacement surgery has evolved into a very successful interven-
tion. This has been achieved by the global contribution of scientists and sur-
geons. Research is still continuing to improve the outcome and safety of this 
type of surgery. 
 
Blood loss and subsequent transfusion are the important and modifiable safety 
aspects of knee surgery. This chapter has summarised the current variety of 
techniques and strategies available. In chapter 2, I examine the current applica-
tion of TXA in orthopaedic practice. 
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Chapter 2 
Literature review, system-
atic review and meta-
analysis
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2.1 Overview 
Since the era of total knee replacement (TKR) began in the late 1960s, it has 
become one of the commonest operations in orthopaedic practice. In England 
and Wales, there were 65 979 TKRs performed in 2008 [3]. The number is 
probably higher as the national joint registry is not mandatory.  
 
TKR is frequently associated with transfusion of allogenic blood [8, 53]. In my 
centre (The University Hospital of North Tees and Hartlepool), around 30% of 
patients who underwent TKR received allogenic blood transfusion periopera-
tively in 2006. Although, serological screening has reduced the risk for viral in-
fection to a very low level [54, 55], patients are still concerned about this poten-
tially serious complication. Allogenic blood transfusion can also be associated 
with other non-infectious complications such as haemolysis, immunosuppres-
sion, transfusion-related acute lung injury and even death [56]. Therefore, 
strategies to avoid exposure to allogeneic blood need further development. 
Amongst the technologies to minimise the need for blood transfusion is the use 
of the antifibrinolytic drugs such as Aprotinin, Tranexamic acid (TXA), and epsi-
lon aminocaproic acid (EACA) [57, 58]. 
 
Antifibrinolytics stop bleeding by inhibiting the dissolution of blood clots through 
different mechanisms (see chapter 1). They have been successfully used to 
stop bleeding after dental extractions, removal of tonsils, prostate surgery, 
heavy menstrual bleeding, eyes injuries and in patients with haemophilia. Nu-
merous studies, including RCTs have investigated the efficacy of intravenous 
use of antifibrinolytic agents in reducing blood losses and transfusion require-
ments in TKR. These studies have been variously criticised for poor design, low 
power, inconclusive results and inadequate follow up.  
 
There are a few systematic reviews and meta-analysis on the antifibrinolytics 
effects on blood loss and blood transfusion. The reviews vary in quality and 
their inclusion and exclusion criteria. Although, they are useful in showing a 
positive effect of antifibrinolytic agents in reducing blood loss and blood transfu-
sion in elective surgery in general; none are specific for TXA in TKR. This cre-
ates a confusing message about the value of TXA in TKR, particularly when 
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considering some complications which are more relevant for other surgeries 
such as cardiac surgery than TKR. 
 
A Cochrane review led by Professor Henry from Australia [59] studied 211 trials 
that used one or more of the three antifibrinolytic drugs (Aprotinin, TXA and 
EACA). One hundred and forty seven trials were conducted in cardiac surgery, 
42 trials were in orthopaedic surgery, 14 in liver surgeries, 4 in vascular surgery, 
2 in thoracic surgery, 1 in neurosurgery and 1 in orthognathic surgery. One 
hundred and sixteen trials evaluated Aprotinin, 45 evaluated TXA and 11 eva-
luated EACA versus control. Thirty nine trials compared Aprotinin, TXA, and 
EACA.  
 
The Cochrane review concluded that antifibrinolytic drugs are effective in reduc-
ing blood loss, the need for allogeneic red cell transfusion, and the need for re-
operation due to continued post-operative bleeding in cardiac surgery (where 
most trials were performed) and stated that lysine analogues (TXA and EACA) 
are probably as effective as Aprotinin and are cheaper. The evidence was 
stronger for TXA than for EACA.  
 
Paul Zufferey [58] reviewed 43 trials of antifibrinolytic in orthopaedic practice. 
Twenty five were in THR, 12 in TKR, 4 in spine surgery and 2 in cancer surgery. 
He included the studies that used intravenous preparations only. Twenty trials 
used TXA with a total of 1084 patients. Only studies with a transfusion protocol 
were included in the analysis which resulted in 4 studies of TXA being excluded. 
In agreement with Professor Henry, he found Aprotinin and TXA reduced the 
blood loss and blood transfusion rate but in contradiction to Professor Henry, he 
found that EACA did not lead to a significant reduction in blood transfusion or 
blood loss.  
 
Ho and Ismail [60] studied the effect of TXA on reducing blood transfusion after 
total hip and knee joint replacements. Blood loss was collectively defined as 
„perioperative blood losses despite including results of total blood loss as well 
as postoperative blood loss under this definition when studies were analysed. 
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Of special mention, the Bart study [61] findings cast a shadow on the safety pro-
file of Aprotinin which was terminated prematurely due to high mortality in the 
Aprotinin group. This was a multicentre, blinded study to determine whether 
Aprotinin was superior to either TXA or EACA in decreasing postoperative 
bleeding and other clinically important outcomes such as death. It recruited 
2331 participants undergoing cardiac surgery. They were randomly assigned to 
one of three groups: 781 received Aprotinin, 770 received TXA, and 780 re-
ceived EACA. 
 
The primary outcome was massive postoperative bleeding, which was defined 
as bleeding from chest tubes that exceeded 1.5 litres during any 8-hour period 
or massive transfusion, which was defined as the administration of more than 
10 units of blood within 24 hours after surgery. Secondary outcomes included 
death from any cause at 30 days. The trial was terminated early because of a 
higher rate of death in patients receiving Aprotinin. At 30 days, the rate of death 
from any cause was 6.0% in the Aprotinin group, as compared with 3.9% in the 
TXA group (relative risk, 1.55; 95% CI, 0.99 to 2.42) and 4.0% in the EACA 
group (relative risk, 1.52; 95% CI, 0.98 to 2.36). The relative risk of death in the 
Aprotinin group, as compared with that in both groups receiving lysine analo-
gues, was 1.53 (95% CI, 1.06 to 2.22).  
 
These results have led to the underutilisation of these potentially valuable 
agents in orthopaedic practice. Hence the study described in this thesis aims to 
evaluate TXA further. It is cheaper and potentially as effective as Aprotinin as 
shown by the Cochrane review [62]. It is safer than Aprotinin as suggested by 
the Bart study [61]. In contrast to EACA, it is 10 times more potent [62] and its 
reputation for minimising blood loss has not been questioned in the literature 
[58]. 
 
2.2 Objectives  
This review investigates the evidence for the efficacy of TXA in reducing pe-
rioperative blood loss and blood transfusion after TKR. Additional objectives in-
clude changes in clinical outcomes such as reduction in re-operation rates or 
increase in complication rates and patients outcome measures. 
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2.3 Methods  
The review was conducted in accordance with guidelines described in the 
Cochrane handbook for systematic review and meta-analysis of interventions 
[63]. In order to meet the methodological requirements of a Cochrane review, 
the review team included a second reviewer (MS) who assisted with the review 
process. Two senior reviewers (AN & JM) provided methodological advice and 
resolved disagreement about study selection and abstraction (see acknowl-
edgement).  
 
2.3.1 Criteria for considering studies for this review  
2.3.1.1 Types of studies  
Randomised controlled trials (RCTs) and quasi-randomised (for example, allo-
cation by hospital number or date of birth) trials have been considered within 
this review. 
  
2.3.1.2 Types of participants  
The participants were adults who underwent a primary TKR regardless of the 
type or the size of prosthesis used. Synchronous or sequential bilateral primary 
TKR and revision surgery for TKR were excluded. 
 
2.3.1.3 Types of interventions  
The intervention considered was the use of TXA. Control groups could be a pla-
cebo or another antifibrinolytic. 
 
2.3.1.4 Types of outcome measures  
The primary outcome measure was: 
1. The proportion of patients who were transfused with allogeneic blood, 
with autologous blood, or with both. 
The secondary outcome measures were: 
1. The amount of blood lost perioperatively (ml). This includes operative 
blood loss, drain blood loss and total blood loss. 
2. The amounts of allogeneic and autologous blood transfused (ml). 
3. Length of stay (LOS) (days). 
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4. Functional knee outcome measures (e.g Oxford knee score). 
5. General quality of life outcome measure (e.g. SF-12, SF-36 or EuroQol). 
6. Complications: death, non-fatal myocardial infarction, stroke, deep vein 
thrombosis, pulmonary embolism, any thrombosis, renal failure and re-
operation due to bleeding). 
 
2.3.2 Search methods for identification of studies  
The following exploded MeSH terms were used for the initial literature search: 
“Antifibrinolytics”, “Tranexamic acid”, “Cyklokapron”, “Aprotinin”, “Trasylol”, ”ep-
silon aminocaproic acid” and “ Amicar”. Text searches of key fields were in-
cluded. A MEDLINE search was then refined to clinical trials and randomised 
controlled trials in human adults. The search was extended to other data bases, 
namely EMBASE, the Cochrane Controlled Trials Register, HealthSTAR and 
CINAHL, Google and Google scholar for trials of antifibrinolytics and total knee 
replacement published in any language from 1966 to December 2007. The bib-
liographies of retrieved trials and other relevant publications, including reviews 
and meta-analyses, were examined for additional articles. 
 
Additionally, we searched the following websites to identify unpublished and 
ongoing studies:  
1. Current Controlled Trials (www.controlled-trials.com) 
2. Centre Watch (www.centerwatch.com) 
3. Trials Central (www.trialscentral.org/ClinicalTrials.aspx) 
4. The UK National Research Register (www.nrr.nhs.uk) 
 
We also searched the Journal of Bone and Joint Surgery - British Volume and 
American Volume (www.ejbjs.org), and the American Academy of Orthopaedic 
Surgeons (www.aaos.org). 
 
2.3.3 Data collection and analysis  
2.3.3.1 Selection of the studies 
Two authors (SA & MS) independently applied the search strategy, selecting 
references from the database searches. Article titles and abstracts were re-
viewed independently and articles were retrieved. When appropriate, references 
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of retrieved articles were reviewed for further studies. The two authors inde-
pendently assessed each full study report to see if it met the review inclusion 
criteria. Disagreements were discussed with the senior reviewers (AN & JM) 
and if no consensus could be reached, the study was excluded. 
 
2.3.3.2 Assessment of methodological quality of included studies 
The review authors used a modification of the generic evaluation tool used by 
the Cochrane Bone, Joint and Muscle Trauma Group [64] (Table2.1). Two au-
thors (SA & MS) assessed the methodological quality of each study. Disagree-
ment was resolved by the senior reviewers (AN & JM). The total quality as-
sessment score (QAS) was reported with each study. 
 
2.3.3.3 Data extraction and management 
A data extraction form was designed and agreed by the review team. A pilot test 
using five articles was performed to ensure the form's consistency. The form 
was then refined accordingly (Appendix 2.1). Initially, two authors (SA&MS) ex-
tracted data independently and reviewed extracted data jointly. Disagreements 
were resolved by consensus or consultation with the senior reviewers (AN & 
JM). If necessary, authors of individual trials were contacted directly to provide 
clarification. 
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Table 2.1 Quality assessment items and possible scores  
A. Was the assigned treatment adequately concealed prior to allocation? 
2 = method did not allow disclosure of assignment. 
1 = small but possible chance of disclosure of assignment or unclear. 
0 = quasi-randomized or open list/tables. 
 
B. Were the outcomes of participants who withdrew described and included in the analysis (in-
tention to treat)? 
2 = withdrawals well described and accounted for in analysis. 
1 = withdrawals described and analysis not possible. 
0 = no mention, inadequate mention, or obvious differences and no adjustment. 
 
C. Were the outcome assessors blinded to treatment status? 
2 = effective action taken to blind assessors. 
1 = small or moderate chance of unblinding of assessors. 
0 = not mentioned or not possible. 
 
D. Were the treatment and control group comparable at entry? (Likely confounders may be age, 
weight or co morbidity). 
2 = good comparability of groups, or confounding adjusted for in analysis. 
1 = confounding small; mentioned but not adjusted for. 
0 = large potential for confounding, or not discussed. 
 
E. Were the participants blind to assignment status after allocation? 
2 = effective action taken to blind participants. 
1 = small or moderate chance of unblinding of participants. 
0 = not possible, or not mentioned (unless double-blind), or possible but not done. 
 
F. Were the treatment providers blind to assignment status? 
2 = effective action taken to blind treatment providers. 
1 = small or moderate chance of un blinding of treatment providers. 
0 = not possible, or not mentioned (unless double-blind), or possible but not done. 
 
G. Were care programmes, other than the trial options, identical? 
2 = care programmes clearly identical. 
1 = clear but trivial differences. 
0 = not mentioned or clear and important differences in care programmes. 
 
H. Were the inclusion and exclusion criteria clearly defined? 
2= clearly defined. 
1= inadequately defined. 
0= not defined. 
 
I. Were the interventions clearly defined? 
2 = clearly defined interventions are applied with a standardised protocol. 
1 = clearly defined interventions are applied but the application protocol is not standardised. 
0 = intervention and/or application protocol are poorly or not defined. 
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J. Were the outcome measures used clearly defined?  
2 = clearly defined. 
1 = inadequately defined. 
0 = not defined. 
 
K. Were diagnostic tests used in outcome assessment clinically useful?  
2 = optimal. 
1 = adequate. 
0 = not defined, not adequate. 
 
L. Was the surveillance active, and of clinically appropriate duration? 
2 = active surveillance and appropriate duration. 
1 = active surveillance, but inadequate duration. 
0 = surveillance not active or not defined. 
 
 
2.3.3.4 Measures of treatment effect 
Continuous data was recorded as mean, standard deviation and group size. 
The treatment effect was the mean difference. We used the weighted mean dif-
ference to summarise trial findings if outcomes were measured in the same way 
between trials. However, we used the standardised mean difference to compare 
trials findings that measured the same outcome, but used different methods. It 
was expected that most trials would measure outcomes in the same way. 
Dichotomous data were expressed as proportions or risks, and the treatment 
effect as a relative risk or risk ratio. Missing data was sought from the authors. 
Where this was not possible or data was missing through loss to follow-up, in-
tention-to-treat principles were used. Trials with multiple arms were conflated to 
a single comparator of TXA or placebo. 
 
Review Manager (RevMan 5, The Nordic Cochrane Centre, Copenhagen), was 
used to present study findings and combine the estimates of the effect of treat-
ments. Summary estimates of the overall effect of treatment are provided in the 
form of a forest plot. The Mantel-Haenszel (H-M) method was used to combine 
studies using a fixed effects model. The presence of statistical heterogeneity 
was assessed through Q and I2 statistics, a value of >50% being considered 
substantial heterogeneity. 
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2.3.3.5 Subgroup analysis  
The following sub-group analyses were prospectively planned: 
1. Diagnosis (rheumatoid vs. osteoarthritis). 
2. Gender (male vs. female) 
3. Cementation technique (cemented vs. uncemmented). 
4. Use of transfusion protocols. 
5. Dose and mode of administration. 
The data on the first three subgroups were lacking and it was not possible to 
conduct meaningful analyses. 
 
2.4 Results  
2.4.1 Description of studies  
Three hundred and twenty three citations were identified as potentially relevant 
studies. Subsequent scrutiny led to the exclusion of 290 of these citations. Full 
publications were obtained for 33 citations. These were assessed and seven 
further citations were excluded, see table 2.2 [16, 60, 65-68]. 
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Figure 2.1 Flow chart of study selection 
Potentially relevant publications 
identified after searching electronic 
databases (n=323)
Studies retrieved for more detailed 
evaluation (n=33)
Relevant studies included in 
systematic review (n=19)
Trials excluded with reasons (1st
selection) (n=290)
Studies excluded after evaluation of full 
text with reasons (2nd selection) (n=7)
The remaining 26 citation referred 
to 19 trials
 
 
 
Table 2.2 Characteristics of excluded studies (2nd selection) 
Excluded studies Reasons for exclusions 
Akizuki 1997a  
Benoni 1997  
Benoni 2000  
Ho 2003  
MacGillivray 2010 
Neilipovitz 2001  
Niskanen 2005  
It is not a randomised controlled trial. 
It is the same trial that was published in1996 (Benoni 1996) 
It deals with hip arthroplasty. 
It is a not randomised trial. 
It recruited concurrent bilateral TKR.  
It deals with patients with scoliosis. 
It deals with hip arthroplasty. 
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The remaining 26 citations referred to 19 RCTs. All involved IV administration of 
TXA. One study additionally examined oral administration. Nineteen RCTs were 
included in the review (table 2.3) (see Appendix 2.2 for a detailed summary of 
the included trials).  
 
Most were small trials with participant number ranging from 24 to136. However, 
they were relatively well designed and the quality assessment scores were high 
in most of the trials. The mode was 24 (the highest possible score) and the 
range was 14-24. Five studies scored less than 20.  
 
Different doses and modes of delivery were used. The dose ranged from ap-
proximately 700mg to 10500 mg [7, 69]. All studies used LMWH as a DVT pro-
phylaxis apart from Ido and Molloy‟s studies [6, 70]. The former did not use any 
chemical prophylaxis and the latter used aspirin. The transfusion trigger was an 
important consideration in the trials designs and apart from Ido‟s study, all stud-
ies specified clearly their transfusion triggers as shown in Table 2.3. 
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Table 2.3: Characteristics of the included studies 
Study N Intervention BT trigger DVT Rx QAS 
Alvarez 2008 95 (1) TXA 10mg/kg IV then 1mg/kg/h infusion for 6h. (2) Control: normal saline. Hb < 80 g/l LMWH 22 
Benoni1996 86 
(1) TXA 10mg/kg IV before tourniquet deflation then 10mg/kg after 3h (an extra dose of 10mg/kg given if blood loss >500ml within 1h or 
1000ml within 4h). (2) Control: normal saline. 
Hb < 85-100 
g/l 
LMWH 22 
Camarasa 2006  136 (1) TXA 10mg/kg IV before tourniquet deflation then 10mg/kg after 3h. (2) EACA 100mg/kg then 3 g/h for 3h.(3)  Control: normal saline. Hb < 80 g/l LMWH 24 
Ellis 2001   30 
(1) TXA 15mg/kg IV before tourniquet deflation then 10mg/kg/h infusion for 12h. (2) Desmopressin 0.3 mcg/kg IV before tourniquet defla-
tion then IV saline over 12h. (3) Control: normal saline. 
Hct < 27% LMWH 22 
Engel 2001   36 
(1) TXA 15mg/kg IV before tourniquet deflation then 10mg/kg after 3h. (2) Aprotinin 1 million units before tourniquet deflation then 0.5 
million units/h for 4h. (3) Control: None 
Hb < 100 g/l LMWH 18 
Good 2003   51 (1) TXA 10mg/kg IV before tourniquet deflation then 10mg/kg after 3 h. (2) Control: normal saline. Hb < 90 g/l LMWH 24 
Hiippala 1995  28 (1) TXA 15 mg/kg IV before tourniquet deflation. (2) Control: normal saline. Hb < 100 g/l LMWH 19 
Hiippala 1997 77 (1) TXA 15mg/kg IV before tourniquet deflation then two additional doses of 10mg/kg after 3-4h and 6-7h. (2) Control: normal saline. Hb< 100 g/l LMWH 22 
Ido 2000   43 (1) TXA 1g IV before tourniquet deflation then 1g after 3h. (2) Control: None. None None 14 
Kakar 2009 24 (1) TXA 10mg/kg IV before tourniquet inflation and 1mg/kg/h until wound closure. (2)  Control: normal saline. Hb < 80 g/l LMWH 22 
Jansen 1999   42 (1) TXA 15mg/kg IV before surgery then 15 mg/kg 8 hourly for 3 days. (2) Control: normal saline. PCV < 26% LMWH 24 
Molloy 2007  150 (1) TXA 500mg IV before tourniquet deflation and 500mg after 3h. (2) Fibrin 10 ml spray. (3) Control: None. Hct < 26% Aspirin 22 
Orpen 2006  29 (1) TXA 15mg/kg at cementation. (2) Control: normal saline. Hb < 100 g/l LMWH 24 
Tanaka 2001 99 
(1) Preoperative: TXA 20mg/kg 10 min before surgery and saline 10 min before tourniquet deflation. (2) Intraoperative: Saline 10 min. 
before surgery and TXA 20mg/kg 10 min before tourniquet deflation. (3) Perioperative: TXA 10mg/kg 10 min before surgery and 
10mg/kg 10 min before tourniquet deflation. (4) Control: normal saline. 
Hb < 70-100 
g/l 
None 24 
Veien 2002   30 (1) TXA 10 mg/kg IV before tourniquet deflation then 10mg/kg after 3h. (2) Control: None Hct < 28% LMWH 22 
Zhang 2007 102 (1) TXA 1 g IV before tourniquet deflation then 1 g after 3h. (2)  Control; normal saline. NA NA NA 
Zohar 1999  40 
(1) TXA 15 mg/kg IV before tourniquet deflation then 10mg/kg/h infusion for 12h. (2) Normovolemic haemodilution (NVHD) group bled to 
target 28%, IV volume maintained with ringer lactate and all the autologous blood was transfused. 
Hct < 27% LMWH 18 
Zohar 2001  40 (1) TXA 15mg/kg IV before tourniquet deflation then 10mg/kg/hr infusion for 12h. (2) Desmopressin 0.3 mg/kg IV then IV saline over 12h Hct < 27% LMWH 22 
Zohar 2004 80 
(1) TXA long 15mg/kg IV before tourniquet deflation then 10mg/kg/h infusion for 12h. (2) TXA short as above but infusion for 2h then oral 
1g at 6 and 12h. (3) TXA oral, 1g 6h preoperative then 6 hourly for 18 h. (4) Control: None 
Hct < 28% LMWH 16 
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2.4.2 Effects of interventions  
2.4.2.1 Blood transfusion 
Sixteen studies (944 participants) provided usable data on the effect of TXA on 
blood transfusion after TKR [6-8, 17-21, 69, 71-77]. TXA led to a reduction in 
the proportion of patients who required blood transfusion (RR 2.72; 95% CI: 
2.25 to 3.27; P=0.00001). In this presentation the RR describes relatively by 
how many times the risk of blood transfusion was reduced. There was signifi-
cant heterogeneity among the studies (Q, P=0.00001; I2 =77%) as in figure 2.2. 
 
 
Figure 2.2 Trials of TXA vs. Placebo; Forest plot of blood transfusion rate 
 
 
There are various ways to measure of the influence of each study upon the 
meta-analytic finding. In our review, we used the standard error as a measure 
for the study size as recommended by Sterne and Egger [78]. The Funnel plot 
(figure 2.3) shows trials scattered asymmetrically around the pooled RR with 
small trials having greater effect. This may be due to smaller trials of lower qual-
ity tending to overestimate true effect. It might also reflect publication bias 
where small negative trials are less likely to be published than small positive 
ones. 
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Figure 2.3 Trials of TXA vs. Placebo; Funnel plot of blood transfusion 
 
2.4.2.2 Amount of blood transfusion 
Fourteen trials including 976 participants (463 in TXA arm and 408 in placebo 
arm) provided usable data on the amount of blood transfused in units. Crude 
pooled data showed that there is a fourfold rise in the number of units trans-
fused when TXA was not used (table 2.4). 
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Table 2.4 Studies reported the amount of blood transfusion 
Study  TXA control 
 N Units Participants Units Participants 
Alvarez 2008 
Benoni1996 
Camarasa 2006   
Ellis 2001   
Engel 2001   
Good 2003   
Hiippala 1997 
Kakar 2009 
Jansen 1999   
Molloy 2007  
Tanaka 2001 
Veien 2002   
Zohar 1999  
Zohar 2004 
Total 
95 
86 
136* 
30* 
36* 
51 
77 
24 
42 
150* 
99 
30 
40 
80 
976 
1 
12 
1 
1 
0 
7 
38 
1 
3 
8 
32 
0 
2 
12 
118 
46 
43 
35 
10 
12 
27 
39 
12 
21 
50 
73 
15 
20 
60 
463 
11 
40 
35 
11 
6 
35 
117 
5 
20 
17 
52 
2 
19 
18 
388 
49 
43 
68 
10 
12 
24 
38 
12 
21 
50 
26 
15 
20 
20 
408 
 
Rate of BT 
Units/participant 
  
0.25 
  
0.95 
 
   
    * Trial has more than one arm. TXA and Placebo only are considered. 
 
2.4.2.3 Blood loss 
Fifteen trials (869 participants) provided usable data on blood loss. Studies 
measured external blood loss as drain volume, total blood loss or a combination 
of both. Ten trials provided data on external (drain) blood loss [17, 19-21, 70-72, 
77, 79, 80]. Using TXA significantly reduced external blood loss by an average 
of 192 ml (95% CI: 168 to 217 m; P = 0.00001). However, there was significant 
heterogeneity in the finding (P=0.00001; I2 =89 %.) (See figure 2.4.) 
 
This finding indicates that there is a robust statistically significant reduction in 
drain blood loss but the magnitude is poorly described by the fixed effect model 
due to heterogeneity among the trial findings. Some systematic variations are to 
be determined. 
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Figure 2.4 Trials of TXA vs. Placebo; Forest plot of drain blood loss* 
 
* Note: the RevMan software produces spuriously precise estimates of the mean difference. Al-
though these have not been edited, only the first 3 or 4 significant figures are meaningful. 
 
Zohar 2004 [21] compared three different modes of TXA administration to pla-
cebo (see table 2.3). These are labelled Zohar 2004 long, Zohar 2004 short, 
Zohar 2004 oral and placebo. They were analysed separately. This may be 
criticised for repeated usage or overinflating the placebo group, however, sensi-
tivity analysis by sequential removal of each arm did not show significant overin-
flation.  
 
Nine trials provided data on the effect of TXA on total blood loss. TXA had a 
more profound effect on total blood loss than drain blood loss. It significantly re-
duced total blood loss by an average of 591ml (95% CI: 536 to 646 ml; 
P=0.00001). Again, there was significant heterogeneity in the finding (P=0.0001; 
I2 =78 %) as in figure 2.6. 
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Figure 2.5 Trials of TXA vs. Placebo; Forest plot of total blood loss 
 
The funnel plot (figure 2.6) showing the effect size against precision is clearly 
not symmetrical. As before, this may be evidence of publication bias where 
some smaller trials with null findings may be missing or may be due to meth-
odological heterogeneity related to study size. 
 
Figure 2.6 Trials of TXA vs. Placebo; Funnel plot of drain blood loss* 
 
* Note: This funnel plot is related to figure 2.4. 
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2.4.2.3 Length of Stay 
Three studies presented data on length of stay (LOS) including 140 participants 
(90 participants received Tranexamic acid and 50 received a placebo). Patients 
receiving TXA spent an average of 0.70 days less in hospital than the control 
group but this was not statistically significant (95% CI: -1.55 to 0.14 days; P= 
0.10).There was no significant heterogeneity in the finding (Q, P=0.58; I2=0%;) 
 
Figure 2.7 Trials of TXA vs. Placebo; Forest plot of length of stay 
 
 
 
 
2.4.2.4 Complications 
2.4.2.4.1 Deep Venous Thrombosis (DVT) 
Thirteen trials provided useful data on DVT including 801 patients of whom 409 
patients received TXA. The use of TXA was not associated with increased risk 
of DVT, RD 0% (95% CI: -0.04 to 0.03; P=0.98). There was no evidence of het-
erogeneity (Q; P=0.98; I2=0%). A similar finding was shown by Henry et al [62] 
and Zufferey et al [58]. 
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Figure 2.8 Trials of TXA vs. Placebo; Forest plot of DVT rate 
 
 
The funnel plot shows trials scattered symmetrically around the pooled RD. 
 
Figure 2.9 Trials of TXA vs. Placebo; Funnel plot of DVT rate 
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2.4.2.4.2 Pulmonary embolism (PE) 
There were five cases of pulmonary embolism within 18 trial reports. One oc-
curred in a patient who received TXA and the rest in the control group. This was 
not statistically significant and there was no significant heterogeneity (Q, P= 
0.27 and I2= 0%). 
 
Figure 2.10 Trials of TXA vs. Placebo; Forest plot of PE rate 
 
 
2.4.2.4.3 Mortality 
Although seldom reported by trials, there were two reported deaths. Hiippala 
1997 reported one death in the control group.  Camarasa 2006 reported one 
death in a patient who had received TXA and died six months later from unre-
lated condition (author communication). Statistically there was no increased risk 
associated with the use of TXA RD 0% (95% CI:-0.05 to 0.05; Q, P=0.89) and 
there was no evidence of significant heterogeneity (I2=18%). 
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Figure 2.11 Trials of TXA vs. Placebo; Forest plot of mortality rate 
 
 
2.4.2.4.4 Other outcomes 
We compared any other reported adverse events among the groups such 
haematoma formation, aggregated infections, etc. There was no significant dif-
ference between the groups. This should be interpreted with caution as this is 
aggregate of other events which might not be consistently reported across stud-
ies. 
 
Figure 2.12 Trials of TXA vs. Placebo; Forest plot of other complications 
 
 
2.5 Discussion  
A systematic review and meta-analysis with homogeneity of findings with multi-
ple trials is regarded as level Ia evidence. This review focused on the use of 
TXA in total knee replacement as a single treatment modality. This was to re-
duce variability found in other reviews relating to other antifibrinolytic agents or 
other types of surgery. 
 
The most convincing finding for TXA is its effect on blood transfusion rate. The 
review findings confirm a positive effect of the use of TXA in reducing the pro-
portion of patients who received blood transfusion.  
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There was significant heterogeneity in the study findings; subgroup analysis 
among the studies showed a consistent but heterogeneous effect when ana-
lysed according to transfusion protocol (Hb, Hct or PCV triggers), low or high 
dose, single or multiple doses, or the timing of administration (see table 2.5 and 
figure 2.13). Interestingly, there is a direct relationship between the dose of TXA 
and the reduction in blood transfusion rate. 
 
Table 2.5 Subgroup analysis of transfusion rate by dose of TXA 
 
Trial ID 
 
TXA 
 
Control 
 
Mean 
dose 
(mg) 
 
Risk ratio (RR) 
 [95 % CI] Trans-
fused 
Total Trans-
fused 
Total 
High dose 
Ellis 2001 1 10 7 10 9450 7.00  [1.04, 46.95] 
Jansen 1999 2 21 13 21 10500 6.50  [1.67, 25.16] 
Zohar 1999 2 20 13 20 9450 6.50  [1.68, 25.33] 
Zohar 2001 3 20 11 20 9450 3.67  [1.2, 11.19] 
Zohar 2004Long 3 20 12 20 9450 4.00  [1.3,12.5] 
Total  11 91 56 91  5.09  [2.86, 9.08] 
  
Low dose 
Alvarez 2008 1 46 6 49 1120 5.63   [0.70, 45] 
Benoni 1996 8 43 24 43 1400 3.00   [1.52, 5.92] 
Camarasa 2006 1 35 23 68 1400 11.64 [1.67, 84] 
Engel 2001 0 12 3 12 1750 7.00   [0.40, 122.44] 
Good 2003 3 27 14 24 1400 5.25   [1.71, 16.08] 
Hiippala 1995 10 15 12 13 1050 1.38   [0.94, 2.05] 
Hiippala 1997 17 39 34 38 2450 2.05   [1.41, 2.98] 
Molloy 2007 5 50 11 50 1000 2.20   [0.82, 5.87] 
Orpen 2006 1 15 3 14 1050 3.21   [038, 27.4] 
Tanaka 2001 47 73 26 26 1400 1.53   [1.28, 1.83] 
Veien 2002 0 15 2 15 1400 5 .00  [0.26, 96.13] 
Zohar 2004Short 
 
6 40 12 20 4450 4.00   [1.75, 9.09] 
Total 99 410 170 372  2.41   [1.99, 2.93] 
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Figure 2.13 Subgroup analysis of transfusion rate  
by dose of TXA; Forest plot 
 
When the weighted effect estimates (RR) are plotted against the estimated 
mean dose used in the trials, there seems to be a trend in the relationship. The 
effect was larger and homogenous in trials that used higher doses of TXA (RR 
5.09; Q; P< 0.00001; I2=0%) but this was not true for the trials that used low 
doses. Further scrutiny of figure 2.14 showed that most trials used a dose of 
less than 5000 mg of Tranexamic acid while a few used almost double dose 
(about 10 000 mg).  
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Figure 2.14 Scatter plot of TXA doses vs. risk ratio  
for blood transfusion reduction 
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The review has also shown that TXA significantly reduces external and total 
blood loss. However; there is significant heterogeneity among the included stud-
ies as shown by the high value of I2 and therefore the results should be inter-
preted with caution. 
 
There are several sources of the heterogeneity that can be summarised as fol-
lows:  
1. Drain blood loss was measured at various times after the operation limit-
ing comparability. Clearly measuring the drain blood loss after 24 hours 
would show less blood loss than measuring it after 48 hours. 
 
2. Authors of the included trials have used different terms interchangeably. 
For example, some authors used „total blood loss” to refer to the “total 
drain loss”, others used the same term to refer to the combined operative 
and postoperative blood loss. Some authors used the term „recovery 
drain loss‟ or „ward blood loss‟ without specifying the timing of measure-
ment. 
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3. Different measures are used to describe the blood loss including mean, 
median, SD and range. 
4. Operative techniques varied among the trials. Some authors released the 
tourniquet before closing the skin to stop any bleeding vessels and then 
inserted the drain catheter and closed the wound. Others did not do this 
relying on the pressure dressing to stop such bleedings vessels. The first 
method would be expected to have more operative bleeding but less 
postoperative (drain) blood loss. 
5. The dose, timing and the mode of administration of the TXA were differ-
ent among different studies as shown in tables 2.3 and 2.5. 
6. Figure 2.6 showed some evidence for possible publication bias where 
some smaller trials with null findings may be missing. 
 
In comparison with subgroup analysis of blood transfusion rate, the dose-effect 
relationship is more complicated and difficult to predict. When the mean differ-
ence of drain blood loss in the TXA group is plotted against the estimated mean 
dose used in the trials, there is a smaller difference in the trials that used higher 
doses (figure 2.15).  
 
Figure 2.15 Scatter plot of TXA doses vs. reduction 
 in mean drain blood loss 
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When the percentage reduction in the mean drain blood loss is plotted against 
the estimated mean dose used in the trials, the magnitude of reduction in drain 
blood loss was similar. Drain blood loss reduced by 40-60%. Interestingly, the 
one study of oral TXA showed the least percentage reduction (7.2%) in the 
mean blood loss as shown in (figure 2.16).  
 
Figure 2.16 Scatter plot of TXA doses vs. percentage  
reduction in mean drain blood loss * 
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* The study that used oral TXA is represented by an orange diamond. 
Theoretically, TXA carries a risk of thrombosis. However the review did not 
show an association between the use of TXA and the increased risk of DVT, PE 
or mortality. 
 
Interestingly, figure 2.10 showed there were less PE events in the TXA group in 
comparison with control. Although this did not reach statistical significance, it is 
possible that TXA may reduce thrombosis by reducing blood transfusion which 
is a thrombogenic intervention. 
 
The review identified a number of non randomised studies that nonetheless 
provide interesting correlation of findings. A recent study from Spain [81] evalu-
ated the effect of TXA on blood transfusion and thromboembolic complications 
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in TKR. They retrospectively studied 414 patients, 215 immediately before in-
troducing TXA treatment (control group) and in 199 patients after its introduc-
tion. Patients undergoing TXA treatment were without a history of thromboem-
bolic disease. Fifty-four per cent of the control group patients (before introduc-
ing TXA) received blood transfusion while only 17.6% of TXA group patients re-
ceived blood transfusion.  Thromboembolic complications were diagnosed in 
2.8% of the patients in the control group (before introducing TXA) and in 1.5% 
in the TXA group. Asymptomatic distal deep venous thrombosis was found in 54 
(14.8%) of TXA group patients and 54 (30.1%) of control patients (before intro-
ducing TXA). These latter findings were not statistically significant. However 
they support our impression that TXA may reduce risk of thromboembolic com-
plications. 
 
In conclusion, this review and meta-analyses have shown that TXA delivered 
systemically (intravenously or orally) has a marked beneficial effect in reducing 
blood loss and blood transfusion.  
 
Although, no increase in adverse effects of TXA is evident with such a mode of 
delivery, the orthopaedic community is still sceptical about its potential systemic 
side effects. None of the trials were powered to detect an increase in such rare 
side effects. Topical (intra-articular) use of TXA may overcome this problem.  
 
2.5.1 Limited evidence for the use of topical TXA 
The effect of topically applied TXA on blood loss has been reported in two stud-
ies in oral surgery [82, 83], three studies in cardiac surgery [84-86], one in blad-
der surgery [87], one in gynaecology [88] and one study in spinal surgery [89] . 
 
Sindet-Pedersen performed two studies using topical TXA in oral surgery in pa-
tients with bleeding disorders. The first study [83] investigated the effect of add-
ing systemically and locally delivered TXA on factor VIII concentrate in haemo-
philic patients. The study showed that topically applied TXA as a supplement to 
systemically delivered TXA significantly reduced the amount of replacement 
therapy with factor VIII. The second study [82] was a randomised controlled, 
double-blind trial of 39 patients undergoing oral surgery. Patients were receiving 
anticoagulant agents because of the presence of a prosthetic cardiac valve. The 
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patients did not stop anticoagulant therapy. Before wound closure, the wound 
was irrigated with 10 ml of a 4.8 percent aqueous solution of TXA in 19 patients 
and with a placebo solution in 20 patients. For seven days thereafter, patients 
were instructed to rinse their mouths with 10 ml of the assigned solution for two 
minutes four times a day. Eight patients in the placebo group had a total of 10 
postoperative bleeding episodes, whereas only 1 patient in the TXA group had 
a bleeding episode (P = 0.01). There were no systemic side effects.  Another 
study showed that mouth washing with TXA does not lead to increase in serum 
levels [90] . 
 
De Bonis [84] conducted a small prospective, randomised, double-blind trial of 
patients undergoing coronary artery bypass operations: twenty patients re-
ceived topical TXA and 20 received placebo. 
Chest tube drainage in the first 24 hours was 485 ± 166 ml in the TXA group 
and 641 ± 184 ml in the placebo group (P = 0.01). Total postoperative blood 
loss was 573 ± 164 ml and 739 ± 228 ml, respectively (P = 0.01). There was no 
significant difference in blood transfusion between the two groups. TXA could 
not be detected in any of the blood samples collected blinded from 24 patients 
to verify whether any systemic absorption of the drug occurred.  
 
A randomised controlled trial from Egypt recruited 100 patients scheduled for 
elective open heart surgery. In one group, TXA (2g in 100 ml of saline solution) 
was poured into the pericardial cavity before sternal closure. The placebo group 
received 100 ml of saline. Blood loss was significantly higher in the placebo 
group compared to topically applied TXA (1208 ± 121 ml vs. 733 ± 93 ml; P< 
0.001). The placebo group received (4.54 ± 1.4 units) as compared to TXA 
(2.64 ± 1.5 units) (P < 0.01).  
 
In a recent publication, Baric-Daver [86] and colleagues compared the efficacy 
of topical application of 1 million IU of Aprotinin, 2.5 gram of TXA and a placebo 
in 300 adult undergoing cardiac surgery. They concluded that topical use of ei-
ther TA or Aprotinin efficiently reduces postoperative bleeding. The authors 
noted that TXA seemed to be at least as potent as Aprotinin, but potentially 
safer and with better a cost−effectiveness ratio. 
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Krohn investigated the effect of TXA given locally in the wound after spinal sur-
gery in 30 patients [89]. Sixteen participants received topical TXA and 14 re-
ceived a placebo. Blood loss was reduced by half from 525 (325-750) ml to 252 
(127-465) ml, (P = 0.02). None received allogeneic blood transfusion; however, 
two patients received autologous blood in the TXA versus 9 in the placebo 
group. 
 
Compared with IV administration there are obvious potential advantages to the 
topical use of TXA. It is easier to prepare, quicker to administer and provides a 
higher concentration at the bleeding site without systemic involvement. Hence, 
this mode of administration was chosen to be investigated in a placebo-
controlled trial of topical (intra-articular) TXA in total knee replacement. 
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Chapter 3 
Research Methodology 
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3.1 Introduction  
It is apparent from the systematic review of published studies (chapter 2) that 
no trial has been attempted of topical Tranexamic acid (TXA) to reduce bleeding 
in total knee replacement (TKR). Thus, the research hypothesis is that topically 
applied TXA can reduce blood loss and blood transfusion significantly in TKR. 
The rationale for topical (intra-articular) application includes: 
1. Delivering a maximum concentration at the bleeding site, potentially en-
hancing the treatment effect. 
2. Reducing systemic TXA concentration, which may reduce systemic side 
effects. 
3. Quicker preparation and easier application. 
 
Randomised controlled trials (RCT), when appropriately designed, conducted, 
and reported, represent the gold standard in evaluating healthcare interventions 
[91]. They are prospective in design with random allocation of participants to 
control and intervention groups. When adequately powered and designed an 
RCT can detect differences between a new treatment (such as our intervention) 
and routine practice with the difference confidently attributed to the intervention.  
Hence, this design was chosen to investigate topical (intra-articular) TXA in 
TKR surgery. 
 
The trial research protocol (Appendix 3.1 Research protocol) and methodology 
were developed and reviewed by official research bodies, internal and external 
reviewers who are experts in their fields. Comments received strengthened dif-
ferent aspects of the trial methodology and refined the protocol to adequately 
address the research question.  
 
Consensus amongst clinical colleagues was that a reduction in the blood trans-
fusion rate from 30% to 10% and a 50% reduction in blood loss would be clini-
cally important. This view was supported by the literature and several studies 
which showed this amount of reduction is achievable using antifibrinolytics. As 
seen in chapter 2, TXA and other antifibrinolytics agents when used intrave-
nously reduced blood loss and blood transfusion by about 50%.  
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3.2 Trial design 
This was a parallel arm, double blind randomised controlled trial. Participants, 
surgeons and assessors were blinded to the assigned intervention. Allocation to 
treatment and placebo groups was in the ratio 1:1. 
 
3.3 Recruitment 
Patients were introduced to the trial in the pre-assessment clinic at approxi-
mately 3 weeks before their operation. The trial was discussed with them and a 
written information sheet was supplied (Appendix 3.2 Patient information sheet). 
Contact details were provided so that potential participants could discuss any 
issues before admission.  
 
On admission, medical records of potential participants were checked to confirm 
that they met the inclusion criteria and they had not already refused to take part 
in the trial. Then they were approached by a designated, trained research staff. 
The trial was explained again, participants were given the opportunity to ask 
any further questions. If they agreed to take part in the study, they were asked 
to complete and sign the consent form (Appendix 3.3 Consent form). It was re-
peatedly made clear that there was no requirement to participate and that re-
fusal would not prejudice continued care in any way. The general practitioners 
(GP) of the recruited patients were informed by a postal letter (Appendix 3.4 
General practitioner notification letter). 
 
Outcome measures (Oxford knee score and EuroQol) were completed in the 
pre-assessment clinic; however, if this was not the case, they were completed 
at this stage. Baseline demographics were recorded in data collection sheet 
(Appendix 3.5 Data collection sheet). 
 
3.4 Inclusion and exclusion criteria 
Inclusion criteria:    
1. Patients undergoing a unilateral primary cemented total knee replace-
ment. 
 
Exclusion criteria: 
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1. Patients undergoing primary total knee replacement for trauma or tu-
mour, bilateral TKR or revision TKR. 
2. Allergic to TXA. 
3. Bleeding tendency (e.g. haemophilic and platelets disorders). 
4. Warfarin, treatment dose of LMWH or conventional heparin. 
5. Paget‟s disease. 
6. History of DVT or pulmonary embolism. 
7. Renal failure with creatinine > 250 micromole/l. 
8. Pregnant (all female subjects of child bearing potential must have a 
negative pregnancy test). 
 
Permitted therapies included: 
1. Aspirin. 
2. Subcutaneous prophylactic conventional or LMW heparin.  
 
Some exclusion criteria were included to minimise the variation in blood loss. 
Small numbers of patients with haemophilia, platelets disorders and Paget‟s 
disease could bleed excessively and adversely affect the results. However, par-
ticipants with such exclusion criteria may be ideal candidates for TXA treatment. 
Exclusion criteria were printed as a checklist on the back of the consent form. 
All items in the list had to be checked when patients were randomised (Appen-
dix 3.6 Trial checklist). 
 
3.5 Allocation and blinding 
On arrival to theatre, a designated research nurse verified the relevant docu-
ments and ensured eligibility for inclusion in the study. The participant was then 
randomised through the sealed envelope web site: 
http://www.sealedenvelope.com/tranxk/ 
 
“Sealed Envelope” is an independent company that provides online / phone 
randomisation. Designated theatre staff were issued with passwords and 
trained to randomise participants, prepare the study medicine and complete the 
trial registry which was kept in theatre as described in the theatre protocol (Ap-
pendix 3.7 Pharmacy and theatre protocol).  
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This method of randomisation protects the concealment of allocation, removing 
potential biases and inefficiencies that can occur with traditional sealed enve-
lope or coin tossing methods. The allocation of treatment was kept concealed 
from all professionals delivering patient care. Both treatment and placebo have 
the same colour, smell and feel ensuring blinding is maintained throughout the 
trial. 
 
Blocked randomisation was used in blocks of six in order to keep the sizes of 
treatment groups similar. Randomisation was stratified at the level of the sur-
geon to achieve balance within the two groups since differences among sur-
geons were seen as an important potential source of variation. 
 
The trial registry was kept in theatre and could be accessed in emergency situa-
tions. A trial label was stuck on the front of each participant medical record 
showing the name of the trial, the identifier number, date and contact details. 
 
3.6 Intervention 
The operation was performed in the standard manner as described in chapter 1. 
Normally, no chemical intervention is used to reduce blood loss. In this study, at 
the end of the operation and before closing the wound, the study drug (either 
TXA or a placebo) was applied by spray into the wound. The wound was then 
closed and dressed in the normal way followed by the release of the tourniquet. 
Drains were released after one hour in recovery as is routine.  
 
The designated theatre staff prepared the study drug under completely aseptic 
conditions. Tranexamic acid (1 g) was made up to 50 ml with normal saline. 
Placebo was 50 ml of saline.  
 
Type of anaesthesia, type of warming, tourniquet time, operative blood loss and 
any unexpected events were all recorded on the trial data collection sheet (Ap-
pendix 3.5 Data collection sheet). 
  
Operative blood loss (ml) was calculated by subtracting the washout fluid from 
suction drain volume. This was added to the amount soaked up by the swabs. 
75 
 
Swabs were weighed before (dry weight) and after the operation. The difference 
between the two equals the amount of blood soaked up by the swabs. 
 
Because TKR is usually performed in a bloodless field using a tourniquet, op-
erative blood loss was negligible unless the tourniquet was faulty or inappropri-
ately applied. 
 
3.7 Outcome measures 
3.7.1 Primary outcome: blood transfusion 
The need for blood transfusion was the primary outcome measure given its im-
portant for patients, doctors and managers. The proportion of participants who 
received blood transfusions and the amount of blood transfusions in units were 
recorded for both arms of the trial until patients were discharged. 
 
Although guidelines are available for blood transfusion, there is a wide variation 
in the blood products prescribed in different regions and hospitals in the UK [92, 
93]. To standardise blood transfusion practice and prevent unnecessary blood 
transfusion (chapter 2), a blood transfusion policy was introduced (Appendix 3.8 
Blood transfusion policy). This policy was based on the recommendation of the 
British Orthopaedic Association (BOA) [28], Blood Transfusion Task Force, The 
British Committee for Standards in Haematology [52] and the UK blood transfu-
sion and tissue transplantation services [94].  
 
The policy regulated the blood transfusion indications as follows: 
 Blood transfusion is not indicated when Haemoglobin concentration is 
more than 10 g/dl. 
 Blood transfusion is indicated when Haemoglobin concentration is < 7 
g/dl. Blood transfusion should be given in relation to the rate of red cell 
loss. In otherwise stable patient, 2 units of red cell should be transfused 
and then the clinical situation and Haemoglobin concentration should be 
reassessed. 
 In patients who tolerate anaemia poorly, for example, patients over 65 
years or those with cardiovascular diseases or respiratory diseases, con-
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sider adopting a higher threshold level for blood transfusion (when Hae-
moglobin concentration is < 8 g/dl). 
 Blood transfusion is indicated in patients with haemoglobin between 7 
and 10 g/dl if they are symptomatic.  
 The Haemoglobin level should be checked the next day after the transfu-
sion and the same protocol is applied if the Haemoglobin level is low. 
 
3.7.2 Secondary outcomes 
3.7.2.1 Drain blood loss (first 48 hours) 
Total knee replacement is performed in a bloodless field. The blood is exsan-
guinated from the limb and a tourniquet applied around the thigh. At the end of 
the operation, a vacuum drain is placed in the joint cavity. The wound is closed 
and a pressure dressing is applied. Then the tourniquet is released allowing the 
blood to flow into the limb. Any bleeding is removed by the vacuum drain. 
Hence drain blood loss is a good reflection of total blood loss after total knee 
replacement.  
 
Measuring the drain blood loss was standardised as follows: 
1. Drains should remain clamped after the operation for 30 minutes. 
2. The reading should be performed by placing the drain bottle on a flat ta-
ble with the eyes level with the blood level. 
3. The amount of blood is recorded at least twice a day. 
4. When the drain becomes full, it is clamped, recorded and replaced. The 
time of replacement is noted. 
5. The drains are removed after 48 hours. 
The outcome was the total amount of drainage over 48 hours measured in ml.  
 
3.7.2.2 Haemoglobin and Haematocrit drops 
Blood tests were performed in the pre-assessment clinic and on the second 
postoperative day unless there was a specific reason to do it earlier or more 
frequently. Fall in the Hb and Hct levels are good indicators of blood loss during 
surgery. However, these levels may be normal during the immediate postopera-
tive period and not reflect the true amount of blood loss. This is because during 
acute blood loss, there is a loss of both red blood cells and plasma (solutes and 
solvent) so the concentration remains normal or minimally changed. The body 
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starts compensating over the first 48 hours by conserving water thus diluting the 
blood. Therefore Hb and Hct levels will fall subsequently. 
 
3.7.2.3 Generic quality of life measure (the EuroQol Questionnaire)  
The EuroQol Questionnaire is designed for self-completion by participants in 
two parts: EQ-5D and EQ-VAS. It is cognitively simple and takes only a few 
minutes to complete (Appendix 3.9 the EuroQol Questionnaire). The EQ-5D de-
scriptive system is comprised of five questions in the dimensions of: mobility, 
self care, usual activities, pain/discomfort and anxiety and depression. Each di-
mension has three levels scored from 1 to 3: no problems (1), some problems 
(2) and severe problem (3).  For example, state 11111 indicates no problems on 
any of the 5 dimensions while state 11223 indicates no problems with mobility 
(1) and self care (1), some problems with performing usual activities (2), mod-
erate pain and discomfort (2) and extreme anxiety or depression (3). This de-
scriptive system can be converted to a weighted index to aid statistical compari-
son. Additionally, the EQ-VAS records the participant‟s self rated health on a 
vertical visual analogue scale (VAS) where the top of the scale represents the 
best imaginable health state and the bottom of the scale represents the worst 
imaginable health state.  
 
EuroQol instrument was developed by the EuroQol group between 1987 and 
1990 [95] and underwent subsequent validation and reliability testing. The Eu-
roQol questionnaire has been assessed for construct and convergent validation 
as well as test-retest reliability [96, 97] 
 
There are studies which looked at other aspects of the valuation of the EuroQol 
such as response-bias, feasibility, interclass reliability and effect of duration. 
These provide evidence that the EuroQol is a valid, reliable, patient and clini-
cian friendly instrument. 
 
The questionnaire is completed in the pre-assessment clinic or on admission for 
preoperative health state and at about 3 months after the operation in the follow 
up clinic for postoperative health state. This was completed as recommended 
by the EuroQol group in their user guide version 1.0 November 2007 [98]. 
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3.7.2.4 Disease specific scale: Oxford knee score  
The Oxford knee score was developed by the Oxford Group in 1998. It has 
been validated against the Health Assessment Questionnaire, SF-36, The 
American Knee Society Scoring System, The WOMAC (Western Ontario and 
McMaster Universities) Index of Osteoarthritis, the Nottingham Health Profile 
(NHP), and sickness impact profile [99-101]. It is comprised of 12 questions 
each scored from 4 to 0, with 4 representing the best outcome/least symptoms 
(Appendix 3.10 The Oxford knee score). The scores of each question are added 
so that the overall figure lies between 0 to 48 as recommended [102]. The OKS 
is completed in the pre-assessment clinic or on admission and at about 3 
months after the operation. 
 
3.7.2.5 Length of stay (LOS) 
All participants were admitted on the day of surgery as per routine practice. The 
discharge day was not counted as part of length of stay. For example, a patient 
who was admitted on the first day of May and discharged on the fifth of May 
would have stayed 4 days only. Patients who were transferred to other speciali-
ties due to complications were not considered discharged and the period was 
counted as part of the LOS. 
 
3.7.2.6 Economic analysis 
Inpatient resources that might vary between the TXA and placebo groups were 
identified and recorded for each participating patient. These included length of 
stay, blood transfusion, TXA and complications. Resources were costed using 
hospital unit costs. The economic analysis took the form of a cost and conse-
quences analysis where the net cost of care is set against the profile of treat-
ment effects rather than having one unambiguous treatment effect (cost-
effectiveness analysis) 
 
3.7.2.7 Complications 
3.7.2.7.1 Wound infection 
Wound infection occurs in 0.2-1.7% of patients and determined by a clinical di-
agnosis. Swelling, redness, hotness, tenderness and high temperature are car-
dinal signs of infection, which is usually associated with rising white blood cell 
and inflammatory markers and confirmed by microbiological test. For the pur-
79 
 
pose of the study, clinical findings are essential to the diagnosis of infection, 
with or without investigative confirmation. Raised WBC and inflammatory mark-
ers are common after TKR. Microbiology swabs can be contaminated and can 
be inconclusive. Infection is considered superficial if resolved with oral antibiot-
ics only and it is considered deep if not controlled with oral antibiotic or required 
a washout/ debridement or revision surgery [103, 104]. 
 
3.7.2.7.2 Deep venous thrombosis (DVT) 
The occurrence of DVT after TKR is controversial and its frequency has 
changed with the changing practice of joint arthroplasty over the decades. Early 
studies when patients were kept immobilised in bed for long period of time 
showed a very high incidence of 41%-85% for distal DVT and 5-22% for proxi-
mal DVT [105]. More recent studies report much lower rates. DVT is taken seri-
ously by the orthopaedic team because its treatment by anticoagulation carries 
a significant risk to joint replacements by haematoma or infection. Two thirds of 
DVTs are silent and do not cause symptoms, others can present with classical 
features of swelling of the leg, hotness and pain in the calf. Unfortunately, these 
symptoms and signs are very common after TKR making clinical diagnosis un-
reliable. The current practice is to start patients with suspected DVT on a treat-
ment dose of LMWH and perform a confirmatory test such as a Doppler ultra-
sound or venogram as soon as possible. Ultrasound has an average sensitivity 
and specificity of 97% for proximal deep vein thrombosis [106]. Contrary to di-
agnosing infection, the diagnosis of DVT in our study is based on confirmatory 
ultrasound rather than the clinical finding. If the scan is negative, the diagnosis 
of DVT is excluded. Occasionally, when the clinical picture of DVT is convinc-
ing, the ultrasound scan is repeated.  
 
3.7.2.7.3 Pulmonary embolism (PE) 
Pulmonary embolism occurs when a thrombus or clot migrates to the lung. It 
can be asymptomatic, symptomatic or fatal. As with DVT, the incidence is con-
troversial and the reported figures of symptomatic PE vary from 1.5 to 10% and 
fatal PE from 0.1 to 1.7%. Unfortunately, all available objective tests have clini-
cal or practical limitations. The ventilation–perfusion lung scan has been the 
first-line test for more than 20 years. However, 60% to 70% of lung scans are 
non-diagnostic. Use of helical CT in the diagnosis of PE has not been ade-
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quately evaluated, particularly in peripheral PE. The safety of withholding anti-
coagulant treatment in patients with negative results using helical CT is uncer-
tain. Pulmonary angiography is the gold standard, but it is invasive and expen-
sive, may be impractical or unavailable in some clinical settings and carries car-
diac or pulmonary complications in 3% to 4% of patients. In our current practice, 
a physician is consulted to make a definite diagnosis. Pragmatically, if a patient 
were treated for PE by a physician, they were regarded as having a PE. The 
use of a confirmatory test was noted [105, 107, 108] . 
 
3.7.2.7.4 Myocardial infarction (MI) 
The reported incidence of MI is 0.4% usually presenting as chest pain which 
must be differentiated from other causes of chest pain common in patients on 
orthopaedic wards. An MI can be silent without any pain, particularly in postop-
erative patients with diabetes mellitus. Within the trial, the diagnosis of MI 
needed to be confirmed by rising cardiac enzyme (Troponin T) and / or ECG 
changes in the form of ST elevation, Q-wave and T wave changes [109]. 
 
3.7.2.7.5 Cerebrovascular accident (CVA) 
CVA is not common after joint replacement and diagnosis can be difficult be-
cause similar clinical events can be caused by different pathological processes. 
A CT scan is the gold standard test, readily available in our centre as indicated 
for patients with a suspected stroke. A CT scan will usually demonstrate the site 
of a lesion and distinguish between a haemorrhage and infarction. It also rules 
out or shows unexpected causes. A limitation of CT scan comes in diagnosing a 
CVA caused by infarction as it may take several days before an infarction is de-
tectable by a CT scan [15]. 
 
3.7.2.7.6 Death before discharge 
Seah et al [108] reviewed 2219 TKRs performed in their centre from 1998 to 
2001. They found the mortality rate within 30 days of TKR was 0.27% (6 of 
2219 patients). Gill [110] investigated 90 day mortality in 3048 consecutive pri-
mary TKRs, the mortality rate was 0.46%. Death before discharge was recorded 
although the study was not powered to show changes in this outcome. 
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3.8 Number of subjects and duration 
3.8.1 Number of subjects (sample size) 
To detect a reduction in the transfusion rate from 30% to 10% with 80% power 
and alpha of 5% required a sample size of 144 patients (72 in each group) (cor-
rected Fisher exact test). 
 
A previous study [111] reported mean blood loss of 1191 ml (SD 669) following 
TKR. By design, 90% power to detect a 50% reduction in mean blood loss (from 
1191ml to 595ml) at the 5% significance level requires 54 patients (27 in each 
group). Thus the study was overpowered to detect reduction in blood loss (Ap-
pendix 3.11 Power calculation). 
  
The aim was to recruit 150 patients allowing for dropout rate of 10% and provid-
ing adequate power for both primary and secondary endpoints.  
 
3.8.2 Time frame 
Our centre performs around 400 total knee replacements a year. From past ex-
perience, it was estimated that 50% would be willing to participate and that it 
would take about one year to complete recruitment.          
 
3.9 Deep venous thrombosis prophylaxis protocol 
Deep venous thrombosis and pulmonary embolism are not uncommon after 
knee replacement. There has been a wide range of prophylaxis protocols for 
DVT and PE. These have ranged from Physical methods (such as graduated 
compression/anti-embolism stockings, foot impulse and intermittent pneumatic 
compression devices) to pharmacological treatments (such as heparin and war-
farin). Both physical and pharmacological treatments have been shown to re-
duce the incidence of DVT under study conditions. 
 
The pharmacological methods carry a low but significant risk of bleeding. Under 
some circumstances, a low volume bleeding can be a very major complication. 
A few millilitres of bleeding into the brain or compressing the spinal cord within 
the vertebral canal can cause death or permanent disability. Small haemato-
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mata entering an artificial joint can lead a serious infection causing the opera-
tion to fail, leaving the patient worse off than before surgery. 
 
Our centre has a clear protocol for deep venous thrombosis prophylaxis which 
includes the followings: 
 High risk patients (such as patients with a previous history of DVT or PE 
or overweight with a BMI of more than 30 g/m2) should receive a low mo-
lecular weight heparin and calf pump. 
 Low risk patients should receive a calf pump only. 
Patients with previous history of DVT and PE were excluded from our study. 
 
3.10 Withdrawal from the trial 
All patients were permitted to withdraw from the study at any point without 
prejudice to the routine care available. 
 
3.11 Data management and analysis 
All data was stored on a hospital computer in accordance with the Data Protec-
tion Act and accessible only to researchers and the Research Governance 
Committee. The master excel sheet contained no identifiable records. Each pa-
tient had a unique identifiable number which could be traced (if needed) to a 
particular patient. The spreadsheet was encrypted and password protected to 
prevent access in case of accidental loss.  
 
Data analysis was conducted on an intention to treat basis and checked for 
normality using the Kolmogorov-Smirnov test (KST) and the Shapiro-Wilk‟s test 
(SWT). The former was utilised when the sample size more than 50 which was 
the case for most of analyses. The latter test was used when sample sizes are 
small (n < 50). If substantial non-normality was indicated (p<0.05) then non pa-
rametric estimate was provided alongside the parametric findings.  
 
Consistent with large sample assumption, parametric tests were used through-
out. The premise of central limit theorem and large samples is that the theoreti-
cal distribution of sampled means will be normal even if the sampled data are 
not. Where KST or SWT indicated substantial non normality in the sampled 
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data, a bootstrap estimate was provided to explore robustness of estimates 
[112]. Continuous outcomes were analysed by independent (unpaired) t-tests. 
Blood loss, volume transfused, Hb and Hct drop, EuroQol index, Oxford knee 
score, length of stay and overall cost are continuous data. Categorical out-
comes were analysed using Chi Square test or Fisher exact test depending on 
the sample size. The proportion of patients requiring blood transfusion, the pro-
portion of patients taking antiplatelets or anticoagulants and the proportion of 
patients whose operation was done by a particular surgeon are categorical 
data.  
 
The primary endpoint was the proportion of patients undergoing transfusion. 
Secondary endpoints were seen as supportive to the primary endpoint only. 
Thus there is no adjustment of statistical significance for multiple inferences. All 
tests were two-tailed and considered statistically significant at the 5% level. Sta-
tistics were obtained using SPSS for Windows statistical programme version 19 
(SPSS Inc., Chicago, USA). 
 
3.12 Safety Profile 
3.12.1 Definitions 
Adverse Reaction (AR):  A treatment related untoward and unintended re-
sponse in a participant to the study treatment as stated in the Summary of 
Product Characteristics (SmPC) for TXA. The followings are recognised reac-
tions to TXA [113]: 
 
1. Nausea 
2. Dizziness 
3. Vomiting 
4. Diarrhoea 
5. Allergic skin reaction (uncommon) 
6. Rare cases of thromboembolic events and impaired colour vision have 
been reported with use of TXA. 
 
Adverse Event (AE): Any untoward medical occurrence in a participant to whom 
the study drug has been administered. These include the complications of TKR 
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as well as ARs mentioned above. The followings have been reported as poten-
tial complications [50, 103-105, 108, 109]  
 
1. Nausea and Vomiting. 
2. Dizziness. 
3. Pain (acute and chronic). 
4. Bleeding. 
5. Stiffness. 
6. Neurovascular injuries. 
7. Deep venous thrombosis. 
8. Chest infection. 
9. Pulmonary embolism. 
10. Myocardial infarction. 
11. Cerebrovascular accidents. 
12. Infection. 
13. Loosening of the prosthesis. 
14. Death. 
 
Serious Adverse Event (SAE) or Serious Adverse Reaction (SAR): Means any 
of the above AEs or ARs respectively if:  
 
1. They results in death. 
2. They are life threatening. 
3. They results in inpatient hospitalisation. 
4. They results in a persistent or significant disability / incapacity. 
5. Important medical events that may not result in death, be life threatening, 
or require hospitalisation may be considered serious adverse drug 
events when, based on appropriate medical judgement, they may jeop-
ardise the patient and may require medical or surgical intervention to 
prevent one of the outcomes listed in this definition. Examples of such 
medical events include acute renal failure, allergic bronchospasm requir-
ing intensive treatment or blood dyscrasias. 
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Suspected Serious Adverse Reaction (SSAR): means one of the above men-
tioned adverse reactions of the Tranexamic acid that is classed in nature as se-
rious. 
 
Suspected Unexpected Serious Adverse Reaction (SUSAR): means an adverse 
reaction that is classed in nature as serious and which is not consistent with 
prior information about Tranexamic acid. 
 
3.12.2 Adverse Events / Reactions Monitoring 
The occurrence of serious and non serious AEs and ARs in patients on both 
trial arms were recorded while they were in hospital or at each subsequent hos-
pital visit. Patients were asked about hospitalisations, consultations with other 
medical practitioners, disabilities or incapacity or whether any other adverse 
events had occurred.  
 
SAEs were assessed and recorded in the patient‟s medical notes including the 
start dates (if known) of the onset of the event as well as the date the event 
stopped or changed, treatment and outcome; if applicable. 
 
3.12.3 Adverse Event / Reaction Reporting 
A standard operating procedure was developed to regulate AE and AR report-
ing. This includes the following: 
 
 Non serious adverse events were recorded but not reported to the regu-
latory authorities. These are quite common and mostly self limiting in the 
first few days after surgery.  
 Serious adverse events were reported to the Principal and Chief Investi-
gators within 24 hours and evaluated for seriousness, expectedness and 
severity by them. 
If there was a significant increase in the incidence of SAEs above the re-
ported incidence, the local trust R&D department (the sponsor) was in-
formed and consulted. The causality of each SAE was evaluated by the 
data monitoring committee (see below) and if the causality of these SAEs 
was linked to the Tranexamic acid, it was reported to the Medicine and 
Health Products Regulatory Authority (MHRA) and Research and Ethics 
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NHS Committee (REC) within 7 days if the event was fatal or life threat-
ening or 15 days if the event was not fatal or life threatening. 
 In accordance with the EU directive (article 16 & 17) the principal investi-
gator reported SUSARs to the chief investigator and the local trust R&D 
department (the sponsor) within 24 hours of becoming aware of the 
event. The chief investigator and the sponsor reported SUSARs to the 
MHRA and REC within the required reporting timelines. 
 
We provided the following information when reporting an SAE: 
 
1. Protocol identification (Centre number and patient unique identification 
number). 
2. Subject identification (Patient initials, date of birth, sex). 
3. The description of the SAE, intervention and the outcome. 
4. Relevant medical background. 
5. Any other available information requested by the MHRA and REC or the 
local R&D department. 
 
3.12.4 Data monitoring committee and interim analysis 
A data monitoring committee was convened and included Professor James Ma-
son and Professor Hungin from the School of Health and Medicine, University of 
Durham. They were not actively involved in the delivery of research project. 
Data were reviewed by them when 75 patients had been recruited to assess the 
safety profile or earlier if safety concerns arose. The O‟Brien-Fleming approach  
[114] was used to conduct one interim analyses for the first 75 participants. Ex-
ample calculations for prematurely stopping the trial were conducted (see Ap-
pendix 3.12 for detailed interim analysis calculations). 
 
The primary outcome was blood transfusion rate. A reduction in the rate from 
30% to 10% was considered significant. The study was aimed to recruit 150 to 
achieve 80% power at alpha of 0.05. The equivalent nominal P-value to stop the 
trial prematurely is 0.003 for the first 75 patients. 
Simulating this calculation means the trial would be stopped if 19 out of 37 pa-
tients received a blood transfusion in the placebo group versus 5 out of 38 in 
the TXA group. This would be statistically significant with a P-value of 0.000393. 
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Another scenario to stop the trial prematurely would be if there was an increase 
of the proximal DVT incidence from 15% to 25%. The nominal P-value to stop 
the trial would be 0.0002. For example, this would happen if 21 patients out of 
38 who received TXA developed DVT versus 5 patients out of 37 who received 
placebo developed DVT. This would give a P-value of 0.00021.   
 
Theoretically, these interim analyses involve alpha spending and the value of 
statistical significance for the study endpoint should be adjusted. Given the 
small alpha spend; statistical significance remained at 5% for the primary end-
point.
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Chapter 4 
Results  
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4.1 Introduction 
The evidence for the value of Tranexamic acid (TXA) by IV administration in to-
tal knee replacement (TKR) surgery has been established (chapter 2). The use 
of TXA topically applied to the joint is novel and thus is the subject of a trial. The 
methods of the trial are reported in chapter 3 and the findings are summarised 
in this chapter.  
 
4.2 Ethical approvals 
The trial was started on the 1st August 2008 after obtaining the mandatory ap-
provals from: 
1. University Hospital of North Tees and Hartlepool Research and Devel-
opment Department: 7 April 2008 (Reference ORTHO-13) (Appendix 
4.1). 
2. National Research Ethic Service/ Newcastle and North Tyneside 2 Re-
search Ethics Committee: 6 June 2008 (Reference 08/H0906/57) (Ap-
pendix 4.2). 
3. Local Research Ethics Committee /County Durham & Tees Valley 2: 23 
June 2008 (Appendix 4.3). 
4. Medicine and Health Products Regulatory Authority (MHRA): 17 July 
2008 (Reference 21166/0001/001-0002) (Appendix 4.4). 
 
4.3 Recruitment and participants’ flow chart 
Recruitment occurred in the period from 14 August 2008 to 17 June 2009. 
Three hundred and eighty patients were scheduled for TKR during this period. 
One hundred and sixty were not approached at admission due to the non avail-
ability of the designated research staff.  Thirty five refused to take part in the 
study; twenty seven patients were excluded for various reasons such as a histo-
ry of previous DVT, PE or were on Warfarin. One hundred and fifty eight pa-
tients were consented and randomised into the study. One patient allocated to 
TXA was excluded as he underwent a unicompartmental knee replacement 
(UKR) instead of TKR. He did not receive TXA and no postoperative data was 
collected. Therefore the study consisted of 157 participants, 78 were rando-
mised to a placebo and 79 were randomised to TXA (Figure 4.1). Of all patients 
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scheduled for TKR during the study period 42% participated. Of all patients eli-
gible and invited, 82% participated. 
 
Figure 4.1 Flow chart of patients’ recruitment and allocation 
Exclusion criteria (n=27)
Patients not approached due 
to staff unavailability (n=160)
Analysed (n=78)Analysed (n=79)
Received placebo (n=78)Received TXA (n=79)
Assigned to placebo (n=78)Assigned to TXA (n=79)
Randomised (n=158)
Patients scheduled for TKR 
(n=380)
Patients approached (n=193) Refused (n=35)
Excluded UKR 
(n=1)
 
4.4 Characteristics of the study population 
The two groups were compared in terms of baseline demographic characteris-
tics, preoperative and operative variables to assess comparability as shown in 
table 4.1 (see Appendix 4.5 for detailed statistical analyses). There was a 
chance imbalance in gender with a greater proportion of male patient in the pla-
cebo group (56% versus 39%) in the TXA group (2; P=0.025). The effect of this 
imbalance upon the findings was explored in a sensitivity analyses (see 4.6.5), 
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although there is no prior rationale to believe gender will interact with treatment 
study. 
 
Table 4.1 Baseline characteristics of the study population* 
Variables  Placebo  TXA P-value  
Number  78 79   
Age  (y) 67.1   (SD 10.2) 65.5   (SD 9.6) 0.316  
Male (%) 44      (56%) 30      (38%)  0.025†  
BMI (kg/M2)  31.05 (SD 5.03) 32.24 (SD 5.93) 0.209  
OA / RA  65/3 72/4  0.448  
IHD (%) 14      (18%) 12      (15%)  0.327  
HT (%) 43      (55%) 39      (49%)  0.144  
CVA / TIA (%) 4        (5%) 1        (1%) 0.159  
DM (%) 5        (6%) 6        (8%) 0.557  
Antiplatelets (%) 27      (35%) 25      (32%) 0.306  
NSAID (%) 21      (27%) 25      (32%) 0.422  
Preoperative HB (g/dl) 
Preoperative Hct 
13.6   (SD 1.3) 
0.397 (SD 0.036) 
13.2   (SD 1.3) 
0.39   (SD 0.038) 
0.134  
0.228 
Preoperative ROM (°) 93.55 (SD 28.14) 96.38 (SD18.38) 0.609 
Preoperative OKS  19.4   (SD 7.7) 19.34 (SD 7.7) 0.968  
Preoperative EQ index  0.431 (SD 0.33) 0.377 (SD 0.31) 0.351  
Preoperative EQ VAS (100) 59.35 (SD 18.3) 61.48 (SD 21.8) 0.579  
DVT prophylaxis (LMWH) (%) 32      (41%) 38      (48%) 0.580 
Tourniquet time (min). 72      (SD 10.2) 74      (SD 10.2) 0.739  
Anaesthesia (GA/SA)  7/65 3/66  0.272 
* See Appendix 4.5 for detailed statistics. 
† Significantly greater proportion of male patients in the placebo group. 
 
4.5 Operative data 
4.5.1 Surgeons 
It is understood that surgeons may vary in their surgical clinical outcomes in-
cluding the level of bleeding and the need for transfusion [115, 116]. Randomi-
sation was stratified by surgeon with a block size of 6 so that each surgeon pro-
vided a comparable number of participants in each arm of the trial. 
 
92 
 
Eight surgeons took part in the trial (Table 4.2). Their contributions varied from 
as low as 2 patients to 37 patients however, this was balanced between the two 
arms of the trial (2; P=0.999). 
 
Table 4.2 Number of procedures performed by surgeons   
  Group Total 
  Placebo TXA   
Surgeon 1 4 4 8 
  2 7 8 15 
  3 7 8 15 
  4 20 17 37 
  5 27 29 56 
  6 1 1 2 
  7 5 6 11 
  8 7 6 13 
Total 78 79 157 
 
 
4.5.2 Type of anaesthesia 
The majority of the participants (125) underwent TKR under spinal anaesthesia 
(SA), ten had general anesthetics (GA), one had GA supplemented with nerve 
block (NB) and one had SA which did not work well and subsequently changed 
to GA (table 4.3). 
 
Table 4.3 Type of anaesthesia used during surgery    
  Group Total 
  Placebo TXA   
Type anaesthesia GA 7 3 10 
  SA 61 64 125 
  GA&SA 0 1 1 
  GA&NB 0 1 1 
Total 68 69 137 
 
There was no difference in the proportion of participants who underwent GA or 
SA in the two arms of the trial (2; P=0.272) 
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4.5.3 Tourniquet times (TT) 
Tourniquet time in our surgical practice is almost equivalent to the operative 
time. All surgeons who took part in the trial followed the theatre protocol which 
stated that the tourniquet should be inflated after draping and before the surgery 
was started. There is a controversy whether tourniquet time affects blood loss 
and subsequent need for transfusion [117-120]. Data on tourniquet times were 
available for more than 85% of the participants. There was no significant differ-
ence between groups (t-test; P=0.788) (table 4.4). 
 
Table 4.4 Tourniquet times between the two arms of the study 
  Group N Mean SD Mean  
Difference 
95% CI  
P-Value 
TT (min) 
  
Placebo 66 73.08 17.284 -0.767 -6.42 to 4.88 
TXA 70 73.84 16.036  0.788 
 
 
4.5.4 Operative blood loss 
All TKRs were performed in a bloodless field using a tourniquet so that intra-
operative blood loss should be minimal [9]. To achieve a true bloodless field 
depends on number factors including the pressure of the tourniquet, the size 
and shape of the leg and the pneumatic cuff, the blood pressure of the patients 
and type of anaesthesia. This range of factors explains the wide range of intra-
operative blood loss in our series (30 ml to 600 ml, median 50 ml). As expected 
intra-operative blood loss was not normally distributed (Kolmogorov-Smirnov 
test; P<0.0001). 
 
The median operative blood loss was 50 ml (range 30-600 ml) in the placebo 
group and 68 ml (range 35-500 ml) in the TXA group.  The difference in me-
dians was 18 ml and this was not statistically significant (Mann Whitney U test; 
P=0.577) (see Appendix 4.6 for detailed statistical analyses).  
 
4.6 Outcomes (postoperative) data 
4.6.1 Blood transfusion 
Fourteen participants received a blood transfusion ranging from 2 to 6 units. 
Thirteen participants (16.7%) were in the placebo group and one patient (1.3%) 
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in the TXA group. There was a statistically significant reduction in the use of 
transfusion (Fisher exact test; P=0.001).  
 
A total of 34 units of blood were used. Thirty two units were transfused to partic-
ipants in the placebo group versus two units only to a participant in the TXA 
group. This was a statistically significant finding (Mann Whitney U, Z=-3.38; 
P=0.001). 
 
Within the Tranx-K trial, a single participant received a blood transfusion in the 
TXA group. She was 76 years old lady, overweight (BMI=48.5) with significant 
co-morbidities including ischaemic heart disease, hypertension and hypercho-
lesterolemia, and on aspirin. Her drain blood loss was 450 ml and her postop-
erative Hb level was 8.6 g/l. She developed chest pain and tachycardia which 
was relieved by her anti-angina treatment. She was given two units of blood as 
per trial protocol. The same patient developed a DVT later which was subse-
quently treated with Warfarin.  
 
4.6.2 Drain blood loss 
Drain blood loss was measured in ml. Data from 83% of participants were eligi-
ble for inclusion and analysis. Some drains were removed without recording the 
amount of blood loss and several drains fell out during recovery. Data on drain 
blood loss was non-normally distributed (KST < 0.001). Although the large 
sample assumption validates a parametric testing approach, non parametric 
findings are also provided.  
 
The mean drain blood was 465 ml (SD 298, N=65) in the placebo group and 
296.7 ml (SD 195.6, N=64) in the TXA group. The mean difference was 168 ml 
(95% CI: 80 to 256 ml, p=0.00025). The Bootstrapped estimate of the mean dif-
ference was 168 ml (95% CI: 85 to 256 ml, P=0.001) (tables 4.5 and 4.6).  
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Table 4.5 Drain blood loss; parametric t-test 
  Group N Mean SD Mean  
difference 
95% CI  
P-value 
Drain  Placebo 65 465 298 168 80 to 256  
   TXA 64 297 196 0.00025 
 
 
Table 4.6 Drain blood loss; non parametric bootstrap  
 Mean  
Difference 
Bootstrapa 
Bias Std. 
Error 
Sig.  
(2-tailed) 
95% Confidence 
Interval 
Lower Upper 
Drain  Equal variances 
assumed 
168 0.347 44 0.001 84 256 
Equal variances 
not assumed 
168 0.347 44 0.001 84 256 
a. Unless otherwise noted, bootstrap results are based on 10000 bootstrap samples 
For completeness, a further non parametric test (the Mann Whitney U) was also 
estimated the finding remained significant (Mann Whitney U, Z= -4.015; 
P<0.001). 
 
4.6.3 Postoperative Hb and Hct 
Blood tests for Hb and Hct were performed on postoperative day 2 unless there 
was a clinical need to do it earlier. There was a full set of data for these va-
riables. Data were normally distributed. There were statistically significant dif-
ference in the reduction of postoperative Hb (-0.83 g/dl; P<0.0001) and Hct (-
0.027; P<0.0001) in the TXA group when compared to placebo (Table 4.7). 
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Table 4.7 postoperative Hb and Hct between the two groups 
  Group N Mean SD Mean  
difference 
95% CI  
P-value 
Postop Hb Placebo 78 10.69 1.35 -0.83 -0.84 to -1.43 
<0.0001   TXA 79 11.52 1.33 
Postop Hct Placebo 78 0.31 0.04 -0.027 -1.26 to -0.41 
  TXA 79 0.34 0.04 <0.0001 
 
 
For completeness these findings were also analysed as change in scores. The 
drop in Hb level after the operation was calculated by subtracting the postopera-
tive Hb level from the preoperative Hb level for the two arms of the trial. The 
mean drop in Hb level was significantly higher in the placebo group. It was 2.89 
g/l in the placebo group vs. 1.75 g/l in the TXA group. Mean difference between 
the two arms was 1.138 g/l (95% CI: 0.84 to 1.43; P<0.00001).  
 
4.6.4 Length of stay (LOS) 
Length of stay data was available for more than 95% of the participants. As data 
were non-normal (Kolmogorov-Smirnov test, P<0.0001), parametric and non 
parametric tests were used to assess the significance of this important out-
come. Patients who received placebo had a mean of stay of 6.1 days in hospital 
while patients received TXA spent 4.8 days with a mean difference of 1.2 days 
(95% CI: 0.053 to 2.425, p-value 0.041), using a parametric approach. Addi-
tionally, the mean and confidence interval were estimated using a bootstrapping 
approach. This found a mean difference of 1.24 days (95% CI: 0.19 to 2.43; 
P=0.052) (Table 4.9). This finding was very similar to the parametric mean and 
confidence interval. 
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Table 4.8 Bootstrap for the length of stay in the two arms of the trial 
 Mean  
Difference 
Bootstrapa 
Bias Std.  
Error 
Sig. (2-
tailed) 
95% Confidence 
Interval 
Lower Upper 
       
LOS Equal variances 
assumed 
1.239 0.0001 0.590 0.052 0.137 2.462 
Equal variances 
not assumed 
1.239 0.0001 0.590 0.053 0.137 2.462 
a. Unless otherwise noted, bootstrap results are based on 10000 bootstrap samples 
 
 
4.6.5 Sensitivity analyses of gender imbalance  
The finding that Table 4.1 reveals that only gender was unusually different be-
tween the two groups. This was explored further by investigating the effect of 
gender (being a male or female) on blood transfusion rate, drain blood loss, Hb 
drop and LOS in the placebo and TXA groups. There were no significant differ-
ences among these outcomes (Table 4.9 and 4.10). Hence, this imbalance be-
tween the two arms of the study regarding the gender had no influence on the 
final conclusion; consistent with prior clinical expectation.   
 
Table 4.9 the effect of gender on the trial findings in the placebo group 
  Variable sex  N  Mean  P-Value  
 
BT  
 
Male 
 
44 
 
5 
 
0.542  
   Female  34  8  
 
Drain (ml)    
 
Male 
 
38 
 
475 
 
0.723 
   Female  29  448  
 
LOS (days)  
 
Male  
 
42  
 
6.33  
 
0.565 
   Female  31  5.71  
 
HB-drop    
 
Male 
 
44 
 
2.95 
 
0.578 
   Female  34  2.82  
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Table 4.10 the effect of gender on trial findings in the TXA group 
  Variable sex  N  Mean  P-Value  
 
BT  
 
Male 
 
30 
 
0 
 
1.000 
   Female  49  1  
 
Drain (ml)    
 
Male 
 
24 
 
357 
 
0.094 
   Female  40  261  
 
LOS (days)  
 
Male  
 
30 
 
4.80  
 
0.894 
   Female  47  4.87  
 
HB-drop    
 
Male 
 
30 
 
1.87 
 
0.337 
   Female  49  1.68 
 
Of interest, both tables revealed that males bled slightly more than females as 
shown by higher drain blood losses and Hb drops. Although, this did not reach 
clinical or statistical significance to influence our conclusions, but the study was 
not powered to detect such a difference (Type II error). 
  
4.6.6 Postoperative outcomes scores 
Postoperative outcome measures (OKS, EQ-5D and EQ-VAS) were completed 
about three months after the operation. Data showed a non normal distribution. 
The differences were estimated parametrically and non-parametrically. There 
were no significant differences between the two arms of the study with regards 
to these three outcomes (table 4.11).  
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Table 4.11 Preoperative and postoperative outcomes scores;  
parametric: t-test 
 Mean 
Placebo 
Mean 
TXA 
Mean  
Difference 
Sig.  
(2-tailed) 
Std. Error  
Difference 
95% Confidence  
Interval  
Lower Upper 
Preoperative 
OKS 
19.4 19.34 0.056 0.968 1.394 -2.704 2.816 
Postoperative 
OKS 
 
35.91 34.83 1.081 0.557 1.832 -2.555 4.717 
Preoperative  
EQ-5D Index 
0.431 0.377 0.054 0.351 0.058 -0.060 0.168 
Postoperative 
EQ-5D Index 
 
0.780 0.705 0.075 0.187 0.057 -0.037 0.188 
Preoperative  
EQ-VAS 
59.35 61.48 2.131 0.579 3.827 -9.714 5.453 
Postoperative  
EQ-VAS 
75.57 75.19 0.382 0.917 3.649 -6.861 7.625 
 
 
4.6.7 Range of motion (ROM) 
Postoperative ROM was measured before the operation and about three 
months after the operation. Data were normal for TXA group but non-normal for 
the placebo group. The differences were estimated parametrically and non-
parametrically and there were no significant differences between the two groups 
of the study (MD=2.8°; 95% CI: -5 to 11, t-test; P=0.45). 
 
4.6.8 Complications 
There were few complications in both arms of the study. These are summarised 
in table 4.12. There were no statistically significant differences between the two 
arms of the study with regards to any of these complications. 
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Table 4.12 Complications in both arms of the trial 
Complications Placebo TXA  Fisher exact test 
Deep Venous Thrombosis  0  2  0.497 
Pulmonary Embolism  0  0   
CVA / TIA  1  0  0.241  
Chest infection  1  0  0.427 
Periprosthetic fracture  1  0  0.427 
Superficial infection  1  1  0.736  
Deep infection  1  0  0.427 
 
 
4.6.9 Cost analysis 
The main cost was that of the index operation which was similar in both arms of 
the trial. However, extra costs were incurred by the cost of blood transfusion, 
LOS and the complications.  
 
Costs were obtained from the Trust‟s Finance department. Hospital procedures 
are charged according to nationally determined tariffs. These are coarsely 
costed by procedures type with some adjustment for complexity. Five tariff 
codes had been used to price the primary TKR in the study (table 4.13). The 
code HO4 was used in the year 2008/9 while others were used in the year 
2009/10. The majority of the operations (n = 104) were priced according to the 
code HO4 which is equivalent to £5663. There was no significant difference be-
tween the two group regarding the tariff codes distribution (2; P=0.29). 
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Table 4.13 Distribution of Tariff codes  
between the two groups of the study 
 Tariff Group Total 
 Code Value (£) Placebo TXA 
Tariff HB21C 4102 6 1 7 
HB21B 4922 18 22 40 
HO4 5663 52 52 104 
HA06Z 7248 1 1 2 
HB21A 7747 1 3 4 
Total 78 79 157 
 
 
Based on tariff charges, the mean cost per patient in the TXA group was £5536 
(SD £607.5) and £5419 (SD £689) in the placebo group. As expected, the data 
was non-normally distributed (KST, P<0.0001). Neither parametric nor non pa-
rametric tests showed a significant difference in the two groups. The limitation 
of the use of tariffs is that they are too crude to capture actual variation in the 
use of resources between patients.  
 
Trial findings showed that patients in the TXA arm had fewer transfusions 2 
units versus 34 units and reduced LOS (4.8 vs. 6.1 days) compared to the con-
trol group. The current cost of one unit of blood is £133 and the cost of one day 
stay in hospital is £230. The cost of two TXA ampoules (1g) is £2.20. The net 
cost of TXA, transfused blood and hospital stay was calculated. The data was 
non- normal (KST P<0.0001). Parametric and non parametric tests were used 
to assess the significance of differences in these patient level costs.  
 
The net cost saving was £333 per patient. The mean net cost was £1117.6 (SD 
537.7) in the TXA group and £1450.8 (SD 1157) in the placebo group. This was 
statistically significant using parametric test (95% CI: 37 to 630; P=0.028) (table 
4.15). A bootstrapping approach based on 10 000 bootstrap samples found a 
similar result to that of the parametric test; mean difference of £333 (95% CI: 
62.35 to 641.21; P=0.044) (table 4.16). 
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Table 4.14 Net cost saving; parametric t-test 
  Group N Mean SD Mean  
difference 
95% CI  
P-value 
Net Cost  
Saving 
  
Placebo 72 1450.88 1156.99 333.27 36.65 to 629.9 
0.028 TXA 77 1117.61 537.7 
 
 
 
 
Table 4.15 Net cost saving; non parametric test: Bootstrap  
 Mean  
Difference 
Bootstrapa 
Bias Std.  
Error 
Sig.  
(2-tailed) 
95% Confidence 
Interval 
Lower Upper 
Net 
Cost 
Equal variances 
assumed 
333.28 0.055 147.23 0.042 62.35 641.21 
Equal variances not 
assumed 
333.28 0.055 147.23 0.044 62.35 641.21 
a. Unless otherwise noted, bootstrap results are based on 10000 bootstrap samples 
 
 
This was not statistically significant using non-parametric test (Mann Whitney U 
test P=0.057). 
 
It was not possible to include the cost of rare complications within studies (see 
4.6.7) because of their chance nature and difficulty identifying total cost of care.  
However, complications identified would be likely to increase the net saving due 
to TXA. 
 
In overview there were borderline statistically significant cost savings which 
should be set alongside the significant reduction in length of stay and transfu-
sion which are important clinical and patient outcomes. 
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4.7 Interpretation of trial findings 
4.7.1 Blood transfusion 
In the systematic review and meta-analysis described in this thesis (chapter 2), 
19 trials were reviewed that used IV TXA in TKR including 1218 participants. 
Thirteen trials compared TXA to a placebo, 2 trials compared TXA to Desmo-
pressin, 1 trial compared TXA to Aprotinin, 1 trial compared TXA to EACA and 1 
trial compared TXA to fibrin spray. All trials but one used IV preparations. The 
mean dose of TXA used ranged from 700 to 10500 mg. 
 
TXA led to a significant reduction in the blood transfusion rate in the 16 trials 
that reported on blood transfusion as an outcome. Of 944 participants, 501 re-
ceived TXA and 443 received a placebo. One hundred and ten (21.9%) partici-
pants received blood transfusion in the TXA group while 214 (48.3%) received 
blood transfusions in the placebo group. Systematically delivered TXA reduced 
the risk of transfusion to about 45% of placebo level (from 48.3% to 21.9%). 
This was statistically significant (RR 2.72; 95% CI: 2.25 to 3.27; P= <0.00001). 
However, there was evidence of significant heterogeneity among the studies (Q, 
P=0.00001; I2 =77%).  
 
The Tranx-K trial recruited 177 participants with 79 receiving TXA and 78 re-
ceived a placebo. One participant (1.2%) only received blood transfusion in the 
TXA group while 13 participants (16.6%) received blood transfusion in the pla-
cebo group. Thus topically applied TXA reduced the risk of transfusion 13 folds, 
a statistically significant finding (Fisher exact test; P=0.001). When compared to 
previous IV administered trials (Figure 4.2 and 4.3), the efficacy of topical TXA 
in reducing blood transfusion was greater. This result was almost matched by 
one trial only (Camarasa 2006) [72] of 127 participants comparing TXA, EACA 
and placebo.  One participant (2.8%) received blood transfusion in TXA group, 
4 (12.8%) received blood in the EACA group and 23 (33.8%) received blood 
transfusion in the placebo group. In spite of the comparable transfusion trigger, 
there was a higher transfusion rate in their placebo group (33.8%) than our 
study placebo group (16.6%). A potential confounding factor was the use of pe-
rioperative Cell Saver in 23.3% of placebo group and 28.6% of the TXA group 
which might have affected the transfusion rate.  
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Figure 4.2 Trials of TXA vs. Placebo; forest plot of  
blood transfusion rate including Tranx-K trial 
 
 
Figure 4.3 Scatter plot of TXA Dose versus the reduction in blood 
transfusion rates* 
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* Tranx-K trial is represented by the red triangle 
 
The implication of the Tranx-K trial finding is that a low dose topically applied 
TXA is more effective than intravenously delivered TXA. This could be ex-
plained by the difference in the volume of distribution of the two mode of deliv-
ery. Intravenous TXA is distributed in the whole body fluid reducing its therapeu-
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tic concentration in the knee while topically applied TXA is distributed in the 
knee joint cavity predominantly, thus achieving a higher therapeutic concentra-
tion.  
 
4.7.2 Drain blood loss 
The meta-analysis (chapter 2) showed that systemically delivered TXA signifi-
cantly reduced external blood loss by192 ml (95% CI: 168 to 217 m; P = 
0.00001) and total blood loss by 591ml (95% CI: 536 to 646 ml; P=0.00001) re-
spectively.  There was significant heterogeneity in the finding (Q, P=0.00001; I2 
=89 %.) and (Q, P=0.0001; I2 =78 %) respectively.  
 
In the Tranx-k trial, this study, the drain blood loss was significantly lower in the 
TXA group. The mean drain blood was 465 ml in the placebo group and 296.7 
ml the TXA group. The mean difference was 168 ml (95% CI: 80 to 256 ml, 
p=0.00025). When this is plotted against other trials results, the study has a 
similar efficacy in reducing drain blood loss to IV TXA, but excluding oral TXA 
(Figure 4.4).  
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Figure 4.4 Graph of TXA dose versus percentage reduction 
 in drain blood loss* 
 
* Tranx-K trial is represented by the red triangle. Trial used oral TXA 
represented by an orange diamond. 
This prompts the question of how topical TXA can be superior in reducing blood 
transfusion in TKR, but no better at reducing drain blood loss.  Operative blood 
loss was negligible in our trial and in published trials and therefore cannot ex-
plain this paradox. 
 
Careful scrutiny of the drain blood loss and transfusion rate among the pub-
lished trials showed no relationship (Table 4.17 and Figure 4.5). For example, 
Zohar [20] showed TXA reduced mean drain blood loss from 259 ml to 110 ml 
and transfusion rate from 65% to 10%.  This is a small amount of drain blood 
loss but a big drop in transfusion rate. Benoni [17] reduced the mean drain 
blood loss from 1210 ml to 520 ml and transfusion rate from 56% to 19%. This 
is a bigger reduction in mean drain blood loss than Zohar, but a smaller drop in 
transfusion rate. 
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Table 4.16Trials providing data on drain blood loss  
and blood transfusion rate 
Study Drain Blood 
loss in placebo  
Transfusion 
rate in placebo 
Drain Blood 
loss in TXA 
Transfusion 
rate in TXA 
Zohar 1999 259 0.65 110 0.10 
Alvarez 2008 551 0.12 170 0.02 
Camarasa 2006 1270 0.34 787 0.03 
Zohar 2001 342 0.55 162 0.15 
Benoni 1996 1210 0.56 520 0.19 
Zohar 2004 short 249 0.60 110 0.10 
Zohar 2004 Long 249 0.60 121 0.15 
Zohar 2004 Oral 249 0.60 231 0.20 
Hiippala 1995 558 0.92 293 0.67 
 
 
Figure 4.5 Graph of the mean differences in drain blood loss  
and risk ratio of blood transfusion rates 
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The review (chapter 2) showed significant heterogeneity in the data of drain 
blood loss in the included trials (Q, P=0.00001; I2 =89 %.) (Figure 2.4) and the 
source of heterogeneity was explored. Tranx-K mean drain blood loss in the 
placebo group data was low when compared to other trials (Figure 4.6). This 
may partly explain the low reduction in mean drain blood loss.  
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Figure 4.6 Mean drain blood loss in the placebo groups in the  
published trials including Tranx-K trial* 
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* Tranx-K trial is represented by the red triangle. 
It is clear that there was a significant amount of blood loss not accounted for. 
The reduction in the amount of drain blood loss and the recorded total blood 
loss were too low to explain the magnitude of reduction in the blood transfusion 
rate. This is true for other published trials.  
 
It is well known that some blood loss is not clinically visible. Eipe [121] showed 
that 64% of surgical blood loss was underestimated using clinical methods as-
sessing blood soaked mops and gauze pieces, measuring blood lost to suction 
bottles and the vacuum drain. He recommended using a biochemical method 
based on Hct. Several formulas can measure the total blood loss using Hct 
changes, such Gross‟s formula [121, 122].  According to this formula, the total 
blood loss can be estimated by the following steps: 
1. The estimated total blood volume (EBV) of an average adult male is 
about 75 ml/kg and that of an average female is about 65ml/kg. 
2. The estimation of red blood cell volume (RBCV) at preoperative Hct.  
RBCV preop = TBV x Hct preop. 
3. The estimation of red blood cell volume (RBCV) at postoperative Hct.  
RBCV postop = TBV x Hct Postop. 
4. The difference in RBCV represents the amount blood loss. 
RBCV dif = RBCV preop- RBCV Postop. 
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5. The blood loss is calculated from the fall in red blood cell volume.  
Blood loss= RBCV dif / Hct Postop. 
The total blood volume of patients at baseline was comparable in the two arms 
of the study. The mean blood volume in the placebo group was 6148 ml (SD 
1595 ml) and 6050 ml (SD 1469 ml) in the TXA group and these variables were 
normally distributed (KST 0.2). The mean difference was 98.6 ml (95% CI: - 
443.8 to 641.1 ml; P=0.72). The mean estimated total blood loss was 1725 ml 
(SD 823 ml) in the placebo group and 918.6 ml (SD 487.3ml) in the TXA with a 
mean difference of 806.3 ml a statistically significant difference (95% CI: 564.7 
to 1048 ml; P<0.0001).This finding was anticipated from fall in Hct and Hb after 
the operation.  
 
The difference between the visible and estimated blood loss, which may also be 
referred to as hidden blood loss,  is caused by haemodilution, haemolysis and 
the blood dissipated in the tissue planes, cavities or drapes. The amount of 
bleeding in the tissues around the wound is difficult to estimate and may be of 
clinical importance. Researchers have tried several techniques to estimate such 
blood loss, all have some limitations.  
 
Benoni et al [17] measured the knee circumference just above the patella on the 
day before surgery and three days after operation. It was found that there was 
no statistical difference between the placebo group and the TXA group in their 
study (2.7± 2.9cm vs. 21.1±4 cm). It is well known that postoperative swelling is 
not always caused by bleeding or haematoma rendering this approach of limited 
value in estimating hidden blood loss. Postoperative swelling can be caused by 
inflammation, tissue swelling, uneven layers closure, anatomical changes 
caused by implant size and position. Furthermore, postoperative swelling re-
duced at various rates among patients.  
 
Ultrasound assessment has been shown as an accurate method to assess the 
number and size of haematomas [123]. Benoni et al [124] investigated the effect 
of TXA on blood loss in total hip replacement (THR) in a placebo controlled trial. 
They used ultrasound to assess the number and size of haematomas in the op-
erated thigh by the same radiologist and found that there was no difference in 
the number and size of haematomas between the two groups (TXA group: 270 
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ml vs. placebo: 319 ml; P=0.20).  Calculating the true volume of effusion and 
haematoma using ultrasound is very difficult because of the numerous synovial 
recesses and complex anatomy of the knee joint and it is operator dependent 
[125]. Furthermore, it is not always readily available and incurs some cost.  
 
In our study, hidden blood loss was estimated using Gross‟s formula. There was 
a statistically significant difference between the two groups with regard to the 
hidden blood loss in favour of TXA use.  The mean difference was 538 ml (95% 
CI: 312 to 763 ml, t-test; P<0.001). The effect of this hidden blood loss on knee 
function was assessed using the Oxford knee score, EuroQol questionnaire, 
range of motion and wound complications. There were no significant differences 
between the above variables in the two groups.  
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4.7.3 Length of stay 
Tranx-K trial found that patients receiving TXA stayed on average 1.24 days 
less than patients receiving placebo (95% CI: 0.19 to 2.43; P=0.052). The 
pooled data from 3 published trials which provided data on LOS (Figure 2.7) 
showed that patients receiving TXA spent an average of 0.77 day less in hospi-
tal than the control group but this was not statistically significant (95% CI: -1.55 
to 0.14 days; P= 0.10). However, including the result of our trial in the analysis 
shifted this to a statistically significant difference of 0.9 day (95% CI: -1.58 to -
0.22; P=0.01) (figure 4.7). 
 
Figure 4.7 Trials of TXA vs. Placebo; forest plot of LOS  
after TKR including Tranx-k study  
 
 
4.8 Summary of findings 
The first trial of topically applied TXA in TKR produced clinically important find-
ings. There was a significant and important reduction in primary end point of 
blood transfusion by 13 folds (16% vs. 1.3%; FET; P=0.01).  This effect was 
greater than that achieved by oral or intravenous modalities published in other 
trials. 
 
Secondary endpoints provided supportive findings consistent with the primary 
endpoint. There were significant reduction in total and drain blood loss, Hb and 
Hct drops and length of stay. There were borderline cost savings from reduced 
transfusion rate and length of stay.  
 
There was no evidence of short term influence on the patient outcome meas-
ures OKS, EQ-5D and EQ-VAS although these measures are not sometimes 
sensitive enough to find small changes in a trial of this size. 
112 
 
 
 
 
 
 
Chapter 5 
The Effect of Tranexamic 
Acid on Artificial Joint  
Materials 
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5.1 Introduction 
A major cause of artificial joint failure is the loosening that occurs as a conse-
quence of wear and tear of the bearing surfaces. Even a well performing pros-
thetic joint releases billions of microscopic wear particles (debris) into the joint 
space. When an excessive amount of debris is generated it may stimulate a se-
vere body reaction in the capsular tissues and bone leading to inflammation and 
osteolysis. The resulting loss of supporting bone may lead to loosening of the 
implants requiring difficult revision surgery. 
 
The artificial knee joint consists of two metal surfaces which are made of cobalt 
chromium (Co-Cr) alloy and an insert made of ultra high molecular weight po-
lyethylene (UHMWPE) (chapter 1). The mechanical properties of these two ma-
terials are influenced by several chemical and physical factors. Oxidation 
breaks down the molecular chains in UHMWPE resulting in increased brittle-
ness and reduced resistance to crack propagation. Historically, there have been 
unfortunate consequences within artificial joints when unexpected and un-
wanted chemical or physical reactions led to severe wear and joint failure. One 
example arose from the storage of artificial implants in air filled packets after 
sterilization using gamma radiation. This mode of storage led to gradual oxida-
tion of the UHMWPE and deterioration of its mechanical properties. This was 
partly overcome by storage within a vacuum-sealed packet. Another example 
was post irradiation thermal treatment to reduce free radicals in the polyethy-
lene. This could cause a partial reduction in crystallinity of the material that, in 
turn reduced the resistance to crack propagation [126]. 
 
The use of local TXA to reduce blood loss in artificial joint replacement might 
effect the biomechanical properties of artificial implants, wear rate and subse-
quent loosening and failure. A rigorous search of the published literature, con-
tact with manufacturers and contact with the community publishing on the use 
of TXA uncovered no research to address this issue. Consequently, reported 
here, is the first study to investigate the effect of local TXA upon artificial joint 
biomechanical properties and performance. The research is named the Bio-
TRANX study. 
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Tranexamic acid is a white crystalline powder. The aqueous solution for injec-
tion has a pH of 6.5 to 8.0 ranging from mild acid to mild alkaline.  
 
5.2 Declaration 
The BioTRANX study was conducted in the Bioengineering laboratory of School 
of Engineering and Computing Sciences, Durham University, South Road, Dur-
ham DH1 3LE between October 2009 and April 2010. All testing materials were 
provided free of charge by DePuy International ltd. 
 
5.3 Methodology 
In this biomechanical study we investigated the effects of TXA on the following 
biomechanical properties of artificial knee materials: 
 
1. Tensile properties of the UHMWPE: 
a. Ultimate strength. 
b. Stiffness. 
c. Young Modulus. 
 
2. The wear rate using a multi-directional pin-on-plate machine. Pins were 
made of UHMWPE and plates were made of Co-Cr. 
 
3. The surface topography of pins and plates before and after wear rate 
testing:  
 
a. Peak-Valley ratio (PV). The distance between the highest peak 
and the deepest valley over the entire evaluation length (Figure 
5.1). 
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Figure 5.1 Peak-Valley ratio (PV) 
 
 
b. Root mean square roughness (rms). An average of the measured 
height deviations taken within the evaluation length or area and 
measured from the mean linear surface.  
c. Surface roughness average (Ra). The average roughness or de-
viation of all points from a plane (centre line) fitted to the test sur-
face (Figure 5.2). 
 
Figure 5.2 Surface roughness average (Ra) 
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5.3.1 Tensile testing  
The test was conducted by gripping the ends of a standardised test specimen 
made of UHMWPE (Figure 5.3), in a tensile test machine (Figure 5.4) and then 
applying a gradually increasing axial load until failure occurs. This produces a 
typical stress-strain curve (Figure 5.5). 
 
Figure 5.3 Tensile specimens made of UHMWPE 
 
 
117 
 
 
Figure 5.4 Tensile testing machine with  
a specimen made of UHMWPE mounted 
 
 
Several calculations can be made to describe the biomechanical properties of a 
material from its stress-strain curve. Stress is the force applied per unit area 
(N/m2). Strain is the change in length divided by the original length. The stress 
obtained at the highest applied force is the Ultimate Tensile Strength. The stiff-
ness is the resistance of material to deformation while Young‟s modulus is 
found by dividing the stress by strain over the linear portion of stress strain 
curve [127]. 
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Figure 5.5 A typical stress-strain curve 
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Fifteen tensile specimens were made of UHMWPE (Figure 5.3), five were 
soaked in TXA solution (1 g / 50 ml saline) for 48 hours, five were soaked in 50 
ml of saline and the other five were used to standardise the tensile testing ma-
chine. Specimens were placed in the testing machine and a gradually increas-
ing load was applied until failure of the specimen. Ultimate tensile strength, 
stiffness and Young‟s modulus were calculated for each specimen.  
 
5.3.2 Wear rate 
In addition to simple load testing, continuous motion wear testing was per-
formed to assess the influence of TXA under accelerated body wear conditions. 
This test was performed using a multidirectional pin-on-plate machine (Figure 
5.6). It is a four station machine applying both reciprocational and rotational mo-
tion. The reciprocation was applied by a sledge moving forward and backward 
over a 4 cm range (± 2 cm) at 60 cycles per minutes. The heated bed, lubricant 
tray, level sensor and plate holders are positioned on this sledge. 
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Figure 5.6 Schematic diagram of the pin-on-plate machine 
 
1= weight to provide load; 2= lever arm; 3= gear; 4= pin holder; 5=UHMWPE pin; 
6=heater bed; 7=Co-Cr plate; 8=motor to provide reciprocation; 9=level sensor; 
10=motor; 11=gear). 
Reproduced with permission of SAGE Publications Ltd, London, UK 
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5.3.2.1 Plates wear rate testing 
The plates were made of Co-Cr. Four plates were fitted to the tray and secured 
with three metal plates and screws. They were covered with lubricant and 
heated to 37° C (body temperature) (Figure 5.7).  
 
Figure 5.7 The pin-on-plate machine sledge with four Co-Cr plates 
mounted 
Co-Cr Plate mounted on the 
sledge
UHMWPE Wear 
debris 
 
 
5.3.2.2 The lubricant 
The lubricant used in all tests was a 24.5% concentration of bovine serum (pro-
tein content: 15 g/l) and was prepared in the following protocol: 
1. Defrost concentrated serum in a heated water bath at a temperature of 
37°C. 
2. Fill a large beaker with 3L of deionised water and place on a stirring 
stage. 
3. Add 6 pellets of Sodium Hydroxide and stir for 5 minutes until the pellets 
have fully dissolved. 
4. Add 29.78 g of EDTA and stir for 5 minutes until the EDTA fully dis-
solves. This was used to prevent calcium deposition.  
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5. Add 8.0 g of Sodium Azide and stir for 5 minutes until solution is clear. 
Sodium Azide was used to slow the growth of bacteria. 
6. Add 1L of concentrated Serum and stir until dispersed equally in solution. 
7. Transfer to 8 x 500ml bottles, label, and store in freezer. 
 
Each test episode consumed a single bottle of lubricant. A lubricant level sensor 
was attached to the lubricant tray to allow the lubricant to be maintained at an 
almost constant level. This was topped up from a reservoir of distilled water.  
The rotational motion was provided by 4 small motors.  
 
5.3.2.3 Pins wear rate testing 
Pins were made of UHMWPE. Each pin was numbered, notched and tightly fit-
ted to the pin holders at the end of each motor (Figure 5.8). The cycle frequency 
was set at 60 per minutes (1Hz). 
 
Figure 5.8 An UHMWPE pin mounted on a motor 
UHMWPE pin mounted on a 
motor
 
The four loaded pins were held in stainless steel holders and mounted so that 
each pin rested on the corresponding plate. A load of 40N was applied to each 
station via a lever arm mechanism.  
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5.3.2.4 Wear rate assessment 
The wear was assessed gravimetrically (loss of mass) and volumetric loss was 
calculated by dividing the mass by the density. Twice a week (approximately 
every 0.25 million cycles), the machine was stopped to allow for the measure-
ment and to clean the machine. The pins and plates were cleaned¸ dried and 
weighed using the following protocol: 
 
Pins and plates cleaning  
1. Rinse with distilled water to remove bulk contaminants. 
2. Immerse in a 1% solution of Neutracon and place in an ultrasonic bath 
for 15 minutes at room temperature. 
3. Rinse in a stream of distilled water. 
4. Immerse in distilled water and place in an ultrasonic bath for 5 minutes at 
room temperature. 
5. Dry with a lint free tissue. 
6. Immerse in Isopropanol for 3 minutes. 
7. Dry with a lint free tissue. 
8. Allow to dry in a biological flow cabinet at room temperature for 30 min-
utes before weighing. 
 
Pins and plates weighing 
1. For this test the Mettler Toledo AX205 Balance was used (accuracy of 
0.01mg). 
2. Place Pin (or plate) 1 on balance and wait for a stable reading and re-
cord. 
3. Repeat for all pins (or plates) in sequence. 
4. Repeat cycle until three readings of each pin (or plate) are within 0.1mg 
of each other. 
5. Use the average of these three values. 
 
Control specimens were used to take account of the lubricants absorption of 
both the pins and plates during the test. The wear volumes were plotted against 
the sliding distance and the gradient of the line provided the wear rate. The 
wear rate was then divided by the load to determine the wear factor, К 
(mm3/Nm). 
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5.3.3 Surface topography 
Surface topography measurements were performed using a Zygo NewView 100 
non-contacting three-dimensional profilemeter. Ten measurements were taken 
of the pins and plates before and after pin-on-plates wear testing. Each meas-
urement provided visual and numerical data of the surface profile of the speci-
mens (figure 5.9). Visual data includes intensity map, two and three dimensional 
profiles of surface roughness. This provides a quick scan of a wider area of the 
specimens to get an overall impression on how rough the surface is. Numerical 
data included peak to valley ratio (PV), root mean square (rms) and surface 
roughness average (Ra).   
 
Figure 5.9 Profilemeter view of surface topography of a Co-Cr plate  
Valley – Lowest surface area
Light microscope 
intensity map
Peak – Highest surface area
3D surface roughness profile
Numerical data (PV, rms
and Ra)
2D surface roughness profile
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5.4 Results 
5.4.1 Tensile testing 
The test showed that the stiffness, Young‟s modulus, load to break and stress 
at break values were not affected by immersion in TXA or saline for 48 hours.  
The two groups were comparable in term of stiffness, Young‟s modulus of elas-
ticity, load at break and stress at break (Table 5.1). There were no statistically 
significant differences comparing saline and TXA immersed UHMWPE. 
 
Table 5.1 Tensile test results of the UHMWPE specimens 
Variable  Specimens  N  Mean  
(SD) 
Mean  
Difference  
P-Value  
(95% CI) 
Stiffness (N/m) Saline 5 81588 
(10518) 
1964 0.740 
(-15146 to 11218) 
TXA 5 83552  
(7262) 
 
Young's Modulus 
(MPa) 
 
Saline 5 923 
(119) 
23 0.740 
(-171 to 127) 
TXA 5 946 
(82) 
 
Load at Break (N) 
 
Saline 5 330 
(33) 
12 0.523 
(17 to -52) 
TXA 5 342 
(20) 
 
Stress at Break 
(MPa) 
 
Saline 5 47 
(5) 
1 0.526 
(2 to -7) 
TXA 5 48 
(3) 
 
 
The stiffness, elastic Young‟s modulus, load to break value and stress at break 
of the soaked specimens (TXA and saline) were comparable to those of control 
specimens (non-soaked specimen) (ANOVA; P=0.79, 0.79, 0.67 and 0.67 re-
spectively).  
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The stress strain curves of the 10 tensile specimens are shown in figure 5.10. 
The graph shows all specimens have an almost identical stress strain curve 
apart from control specimen number 5 which failed at a lower stress. However, 
this did not adversely affect the overall test. It is not unusual to have a faulty 
specimen with a small scratch or defect that affects its tensile properties. 
 
Figure 5.10 Stress strain curves of tensile*  
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*Control specimen number 5 which failed at a lower stress is represented with a blue solid line. 
 
5.4.2 Wear test  
The wear test involved two multidirectional pin-on-plate machines with 8 sta-
tions; four control pins and 4 control plates which were soaked with saline; four 
TXA soaked pins and 4 TXA soaked plates. Another two pins and 2 plates were 
used as a control to measure the weight changes secondary to bovine serum 
absorption. This was deducted or added accordingly from the tested specimen 
at every weighing. 
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Pins and plates were numbered and assigned to stations as in the follows: 
 
TEST 1 / MACHINE 1 TEST 2 / MACHINE 2 
Four stations Four stations 
 Pins:  Pins: 
o TXA (Pins 1 & 2) o TXA (Pins 8 & 7) 
o Placebo (Pins 4 & 5) o Placebo (Pins 6 & 10) 
o Control (Pin 3) o Control (Pin 9) 
 Plates  Plates 
o TXA (Plates 1 & 2) o TXA (plates 8 & 7) 
o Placebo (Plates 4 & 5) o Placebo (Plates 6 &10) 
o Control (Plates 3) o Control (plate 9) 
 Load 40 Newton  Load 40 Newton 
 Stroke 4 mm  Stroke 4 mm 
 Cycles 3731020  Cycles 4064277 
 Distance 149.2 Km.  Distance 162.6 Km 
 
Table 5.2 shows the cumulative volume changes in the pins and plates in each 
group (Placebo or TXA) as measured each time the machines were stopped. As 
expected, the main loss happened to the UHMWPE pins rather than the Co-Cr 
plates as they are softer and prone to wear more rapidly than plates. 
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Table 5.2 Cumulative volume loss in mm3 in plates and pins 
Distance (Km) Plates Pins 
Test 1 Test 2 TXA  
Test 1 
 Plate 
TXA 
 Test2  
Plate 
Placebo 
Test1  
Plate 
Placebo  
Test2  
Plate 
TXA 
Test1  
Pin 
TXA 
 Test 2 
 Pin 
Placebo  
Test 1  
Pin 
Placebo  
Test 2  
Pin 
          
0 0 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 
4 14.2 -0.12659 0.02191 -0.00913 0.13309 -0.14354 -0.87560 -0.46651 -0.71412 
12.4 24.2 -0.19679 -0.00406 -0.00162 0.11503 -0.44677 -1.89833 -0.93122 -1.67405 
30.5 34.8 -0.19517 -0.07608 -0.00446 0.16575 -1.05862 -2.73446 -1.13756 -2.70755 
38.9 47.4 -0.18441 -0.07993 0.00426 0.15276 -1.84989 -3.74284 -1.90192 -3.99762 
49.6 60.7 -0.18949 -0.04098 0.01603 0.14566 -2.76676 -5.03112 -3.31760 -4.91449 
60.8 73.7 -0.19922 -0.01440 0.00751 0.13511 -3.86485 -6.43065 -4.53590 -6.34094 
73.1 88.5 -0.19598 -0.01481 0.01298 0.14262 -5.21055 -8.03652 -5.83495 -7.95219 
84.6 109.5 -0.22113 -0.02090 -0.01116 0.09170 -6.11306 -9.82719 -7.16450 -9.54908 
100.9 130.6 -0.20308 -0.01075 -0.00122 0.14992 -7.75661 -10.77636 -8.57839 -10.65973 
121.9 162.6 -0.21119 0.05336 0.00467 0.14161 -8.64477 -12.32661 -9.52037 -12.13821 
149.2  -0.20308  0.00426  -10.81583  -11.57660  
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Figure 5.11 Graph of volume losses of the pins and plates  
plotted against sliding distance 
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Wear factors were calculated for all pins and plates using the following equa-
tion: 
 
Wear factor= volume loss (mm3) / [sliding distance (m) x load (N)] 
 
Table 5.3 The wear factors of plates and pins 
Number Group Pins wear factor  
( x 10 -6 mm3/Nm) 
Plate wear factor  
( x 10 -9 mm3/Nm) 
1 TXA 2.138 0.004 
2 TXA 1.994 0.005 
8 TXA 1.967 -0.013 
7 TXA 2.354 -0.006 
4 Placebo 2.171 0.008 
5 Placebo 2.193 -0.006 
6 Placebo 2.429 -0.014 
10 Placebo 1.844 0.016 
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There were no statistically significant differences in between the mean wear fac-
tor comparing either plates or pins which were soaked in saline or TXA as 
shown table 5.4.  
 
Table 5.4 The wear factors of plates and pins; Parametric t-test  
  Groups N Mean* SD* Mean 
Difference* 
95% CI   
P-Value 
Plates wear factor 
  
Placebo 4 0.00100 0.013515 0.0035 -0.161 to 0.023 
0.768 TXA 4 -0.00250 0.008583 
 
Pins wear factor 
  
 
Placebo 
 
4 
 
2.15925 
 
0.240433 
 
0.046 
 
-0.319 to 0.411 
0.677 TXA 4 2.11325 0.177184 
* (x10-9 mm3/Nm)  
 
 
5.4.3 Surface topography 
Surface topography measurements are summarised in table 5.5. Plate number 
5 was lost and its surface topography could not be obtained. 
 
Table 5.5 Surface topography  
No Group Plate PV† 
 
Plate rms† 
 
Plate Ra 
 
Pin 
PV 
Pin 
rms 
Pins 
Ra 
Pre* Post** Pre Post Pre Post Post Post Post 
1 TXA 0.296 0.259 0.024 0.019 0.018 0.015 3.833 0.497 0.370 
2 TXA 0.224 0.376 0.036 0.038 0.335 0.030 7.219 0.193 0.124 
8 TXA 0.227 0.597 0.022 0.039 0.017 0.031 3.615 0.648 0.160 
7 TXA 0.418 0.335 0.028 0.034 0.021 0.026 7.184 0.215 0.158 
4 Placebo 0.259 0.103 0.019 0.014 0.015 0.011 1.135 0.020 0.088 
5 Placebo 0.235  0.025  0.020  3.862 0.385 0.222 
6 Placebo 0.231 0.434 0.022 0.029 0.017 0.020 3.577 0.434 0.338 
10 Placebo 0.192 0.386 0.020 0.020 0.016 0.016 5.443 0.428 0.337 
* Pre wears tests. ** Post wears tests.  
†PV: Peak valley ratio (µm); rms: Root mean square roughness (µm); Ra: Surface roughness 
average (µm) (see section 5.3). 
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There was no significant difference in the peak valley distance (PV), rms sur-
face roughness and surface roughness average (Ra) of the plates and pins be-
tween the two groups before and after the pin-on-plate wears tests (see table 
5.6). Hence the null hypothesis of no difference was accepted. 
 
 Table 5.6 Post wear surface topography findings 
  Group N Mean SD Mean  
Difference 
P-Value 
(95% CI) 
Plates  PV 
  
Placebo 3 0.279 0.228 -0.0340 0.856 
(-0.5 to 0.4) TXA 4 0.313 0.240 
Plates rms Placebo 3 0.021 0.0075 -0.0115 0.141 
(-0.0284 to 0.0054) TXA 4 0.0325 0.0092 
Plates Ra  Placebo 3 0.019 0.002 -0.007 
 
0.187 
(-0.02 to 0.005) TXA 4 0.026 0.007 
Pins PV Placebo 4 3.504 1.780 -1.959 
 
0.195 
(-5.24 to 1.32) TXA 4 5.463 2.010 
Pins  rms Placebo 4 0.3167 0.199 -0.0715 0.612 
(-0.542 to 0.3531) TXA 4 0.3882 0.2216 
Pins Ra Placebo 4 0.247 0.119 0.043 
 
0.616 
(-0.16 to 0.24) TXA 4 0.203 0.113 
 
 
5.4 Discussion 
It may take many years to determine the effectiveness of new designs or inno-
vations for artificial joint replacement. Many journals refuse to publish new im-
plants series or interventions if there is less than 10 years follow up. Surgeons 
are very cautious and hesitant about introducing a new intervention without it 
being carefully studied and assessed. The history of artificial joint replacement 
supports this caution. 
 
In this study we investigated the effects of TXA on three important material 
properties. Tensile testing and surface topography were studied using gold 
standard methods. This showed there was no difference in the tensile proper-
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ties and surface topography between the artificial implants that had been 
soaked in saline and those soaked with TXA. 
 
There are several methods to assess the rate of wear. Clinical and radiological 
survival analysis of implanted joints is probably the most useful method, but it 
takes a very long time: some implants can last more than 30 years. Also, pa-
tients are often lost to follow up during such a long period. Joint simulation is a 
reliable predictor but it is quite expensive with limited access. Multidirectional 
pin-on-plate machines are a reasonable alternative and several studies have 
confirmed that they are comparable to joint simulators [128-131]. 
 
Comparing results from 8 stations, there was no significant difference in the 
wear rate factor among the two groups and findings were comparable with the 
wear factors reported in other studies [128, 132]. 
 
In conclusion, laboratory biomechanical testing shows that there are no biome-
chanical adverse affects for artificial joints material from using topical TXA. 
However, a review of the trial patients at 5 years and 10 years of follow up 
would confirm that the clinical and biomechanical profiles of the artificial knees 
have not been degraded. 
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Chapter 6 
Discussion 
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6.1 Overview 
The discussion is structured into three parts. In the first part, the results of the 
TRANX-K trial are examined with reference to the research questions posed at 
the design stage. The second part provides a commentary of the quality of re-
search reported in this thesis commenting on strengths and weaknesses and 
the implications of these. The last part is a summary and conclusion of the the-
sis exploring the potential impact on orthopaedic practice and future research. 
  
6.2 The results of TRANX-K trial 
6.2.1 Can topically applied TXA reduce blood transfusion? 
The Tranx-K trial recruited 157 participants with 79 receiving TXA and 78 re-
ceiving placebo. One participant (1.3%) received blood transfusion in the TXA 
group while 13 participants (16.6%) received blood transfusion in the placebo 
group. Thus topically applied TXA reduced the risk of transfusion 13 fold, a sta-
tistically significant finding (Fisher exact test; P=0.001).  
 
When compared to previous trials, the topical TXA demonstrated a greater ef-
fectiveness in reducing blood transfusion (figures 4.2 and 4.3). Systematically 
delivered TXA reduced the risk of transfusion 2.7 fold: from 16 trials, 110 
(21.9%) participants received blood transfusion in the TXA group while 214 
(48.3%) received blood transfusions in the placebo group (chapter 2).  
 
These findings are in agreement with our hypothesis that topically applied TXA 
should produce a higher concentration of the active ingredient at the bleeding 
site enhancing its potency. This could be explained by the difference in the vol-
ume of distribution of the two modes of delivery. If a drug is required to act on 
an organ (the knee in this thesis), it must be administered to the blood first, then 
distributed widely within the body. A fraction is then diffused to the target organ 
to produce an effect. The distribution in the body is often uneven. Some drugs 
have high affinity to plasma, some are bound to protein and others localised 
within particular organs. Some organs are partially or totally impervious to cer-
tain drugs. Clearly the site of localisation of a drug is likely to influence its action 
[133]. Intravenous TXA distributes in the plasma and varyingly in the fluid of the 
various body compartments reducing its therapeutic level at the knee. Topically 
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applied TXA distributes in the knee joint cavity predominantly achieving a higher 
therapeutic level. Precise information on the concentration attained by TXA in 
various tissues and fluids requires biopsy samples and for understandable rea-
sons this was not possible and beyond the scope of this work. The plasma con-
centration of TXA could be assessed in specialist centres but there is no widely 
available assay to determine this concentration.  However, a previous study 
demonstrated that topically applied TXA in a closed cavity (the pericardium) 
was not absorbed to the systemic circulation [84], hence this was not per-
formed. 
 
6.2.2 Can topically applied TXA reduce blood loss? 
Estimating accurate blood loss in TKR is not a simple procedure and requires 
certain assumptions. Standardisation of surgical technique, timing of tourniquet 
inflation and deflation, type of drain used, timing of drain removal were stan-
dardised across participants in the Tranx-K trial to achieve a consistent meas-
ure of blood loss.  
 
Initially, the drain blood loss was planned to be measured by two independent 
research members. Each would have made three readings with the mean value 
recorded and with subsequent comparison of these means. However, the idea 
was abandoned because of time pressure in busy NHS practice. Instead, re-
search staff were trained to record drain blood loss to a standard procedure 
(3.7.2.1) to minimise variation. 
 
The operative blood loss (occurring before administration of TXA or placebo) 
was more difficult to standardise and accurately measure, including the irriga-
tion fluid use, the volume of fluid and blood in the suction bottle, weighing 
swabs dry then wet and obtaining the difference in mg then convert it to ml.  
There was a wide range of operative blood loss (30 to 600 ml) in spite of the 
fact that surgery was performed in bloodless field: this may be in part due to 
surgical technique but in part due to the complexity of the measure. 
  
Eipe [121] showed that clinical methods such as assessing blood soaked mops 
and gauze pieces, measuring blood lost to suction bottles and the vacuum drain 
underestimate surgical blood loss. He recommended using a biochemical 
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method based on Hct alongside the clinical methods. Several formulas have 
been developed to measure the actual blood loss using Hct changes. In this 
thesis, Gross‟s formula was used [121, 122]. 
 
The mean drain blood was 465 ml (SD 298) in the placebo group and 296.7 ml 
(SD 195.6) in the TXA group. The mean difference was 168 ml (95% CI: 80 to 
256 ml, p=0.00025). Using the Gross formula, the mean total blood loss was 
1725 ml (SD 823 ml) in the placebo group and 918.6 ml (SD 487.3ml) in the 
TXA with a mean difference of 806.3 ml a statistically significant difference 
(95% CI: 564.7 to 1048 ml; P<0.0001). 
 
There was a 37% reduction in the mean drain blood loss.  This reduction is 
lower than the designed 50% reduction in blood loss considered clinical impor-
tant at the design stage (Chapter 3). However the primary design consideration 
of reduction in blood transfusion was more than achieved and this is seen more 
readily in the total blood reduction of 47% using the Gross formula. 
 
Use of varying definitions of blood loss by different trials severely limits mean-
ingful comparison between trials although differences within trials may be inter-
nally consistent and valid. Using the Gross formula to estimate total blood loss 
makes differences in the use of transfusion more readily interpretable and com-
parable, thus it would be helpful if this estimation is provided in future trials of 
orthopaedic surgery.   
  
6.2.3 Can topically applied TXA reduce Length of stay? 
Reduced length of stay is a key outcome for patients and staff. It may help with 
bed occupancy rates, improve productivity, minimise the risk of hospital ac-
quired infection and help patients to return to routine activities more quickly. 
There are several factors influencing the LOS such as the age of patients, as-
sociated co-morbidity, progress with rehabilitation and home situation. Hence, 
there is significant variation in LOS among hospitals, units and patients. Pa-
tients recruited in the study stayed for variable lengths of time ranged from 2 to 
27 days. Within this context of variation TXA reduced the length of stay by an 
average of 1.2 days (T-test, p-value 0.041).  
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This reduced LOS may be due to lower bleeding, higher Hb and faster rehabili-
tation.  Additionally a lower rate of transfusion may reduce subsequent care and 
monitoring (blood transfusion typically necessitates an additional day for obser-
vation).  Both modes may be evident. Analysis of patients who did not receive 
transfusion shows that the placebo group bled more (drain blood loss 460 ml 
versus 294 ml; P=0.001) and had lower postoperative Hb (11 g/dl versus 11.56 
g/dl; P=0.01) when compared to TXA.  LOS did not vary in patients not receiv-
ing transfusion (Placebo: 4.93 days versus TXA: 4.78 days; P=0.663) suggest-
ing that transfusion does adversely affect length of stay (Appendix 6.1).   
 
The systematic review and meta-analysis (chapter 2) included usable data from 
3 trials which provided data on LOS (Figure 2.7) showed that patients receiving 
TXA spent an average of 0.77 day less in hospital than the control group but 
this was not statistically significant (P= 0.10). Including LOS data from Tranx-K 
study increased the pooled mean difference to 0.9 day and this was statistically 
significant (P=0.01) (figure 4.7). 
 
6.2.4 Economic analysis 
There are four common types of economic evaluation of an intervention that can 
be performed [134]:  
 Cost effectiveness (CE): Interventions are evaluated in terms of one 
treatment effect. These interventions are comparing by calculating the 
incremental cost-effectiveness ratio. 
 Cost minimization.  Comparing two interventions that achieve the same 
effectiveness (in some physical measure of value), the cheapest is pre-
ferred. 
 Cost benefit analysis: Costs and benefits are measured in the same unit 
(money) for each intervention with the net benefit (benefit-cost) of each 
intervention is compared.  
 Cost utility analysis: The outcome of each intervention is measured for its 
affect upon mortality (quantity of life) and morbidity (quality of life). It 
measures the additional life years weighted by the quality of life expe-
rienced each year. Interventions are compared by calculating the incre-
mental cost/QALY ratio. 
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Sometimes it is not meaningful to summarise the value of a treatment just in 
terms of one unambiguous outcome.  In the Tranx-K trial reductions in blood 
loss, transfusion and LOS are all valued by clinicians and patients.  In this cir-
cumstance a cost and consequences approach can be adopted as an additional 
formal technique for economic evaluation.  Within this thesis an NHS perspec-
tive was adopted, which may underestimate the value to patients of a faster re-
turn home which may correlate with return to routine activities. 
 
The use of topical TXA caused a net cost saving of £333 per patient (P=0.054). 
A cost and consequences approach is particularly powerful when a cost saving 
is identified as well as positive health benefits across the range of outcomes.  In 
this instance the new treatment (use of TXA) is said to be the dominant strategy 
and no further analysis or modelling is required 
 
Complications of surgery were not included in the cost analysis, since complica-
tions were rare and not statistically significantly different between treatments. 
One complication (periprosthetic fracture) was caused by an accident and is not 
attributable to study treatment: treating this complication was associated with a 
very high cost. Inclusion of the patient level cost of complications identified 
would probably have increased the net saving due to TXA.  
 
In the TXA group, there were two cases of DVT and one superficial infection. 
DVT was treated in outpatients with LMWH then warfarin; superficial infection 
received a short course of oral antibiotic.  
 
In the placebo group, there was one case of TIA, one chest infection, one pe-
riprosthetic fracture, one superficial infection and one deep infection. The first 
two of these happened while the patients were in hospital and some of the cost 
of these has been included in the LOS saving. The superficial infection was 
treated with short course of antibiotic in outpatient. The Periprosthetic fracture 
was admitted to hospital and underwent open reduction and internal fixation al-
most a year after the initial operation. The patient who developed deep infection 
was reviewed in the clinic more frequently than usual because of continuing 
pain and hotness in his knee. His blood tests were inconclusive. He then un-
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derwent bone scan which was very suggestive of infection. Wound swab and 
knee aspiration performed in theatre showed MRSA infection which was treated 
with 2 weeks of oral Linezolid. This is an expensive antibiotic with a 5 day 
course costs £445 [113]. The patient then underwent a revision TKR on the 22nd 
of March 2010, just over one year from the initial operation and he is still under 
follow up. The complications experienced by the last two patients resulted in 
considerable cost to the NHS.  
 
The sixth annual report of the National Joint Registry [3] showed that there were 
around 65 979 primary TKRs performed in England and Wales during 2008. 
Based on the Tranx-K trial findings, routine TXA might save the NHS £1.5 M 
each year. The net social valuation might be greater if this included, for exam-
ple, time absent from work, reduced hospital acquired infection, complications 
of blood transfusion and reduced demand for donor blood. 
 
6.2.5 The affect of TXA on the Oxford Knee Score and EuroQol 
The study intervention was not expected to affect adversely either functional 
outcome or quality of life following total knee replacement. This was formally 
tested using the Oxford Knee Score and EuroQol measures. Participants were 
asked to complete these preoperatively and three months after the operation.  
The Oxford knee score comprises 12 questions each scored from 4 to 0, with 4 
representing the best outcome/least symptoms. The scores of each question 
are added so that the overall figure lies between 0 and 48. The mean preopera-
tive OKS scores were TXA: 19.40 and Placebo: 19.34, with a mean difference 
of 0.05 (P=0.96). Postoperatively these scores rose TXA: 34.83 and Placebo 
35.91, with a mean difference of -1.08 (P=0.55).  As expected there was signifi-
cant improvement in the OKS after TKR in both groups, the mean improvement 
in both groups was 15.59 (P< 0.0001) consistent with findings from other stud-
ies. 
 
The EuroQol questionnaire consists of a descriptive system (ED-5D) and a vis-
ual analogue scale (EQ-VAS).  The EQ-5D descriptive system was converted to 
a weighted index. The mean preoperative EuroQol index was 0.43 in the pla-
cebo group and 0.38 in the TXA group: mean difference 0.054 (P=0.35). Simi-
larly the mean preoperative EQ-VAS in the placebo group was 59.35 and 61.48 
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in the TXA group: mean difference 2.1 (P=0.579). As anticipated, scores in-
creased in both arms following TKR. The mean postoperative EuroQol index 
was 0.78 and 0.71 in the TXA group: a mean difference of 0.075 (P=0.187). The 
mean postoperative ED-VAS in the placebo group was 75.6 and 75.2 in the 
TXA group: mean difference 0.38 (P=0.579).  Thus there were no statistically 
significant differences in baseline or 3 month quality-of-life measures. Compar-
ing the preoperative and postoperative scores in both groups taken together 
showed improvement in the EQ-5D: 0.311 (P<0.0001) and ED-VAS: 11.7 (P< 
0.0001).  
 
6.2.6 Complications following TKR 
TKR is a successful and common operation but not risk free. There are a num-
ber of potential complications and some of them can be serious. In the review 
(chapter 3), we identified the relevant complications and the methods to identify 
them within a three month trial follow up period. Table 4.13 summarises the 
complications in both groups of the Tranx-K trial. There were 3 complications in 
the TXA group (2 DVTs and one superficial infection) and 5 in the placebo 
group (1 TIA, 1 chest infection, 1 periprosthetic fracture, 1 superficial infection 
and 1 deep infection). There were no significant differences between the two 
arms in the frequency of these complications. This should be interpreted with 
caution as the study was not designed to detect a difference in these complica-
tions. The low incidence rate of their occurrences would necessitate a very 
large number of participants to detect a difference precisely. 
 
6.3 The effect of TXA on artificial implants (BioTRANX study) 
Some surgeons have expressed concern that topical TXA may degrade artificial 
implants. Personal communication with authors of studies that used intravenous 
TXA in TKR did not reveal adverse effects but there was no formal scientific 
study that examined this issue. This led to development of the BioTRANX study 
(chapter 5) which investigated the effects of TXA on tensile properties, wear 
rate and surface topography. There was no difference in the tensile properties 
and surface topography between the artificial implants that had been soaked in 
saline and those soaked with TXA for 48 hours. For example, wear rate was 
tested using a multidirectional pin-on-plate machine comparing results from 8 
stations after 4 millions cycle (160 Km). These findings are reassuring. How-
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ever, there are limitations to biomechanical tests as they may not always pro-
duce data comparable to living models. The possible alternatives are clinical 
and radiological survival analysis of implanted joints. However, time (some im-
plants can survive more than 30 years) and patient retention make such a study 
unlikely. 
 
6.4 Trial quality measures 
6.4.1 Strength of the study 
6.4.1.1 Overview 
The trial published in this thesis was carefully designed to minimise error (bias 
through the randomised design and sampling error through adequate study 
power) and maximise relevance and importance. The study design, protocol 
and patients information sheet were reviewed by official research bodies, inter-
nal and external reviewers who are experts in their fields. All criticisms (positive 
or negative) were considered and incorporated in the final proposal. The trial 
was developed to a standard to fulfil the CONSORT recommendation [91],  reg-
istered with the European Clinical Trials Database, and granted ethical and 
MHRA approval.  It secured funding from the Research and Development office 
and the department of Trauma and Orthopaedics of the University Hospital of 
North Tees and Hartlepool.   
 
In preparation, an extensive literature review was undertaken, which included a 
systematic review and meta-analysis of published trials. Critical appraisal of 
these trials helped identify design strengths and avoid weakness.  Most trials 
were small and were assessed to have varying quality: nineteen trials were in-
cluded of which only 3 recruited more than 100 participants. Two of these have 
more than three arms.  
 
The Tranx-K trial had clear objectives and a well-defined primary outcome 
(blood transfusion rate) and supportive secondary outcomes. A standard oper-
ating procedure was introduced to standardise the measurement of outcomes to 
reduce variation among different surgeons. There was 100% compliance with 
this standardisation. 
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Inclusion and exclusion criteria were operationalised by a two stage safety 
check list to maximise adherence to these criteria. The first check was intro-
duced before consenting patients to the trial. A research member checked all 
necessary boxes on the consent form before approaching potential participants. 
Then, at randomisation, inclusion and exclusion criteria had to be checked be-
fore proceeding to the randomisation process.  
 
Tranx-K was a pragmatic trial [135], measuring effectiveness of tranexamic acid 
in total knee replacement surgery as routinely practiced rather than in idealised 
conditions. For this reason, the trial sought to minimise changes in routine prac-
tice to enhance generalisability. The participants received normal standard of 
care for TKR provided in our centre. Normally, no chemical intervention is used 
to reduce blood loss. In this study, at the end of the operation and before clos-
ing the wound, the study drug, which was either TXA or a placebo, was applied 
by spray into the wound. The wound was then closed and dressed in the normal 
way followed by the release of the tourniquet. Drains were released after one 
hour in recovery as is routine. However standard operating procedures includ-
ing standardised criteria for blood transfusion, timing of drain removal and blood 
tests were introduced to limit variation. 
 
6.4.1.2 Study bias and group comparability 
Blocked randomisation was used in blocks of six in order to keep the sizes of 
groups similar. Randomisation was stratified by surgeon to achieve balance 
within the two groups and design out variation in surgical outcome among sur-
geons. However, there is a limit to how many potentially confounding influences 
can be designed out of a trial by stratification. Randomisation distributes known 
and unknown influences by chance within a trial, but there remains a risk of 
chance mismatches in participants at baseline which may confound the study 
finding. Only gender was unusually different between the two groups (Table 
4.1). This was explored by investigating the effect of gender (being a male or 
female) on trial findings: blood transfusion rate, drain blood loss, Hb drop and 
LOS. Analysis by gender revealed no systematic interaction with these out-
comes (chapter 4). The imbalance between the two arms of the trial is a chance 
occurrence with no bearing upon the trial findings; consistent with prior clinical 
expectation.   
142 
 
 
Patients eligible for the study were approached in the pre-assessment clinic by 
the designated staff nurse who was not actively involved in the study. Patients‟ 
sex, age, weight and co-morbidity were not part of the exclusion criteria. This 
was to ensure a generalisable sample. 
 
Concealment of allocation was ensured by using external online randomisation 
provided by “Sealed Envelope”; an independent company. A designated re-
search nurse randomised patients and prepared the study drug (either TXA or 
Placebo). The health professionals delivering patient care were blinded to the 
treatment allocation. Both treatment and placebo solutions have the same col-
our, smell and feel ensuring blinding was maintained throughout surgery. 
 
6.3.1.3 Protocol adherence 
The simple nature of the study and the intervention encouraged protocol adher-
ence. There were very few deviations from the protocol. At the start of the 
study, two patients were randomised by mistake. The first was a patient who 
was scheduled to have a unicompartmental knee replacement (UKR) or total 
knee replacement depending on the severity of the knee degenerative changes.  
The patient was approached by the research team and agreed that if he had a 
TKR he would be part of the study and subsequently randomised to receive 
TXA. He underwent a UKR and did not receive the TXA. This patient was ex-
cluded from the analysis because he did not fulfil inclusion criterion requiring 
TKR. Blood loss, transfusion rate and LOS are different from those of TKR. 
Measures were taken to prevent a similar scenario to happen again. The sec-
ond patient was randomised by mistake due to a typing error in the theatre list. 
The patient was undergoing a THR and not TKR as written in the theatre list. 
Although, this was noticed when the patient was on the ward, the patient had 
already been randomised and received a code number. This patient was not 
approached to take part in the trial, he did not sign a consent form and he did 
not receive any trial intervention. He was excluded from the study. There was 
no study withdrawal and all participants were followed up for three months as 
stated by the protocol.  
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6.3.2 Weaknesses of the study 
Several weaknesses became apparent through the study. The short follow up of 
3 months might conceal a different long term safety profile for the use of TXA. 
However, TXA has been available since 1964 with a good safety profile. The 
biological half-life of TXA has been determined to be 1.9 hours to 2.7 hours. 
Approximately 90% of an intravenously administered TXA dose is excreted, 
largely unchanged, in the urine within 24 hours. It was thought that 3 month fol-
low up period would be adequate to notice relevant side effects or adverse re-
actions. This may be true but remains untested without long term follow up.   
 
6.3.3 Long term safety 
To explore this longer term safety issue, the BioTRANX study (chapter 5) was 
conducted to investigate potential long term detrimental effects of TXA on the 
biomechanical properties of the artificial joint materials. The study did not iden-
tify any adverse effects, although, such biomechanical studies have their limita-
tions.  
 
Future work is in progress to obtain approvals to review the safety profile in 
tranx-K trial participants after 5 years. This will be implemented on two stages. 
The first stage will include reviewing the medical records of the patients and 
sending them postal OKS and EuroQol questionnaires. If there was significant 
difference between the two groups in the first stage, we will move to the second 
stage which includes calling patients to attend a special clinic for clinical evalua-
tion and radiological assessment.  
 
6.4 Future study 
Long term follow up for the Tranx-K trial is planned. The particular focus is on 
the safety profile of TXA, surgical patency and joint replacement patency over a 
5 years period. There were two DVTs in the TXA and there was none in the pla-
cebo group. When topical TXA use becomes routine, this needs further investi-
gation in a large population of patients.  
 
Research reported in this thesis is running in parallel with similar research work 
involving total hip replacement (THR). A systematic review and meta-analysis of 
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the use of TXA in THR was conducted. There was similar trend in reducing 
blood transfusion and blood loss in THR. A sister trial which is called Tranx-H is 
underway. The aim is to recruit 150 patient undergoing THR to investigate the 
topical use of TXA in THR. There are significant differences in the operative 
techniques comparing THR and TKR, meriting a separate trial. THR is not done 
in a bloodless field as a tourniquet cannot be used for anatomical reasons. Ad-
ditionally, there is less bone cut and more muscle cut in the THR procedure. 
The evidence from these THR studies will complement the evidence for TKR. 
 
6.5 Barriers to adoption 
Intravenous TXA has increased in popularity in orthopaedic surgery over the 
last 10 years. In chapter 2, Lozano [81] published their experience after imple-
menting routine use of IV TXA in joint replacement. Intravenous TXA has be-
come an integral part of enhanced recovery programme for joint replacement in 
the North East region. Trank-X provides evidence that topical TXA may be more 
effective in reducing blood loss, transfusion and LOS in TKR than by the intra-
venous mode.  Additionally topical delivery is easier to prepare and apply, and it 
might be expected that this mode of use would be readily adopted. However, 
there are several barriers to overcome before routine use becomes a reality. 
 
One of the most fundamental principles of medical ethics is “primum non 
nocere” which is a Latin phrase that means "First, do no harm". Thus surgeons 
are usually cautious in adopting new interventions and technologies without an 
adequate evaluation of effectiveness and a long term safety record. This cau-
tion is fully justified particularly when the experience of previous unsuccessful or 
harmful developments is recalled.  
 
The BioTRANX study was designed to assess the potential for long term effects 
on artificial joints material and the results was reassuring. However, these find-
ings may not accurately predict the effect of TXA on inserted joints within the 
body. A plan to review the trial patients in 5 and 10 years is planned, but the 
usefulness of such review will depend on the availability of patients, and in-
volves delay in changes to current patient care. 
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The study findings need replicating by other research groups: reassurance 
against biased methodology or chance findings. 
 
Tranexamic acid is not licensed for topical use in joint replacement. Although 
the process of licensing is underway in the University Hospital of North Tees 
and Hartlepool, off license use may attract litigation if unexpected complications 
arise. The process of licensing is lengthy and involves vigilance and adverse 
reaction monitoring: this can further deter some potential users from early adop-
tion. 
 
Theoretically, TXA can cause thrombosis and pulmonary embolism, although 
this has never been shown in any of the clinical studies we reviewed. However, 
this perceived risk may be a major barrier for adoption by orthopaedic surgeons. 
Joint replacement surgery is associated with an increased risk of DVT and PE. 
In the United Kingdom, this risk is a major public concern that attracted a par-
liamentary inquiry in 2005. The magnitude of such risks and how to reduce 
them are contested and beyond the scope of this thesis, but these potentially 
remain a major barrier against the routine use of TXA.  
 
6.6 Conclusion 
A programme of research has provided evidence for the value of topically ap-
plied tranexamic acid in total knee replacement surgery. The evidence gener-
ated suggests that topically applied TXA is an effective, safe and cost-effective 
modality and should be routinely adopted. Long term surveillance studies are 
appropriate to address remaining uncertainties about safety. 
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2.1 Metanalysis data extraction sheet 
 
Trial ID 
 
Action 
  
Methods 
Allocation: 
 
Blindness: 
 
Duration: 
 
Participants 
     
N     
Age     
Sex     
Dx     
Cement tech     
Implants     
Exclusions     
 
 
Interventions 
1. 
2. 
3. 
 
Outcomes - able to use 
     
Blood loss     
BT 
 
 
Vol     
Units     
Number     
LOS     
Spec. Knee Score     
QOL score     
C 
O 
M
P 
 
Infections     
DVT     
PE     
MI     
CVA     
RF     
Others     
 
Outcomes - unable to use  
 
 
 
Notes 
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Appendix 2.2 Detailed summaries of the included trials 
 
Alvarez 2008  
Methods RCT. Double blind study. March to December 2005. Spain. 
Participants TXA group [N=46, Age 71±9, M/F (7/39)] 
Control group [N=49, Age 72±7, M/F (10/39)] 
Interventions TXA= 10mg/kg bolus + 1mg/kg/hr for 6h 
Control= identical protocol of saline 
O
ut
co
m
es
 
Blood loss TXA 170 ±109 vs. control 551±352 
Transfusion rate TXA 1 vs. control 6 
Transfusion amount 
(U) 
TXA 1 vs. control 11 
Complications No thromboembolic events in either side 
Notes BT trigger Hb 8g/dl - LMWH - QAS = 22 
 
Benoni 1996  
Methods RCT. Double blind study. Sweden. 
Participants TXA group [N=43, Age 76±7,M/F (13/30)] 
Control group [N=43, Age 74±7,M/F 10/33)] 
Interventions TXA 10 mg/kg, repeated after 3 hours. Another dose of TA if blood 
loss >500 ml within 1 hour or 1000ml within 4 hours 
Placebo 
O
ut
co
m
es
 
Blood loss Total blood loss: Total TXA 730±289 vs. control 1410±480 
Drain blood loss: TXA 520 ± 230 vs. control1210 ± 480 ml 
Transfusion rate TXA 8 vs. control 24 
Transfusion 
amount(U) 
TXA 12 vs. control 40 
Complications TXA group (2 superficial infections,4 DVT and 1 PE) 
Placebo group (3 DVT, 1 PE and 7 haematomas) 
Notes BT trigger 85-100 g/l – LMWH - QAS 22 
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Benoni 1996  
Methods RCT. Double blind study. Sweden. 
Participants TXA group [N=43, Age 76±7, M/F (13/30)]. 
Control group [N=43, Age 74±7, M/F 10/33)]. 
Interventions TXA 10 mg/kg, repeated after 3 hours. Another dose of TA if blood 
loss >500 ml within 1 hour or 1000ml within 4 hours. 
Placebo 
O
ut
co
m
es
 
Blood loss Total blood loss: Total TXA 730±289 vs. control 1410±480. 
Drain blood loss: TXA 520 ± 230 vs. control1210 ± 480 ml 
Transfusion rate TXA 8 vs. control 24 
Transfusion amount 
(U) 
TXA 12 vs. control 40 
Complications TXA group (2 superficial infections,4 DVT and 1 PE) 
Placebo group (3 DVT, 1 PE and 7 haematomas) 
Notes BT trigger 85-100 g/l-LMWH-QAS 22 
 
Camarasa 2006  
Methods RCT. Double blind study. March 2004 to March 2005. Spain. 
Participants TXA group [N=35, Age 73 (81-84), M/F 11/26] 
EACA group [N=33, Age 73 (59-80), M/F 4/29] 
Saline group [ N=68, Age 72 (52-85), M/F 14/54] 
Interventions TXA 10mg/kg IV just before the tourniquet release and 3h later 
EACA 100mg/kg IV just before the release of the tourniquet then IV 1 
g/h for 3 hours 
Control = saline 
O
ut
co
m
es
 
Blood loss TXA group 787+/-281 vs. EACA group 810±512 vs. saline 1270±625. 
Transfusion rate TXA 1 vs. EACA 4 vs. control 23 respectively. 
Transfusion amount 
(U) 
TXA 1 vs. EACA 6 vs. control 35. (Combined autologous, homolo-
gous or allogeneic) 
Complications 1 death in TXA group 7 months after his operation* 
No Thromboembolic events were detected. 
Notes BT trigger <8g/l-LMWH-QAS 24 
*Author personal communication. 
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Ellis 2001  
Methods Randomised controlled trial. Double blind. Israel. 
Participants TXA group [N=10, Age 71±5, M/F 4/6] 
Desmopressin [N=10, Age 72±6,M/F 2/8] 
Control [N=10, Age 72±6, M/F3/7] 
Interventions TXA 15mg/kg before inflating the tourniquet, then 10 mg/kg/hr for 
12 hours. 
Desmopressin 0.3 mcg/kg over 30 minutes, then IV saline over 12 
hour. 
Control IV saline 
O
ut
co
m
es
 
Blood loss No data provided 
Transfusion rate TXA 1 vs. Desmopressin 6 vs. control 7 
Transfusion amount (U) TXA 1 vs. Desmopressin 7 vs. control 11 
LOS (days) TXA 10±3 vs. Desmopressin 10±2 vs. control 10±2 
Complications No data on thromboembolic events was provided 
Notes BT trigger PCV <27% -LMWH -QAS 22 
 
Engel 2001  
Methods RCT. Single blind. Germany. 
Participants TXA group [ N=12, Age 71±9, M/F 4/8] 
Aprotinin [N=12, Age 68±11, M/F 3/9] 
Placebo [N=12, Age 66±11, M/F 4/8] 
Interventions TXA 15mg/kg then 10 mg/kg 3h later. 
Aprotinin 1 million units just before deflating the tourniquet and 0.5 
million units 4 h later. 
Control did not receive anything. 
O
ut
co
m
es
 
Blood loss TXA group 800 (9295-1050) vs. Aprotinin 875 (310-1270) vs. con-
trol 865 (245-1370). 
Transfusion rate TXA group 0 vs. Aprotinin 5 vs. control 3. 
Transfusion amount (U) TXA group 0 vs. Aprotinin 7 vs. control 6 units]. 
Complications TXA 2 DVT; Aprotinin 1 DVT and 0 in control. 
Notes BT trigger 10g/l –LMWH-Quality assessment score18 
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Good 2003  
Methods RCT, double blind. Sweden. 
Participants TXA group [N=27, Age 72 (46-83),M/F 9/18] 
Placebo [N=24, Age 72 (50-84), M/F 6/18] 
Interventions TXA 10mg/kg IV just before tourniquet release and 3 hours later 
O
ut
co
m
es
 Blood loss TXA group 385( range 331-586)] vs. placebo 845(range 523-990)  
Transfusion rate TXA group 3 vs. placebo 14 
Transfusion amount (U) TXA group 7 vs. placebo 35 units 
Complications Two DVTs in each group. 1 wound infection TXA group 
Notes BT trigger HB<9g –LMWH- QAS 24 
 
Hiippala 1995  
Methods RCT, Double blind. Finland. 
Participants TXA group (N=15, Age 70(56-82), M/F (2/13)) 
Placebo group (N=13, Age 70(63-78), M/F (3/10)) 
Interventions TXA 15 mg/kg (N=15) vs. Placebo (normal saline 0.9%) (N13) 
O
ut
co
m
es
 Blood loss TXA 847 ml (356) vs. control 154(574) 
Transfusion rate TXA group 10 vs. placebo 12 
Transfusion amount (U) TXA group 1.5 units /patient vs. Placebo group 3.3 per patient 
Complications TXA group had 1 MI. Placebo group had 1 DVT and 1 PE 
Notes BT trigger 10 g/dl -LMWH - QAS 19 
 
Hiippala 1997  
Methods Randomised controlled trial. Double blind study. 19 September 
1994 to 22 April 1996. Finland. 
Participants TXA group (N=39, Age 70±7, M/F 4/35) 
Placebo (N=38,Age 69±5, M/F 8/30) 
Interventions TXA 15mg/kg before the tourniquet release and two additional 
doses of 10mg/kg 3-4 and 6-7 hours later vs. Placebo 
O
ut
co
m
es
 
Blood loss TXA group 689±289 vs. Placebo group 1509±643. 
Transfusion rate TXA group 17 vs. placebo 34 
Transfusion amount (U) TXA group ±1.2 vs. Placebo group 3.1±1.6. 
Complications TXA group (2 DVT, 2 Chest infection and cardiac ischaemia) 
Placebo group (2 DVT and 1 death due to PE.) 
Notes BT trigger 10 g/l –LMWH -Quality assessment score is 22 
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Ido 2000  
Methods Controlled trial. Unblinded. November 1994 to November 1997. Ja-
pan. 
Participants TXA group (N =21) and Placebo group (N=22) 
Interventions TXA 1 g just before the tourniquet release and 1 g 3h later vs. Pla-
cebo 
O
ut
co
m
es
 
Blood loss TXA group 276.9±153.1 vs. Placebo group 518.6±213.6. 
Transfusion rate No data provided 
Transfusion amount (U) No data provided 
Complications No thromboembolic events detected. 
Notes No transfusion trigger - No chemical thromboprophylaxsis - QAS 14 
 
Jansen 1999  
Methods RCT, double blind study. Belgium. 
Participants TXA group [N=21, Age 70.7 (62-80),M/F 5/16] 
Placebo group [N=21, Age 71 (64-84),M/F 3/18] 
Interventions TXA 15mg/kg 30 min before surgery and 8 hourly for 3 days vs. 
Placebo 
O
ut
co
m
es
 Blood loss TXA group 678±352 vs. Placebo group 1419±607 
Transfusion rate TXA group 2 vs. Placebo 13 
Transfusion amount (U) TXA group 3 units vs. Placebo group 20 units 
Complications TXA group none vs. 2 DVT in the placebo group 
Notes BT trigger PCV<26% -LMWH - QAS 24 
 
Kakar 2009  
Methods RCT, double blind study. India. 
Participants Two groups of participants. Bilateral TKRs and Unilateral TKRs. 
The first group was excluded as it is beyond the scope of this re-
view. 
TXA group [N=12, Age 62.4 ±9.4, M/F 3/9] 
Placebo group [N=12, Age 66.2±4.2, M/F 4/8] 
Interventions TXA 10mg/kg IV before tourniquet inflation and 1mg/kg/h until 
wound closure vs. Placebo 
O
ut
co
m
es
 
Blood loss TXA group 160±87 vs. placebo group 270±88 
Transfusion rate No data provided 
Transfusion amount (U) TXA group 1 unit vs. Placebo group 5 units 
Complications No DVT on either side of the trial 
Notes BT trigger Hb < 8 g/l; BT trigger become < 10 g/l when participant 
was older than 60 year or had a co-morbidity – LMWH – QAS 22 
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Molloy 2007  
Methods RCT, All blind apart from the drug provider. December 2004 to Oc-
tober 2005. Northern Ireland. 
Participants TXA group [ N=50] vs. Fibrin [50] vs. Control [50] 
Interventions TXA 500 mg IV before deflation of the tourniquet and 500 mg 3h 
later 
Fibrin 10 ml spray 
Control: none 
O
ut
co
m
es
 
Blood loss TXA group 1225±499 vs. Fibrin 1190 ±490 vs. control 1415±416. 
Transfusion rate TXA 5 vs. Fibrin 7 vs. control 11 respectively 
Transfusion amount (U) TXA 8 vs. Fibrin 11 vs. control 17 units. 
LOS (days) 
 
TXA group 5.10 (2-250) vs. Fibrin group 4.82 (3-11) vs. control 5.86 
(2-33) 
Complications TXA group 1 chest infection 
Fibrin group ( 1 DVT and 1 PE) 
Control group 2 wound infections 
Notes BT triggers Hct < 0.25 at 8 h - Aspirin as DVT prophylaxis – QAS 22 
 
Orpen 2006  
Methods RCT. Double blind study. England. 
Participants TXA group [ N=15, Age 73 (70-78), M/F 8/7] 
Placebo group [ N=14, Age 69 (63-74), M/F 3/11] 
Interventions TXA 15mg/kg IV at the time of cementing vs. Saline 
O
ut
co
m
es
 Blood loss TXA group 660±164 vs. control 726 ±178. 
Transfusion rate TXA 1 vs. control 3. 
Transfusion amount (U) No data provided 
Complications No DVT on Duplex ultrasound. 
Notes BT trigger <10 g/dl –LMWH -QAS 24 
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Tanaka 2001  
Methods RCT. Double blind. Japan. 
Participants Preoperative TXA group: N=24; M/F 7/17; Age 65 (59-70). 
Intra operative TXA group: N=22; M/F 7/15; Age 65 (60-71). 
Perioperative TXA group: N=27; M/F 8/19; Age 65 (59-69). 
Placebo: N=26; M/F 9/17; 65 (58-70). 
Interventions Preoperative: TXA 20mg/kg 10 min before surgery and saline 10 
min before tourniquet deflation 
Intra operative: Saline 10 min. before surgery and TXA 20mg/kg 10 
min before tourniquet deflation 
Perioperative: TXA 10mg/kg 10 min before surgery and 10mg/kg 10 
min before tourniquet deflation 
Placebo 
O
ut
co
m
es
 
Blood loss No data provided 
Transfusion rate Preoperative 16 vs. Intra operative 17 vs. Perioperative 14 vs. con-
trol 26 
Transfusion amount (U) Preoperative 12; Intra operative 22; Perioperative 13.5; Control 13 
Complications Preoperative 11 DVTs; Intra operative 10 DVTs; Perioperative 13 
DVTs; Control: 12 DVTs.  
No PEs. 
Notes BT trigger based on the National Institutes of Health Consensus  
Conference on perioperative transfusion guidelines. 
 
Veien 2002  
Methods RCT, single blind. Denmark. 
Participants TXA group [N=15, Age 70.5±9.5, M/F 4/11] 
Non TXA group ( N=15, Age 69.5±9, M/F 1/14) 
Interventions TXA 10 ml/kg just before the release of the tourniquet and 3 hours 
later. 
Non TXA did not receive any thing. 
O
ut
co
m
es
 Blood loss TXA group 409.7±174.9 vs. Non TA group 761.7±313.1 
Transfusion rate TXA 0 vs. control 2. 
Transfusion amount (U) No data provided 
Complications TXA 0 vs. control 2 
Notes BT Trigger Hct<28% - LMWH - QAS 22 
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Zhang 2007  
Methods RCT. June 2005 to June 2006. China. 
Participants 102 participants (51 in each arm). 
Interventions TXA 1 g IV before tourniquet deflation then 1 g after 3h vs. Placebo 
O
ut
co
m
es
 
Blood loss Drain blood loss: TXA 478 ±172 vs. control 814 ± 156 ml. 
Total blood loss: TXA 559 ± 159 ml vs. control 1208 ± 243 ml. 
Transfusion rate No data provided 
Transfusion amount 
(ml) 
TXA 556 ± 174 ml vs. control 1024 ± 278 ml. 
Complications No DVT in either arms at 6-12 months by the colour Doppler  
ultrasonography. 
Notes Data based on English version of the abstract. 
 
Zohar 1999  
Methods Randomised controlled trial, single blind. Israel. 
Participants TXA group [ N=20, Age 74±7, M/F 4/16] 
NVHD group [N=20, Age 72±5,M/F 7/13] 
Interventions TXA group 15 mg/kg then IV infusion of 10mg/kg for 12 hours. 
NVHD group, bled to target 28%, IV volume maintained with ringer 
lactate and all the autologous blood was transfused. 
O
ut
co
m
es
 
Blood loss TXA 110 ±62 ml vs. NVHD 259±156. 
Transfusion rate TXA group 2 vs. NVHD group 13. 
Transfusion amount (U) TXA 2 group units vs. NVHD group 19 units. 
LOS TXA group 11±30 vs. placebo group 11±4. 
Complications TA group 6 Haematoma. 
NVHD group 6 haematomas, 1 DVT and proceed to have PE 
Notes BT trigger PCV <27% - LMWH - QAS 18 
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Zohar 2001  
Methods Randomised controlled trial. Single blind.Israel. 
Participants TXA group [ N=20, Age 71±5, M/F 8/12] 
Desmopressin [N=20, Age 72±5,M/F 3/17] 
Interventions TXA 15mg/kg before inflating the tourniquet, then 10 mg/kg/hr for 12 
hours. 
Desmopressin 0.3 mcg/kg over 30 minutes, then IV saline over 12 
hour. 
O
ut
co
m
es
 
Blood loss TXA group 162±129 vs. Desmopressin group 342±169. 
Transfusion rate TA group 3 patients vs. Desmopressin group 11 
Transfusion amount (U) TXA group 3 units vs. Desmopressin group 16 units. 
LOS TXA group 9±2 vs. Desmopressin group 10±2 
Complications None in 37 patients. 3 lost to follow up 
Notes Bt trigger PCV <27% - LMWH - QAS 22 
 
Zohar 2004  
Methods Randomised controlled trial, single blind. Israel. 
Participants TXA long [ N=20, Age 73±8, M/F 6/14] 
TXA short [ N=20, Age 69±7, M/F4/16] 
TXA oral [N=20, Age 69±10, M/F 8/12] 
control [N=20, Age 73±7, M/F 7/13] 
Interventions TXA long 15mg/kg 30 mg before tourniquet release then 10 mg/kg 
for 12h. 
TXA short as above but for 2h then oral 1g at 6 and 12 hours. 
TXA oral, 1 g 6hour preoperative then 6 hourly for 18 hours. 
Control: none. 
O
ut
co
m
es
 
Blood loss TXA long group 121+/-810 vs. TXA short 110±38 vs. TXA oral 
231±138 vs. control 249±130.  
Transfusion rate TXA long 3 vs. TXA short 2 vs. TXA oral 4 vs. control 12 
Transfusion amount (U) TXA long 3 vs. TXA short 4 vs. TXA oral 5 vs. control18 
LOS TXA long (8±2) TXA short (8±2) vs. TXA oral (8±2) vs. control 
(9±2) 
Complications No thromboembolic event in either side of the trial. 
Notes BT trigger Hct <28% - LMWH - QAS 16 
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Appendix 3.1 Research protocol  
 
Research Study Protocol 
 
Study Title   
 
Randomised Controlled Trial of the Use of Topical Application of Tranexamic 
Acid in Primary Cemented Total Knee Replacement (TRANX-K). 
 
Study Rationale  
 
Today‟s aging population has resulted in an increase in the number of major or-
thopaedic surgical interventions in the elderly. Total knee replacement (TKR) is 
one of the commonest operations in orthopaedic practice. The second annual 
report of the National Joint Registry showed that there were around 45000 TKR 
performed in England and Wales between 1 January 2004 and 31 December 
2004[1]. The true figure is probably much higher. Literature showed that 20-
70% of patients who had TKR needed 1-3 units of blood [2, 3, 4, 5, 6, 7].  
 
Although safer than ever, allogeneic transfusion is still associated with risks for 
the recipient (haemolysis, infection, immunosuppression, transfusion-related 
acute lung injury and even death).The risk of postoperative wound infections 
correlates with the amount of transfused allogeneic blood products. 
 
Tranexamic acid (TA) is a synthetic antifibrinolytic agent that binds to the lysine 
binding site of plasminogen and blocks the binding of plasminogen to the fibrin 
surface.  Thus plasminogen activation is prevented and fibrinolysis is delayed 
[8]. It has been successfully used to stop bleeding after dental operation, re-
moval of tonsils, prostate surgery, heavy menstrual bleeding, eye injuries and in 
patients with Haemophilia. Numerous studies have confirmed the efficacy of TA 
to reduce blood losses and transfusion requirements in TKR when used intra-
venously [9, 10, 11, 12, 13].  
 
A Cochrane review scrutinised 211 trials that had used antifibrinolytics to re-
duce blood loss and blood transfusion. Of the 211 included trials, 147 were 
conducted in cardiac surgery, 42 trials were in orthopaedic surgery, 14 involved 
liver surgeries, four were conducted in vascular surgery, two involved thoracic 
surgery, one involved neurosurgery and one trial was in orthognathic surgery. 
Forty five trials evaluated the TA. The reviewers concluded that Antifibrinolytic 
drugs are effective in reducing blood loss, the need for allogeneic red cell trans-
fusion, and the need for re-operation due to continued post-operative bleeding 
in cardiac surgery (where most trials were performed), without being offset by 
serious adverse effects. It also recommended that there is no need for further 
placebo-controlled trials of aprotinin or lysine analogues in cardiac surgery. The 
principal need is for large comparative trials to assess the relative efficacy, 
safety and cost-effectiveness of antifibrinolytic drugs in different surgical proce-
duresError! Reference source not found. [14].  
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Almost all these studies had used TA intravenously in different doses ranged 
from 250 mg up to 2.5 gram. Some researchers used multiple doses administra-
tion. In spite of their positive outcome without adverse effects, they have not 
been favoured by the orthopaedic community fearing the systemic side effects 
particularly DVT, pulmonary embolism.  
 
Two studies showed that local Tranexamic acid does not lead to systemic ab-
sorption. Mouth washing with the same compound does not lead to increase in 
its serum levelsError! Reference source not found. [16]. And after it had been 
given topically after pericardiotomy no TA was traced in the systemic 
bloodError! Reference source not found. [15]. More interestingly, in their re-
cent publication, Baric-Daver and colleagues compared the efficacy of topical 
application of 1 million IU of Aprotinin, 2.5 gram of TA and a placebo. They con-
cluded that topical use of either TA or Aprotinin efficiently reduces postoperative 
bleeding. TA seems to be at least as potent as aprotinin, but potentially safer 
and with better cost−effectiveness ratio [19].  
 
Hence our hypothesis, that local TA may provide a high concentration at the 
bleeding site but little or no systemic side effects. In this study Tranexamic acid 
will be applied topically to the exposed tissue around the knee joint prior to the 
wound closure and tourniquet release. It is anticipated that this method of ad-
ministration will be quicker, easier and have less systemic side effect. 
 
Objectives 
 
To find out whether Tranexamic acid will reduce blood loss significantly after 
total knee replacement when applied topically. 
 
A survey was conducted among orthopaedic surgeons, anaesthetist and hae-
matologist to obtain a consensus on what can be regarded as a clinically signifi-
cant difference in reducing blood loss and transfusion rate. It has been agreed 
that 50% reduction in blood loss is clinically significant and health care provid-
ers should consider changing their practice if Tranexamic acid can achieve this 
goal. This view was supported by the literature as several studies showed this 
amount of reduction is achievable using antifibrinolytics [2, 3, 6, 10, 14]  
 
Number of Subjects and Duration. 
 
Primary endpoint: Blood transfusion. 
Secondary endpoint: Drain blood loss. 
 
 
Mean blood loss following TKR is 1191 ml with a standard deviation 669 as 
shown by a previous study [2]. To have a 90% chance of detecting a 50% re-
duction in mean blood loss from 1191ml to 595ml at the 5% significance level, 
54 patients are required (27 in each group).  
 
Blood transfusion is a very important outcome for patients, healthcare providers 
and policy makers. The above number of patients provides very low power to 
detect a difference in the proportion of patients requiring blood transfusion. To 
detect a similar reduction in the current average 30% in our centre, 54 patients 
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only gives 17% power. However, 144 patients (72 in each group) provide 80% 
power to detect a reduction in transfusion requirements from 30% to 10% (Cor-
rected Fisher exact test).  
 
We will aim to recruit 150 patients; this will also allow for any drops out and pro-
vides adequate power for both primary and secondary endpoints.  
 
Our department perform around 400 total knee replacements a year. It is ex-
pected that 50% would take part in the trial and total number will be recruited 
over one year.          
 
 
Trial Design: 
 
A double blind controlled randomised trial including 150 patients undergoing 
unilateral primary cemented total knee replacement. The study will recruit equal 
numbers to treatment and control arms. 
Patients will be approached to participate in the trial in pre-assessment clinic at 
approximately 3 weeks before their operation. The trial will be discussed with 
them and the written information sheet supplied. Contact numbers will be pro-
vided if they want to discuss any issues before they participate in the trial. On 
admission, they will be given the opportunity to ask any further questions and at 
this time they will be invited to sign the consent form. 
 
Inclusion and Exclusion criteria: 
 
Inclusion criteria:    
1. Undergoing unilateral primary cemented total knee replacement. 
 
Exclusion criteria: 
1. Undergoing unilateral primary total knee replacement for trauma or tu-
mour. 
2. Allergic to Tranexamic acid. 
3. Bleeding tendency (e.g. Haemophilic and platelets disorders). 
4. Warfarin, treatment dose of LMWH or conventional heparin). 
5. History of DVT and pulmonary embolism. 
6. Renal failure with creatinine > 250 micromole/l. 
7. Female subjects of child bearing potential must have a negative preg-
nancy test. 
 
Permitted therapies include: 
1. Aspirin. 
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2. Subcutaneous prophylactic conventional or LMW heparin. It is expected 
that most patients will be on LMW heparin [17]. 
 
 
 
Allocation: 
Patients are randomly allocated into either Tranexamic acid group or a placebo. 
Allocation will be managed by designated nurses (who prepare the solutions) 
upon receipt of valid patient details. These nurses will keep allocation con-
cealed from all professionals delivering patient care. Both treatment and pla-
cebo have the same colour and smell thus delivery of the trial intervention will 
be double blinded. 
 
Random allocation will be made in blocks of six in order to keep the sizes of 
treatment groups similar. Randomisation will be stratified by surgeons to 
achieve balance within the two groups regarding this important prognostic fac-
tor. 
 
Intervention: 
The operation will be performed in the standard manner. Normally, there is no 
chemical intervention to reduce blood loss. In our study, at the end of the opera-
tion and before closing the wound, the study drug, which will either be Tranex-
amic acid or Placebo squirted in the wound. The wound is closed and dressed 
in the normal way then tourniquet is released. Drains are released after one 
hour in recovery as per routine.  
 
Study drug is Tranexamic acid 1 gram made up for 50 ml with normal saline. 
Placebo is 50 ml of saline.  
 
 
Outcome measures 
 
Primary outcome: 
 Blood transfusion required (until discharge).(Please, see blood transfu-
sion protocol below) 
 
Secondary outcomes: 
 
 The visible drain blood loss (First 48 hour).  
Total knee replacement is performed in bloodless field. The blood is ex-
sanguinated from the limb and tourniquet applied higher up to keep the 
limb bloodless. After suturing the skin and applying the pressure dress-
ing, the tourniquet is released allowing the blood to flow into the limb. 
Any bleeding will be sucked out by the vacuum drain. Hence drain blood 
loss is good reflection of total blood loss after total knee replacement. 
The outcome is a continuous variable, measured in millilitre (ml) and will 
be analysed by two sample t-test. Fifty percent reduction in mean drain 
blood loss will be considered clinically important. 
 Volume of blood transfused (until discharge). 
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 Haemoglobin and Haematocrit drops (On day 2 postoperatively). 
 General quality of life measure (EuroQol) preoperative and at 3 months 
postoperative. This will be completed as per EuroQol group recommen-
dation in their user guide version 1.0 November 2007 [20] 
 Oxford knee score preoperative and at 3 months postoperative. This will 
be completed as per authors‟ recommendation in their paper “The use of 
the Oxford hip and knee scores” published in the Journal of Bone and 
Joint Surgery 2007 [21]. Each of the 12 questions is scored from 4 to 0, 
with 4 representing the best outcome/least symptoms. The scores from 
each question were added so that the overall figure lies between 48 and 
0, with 48 being the best possible outcome. 
There are several studies confirmed the validity, consistency and sensi-
tivity of the above two outcome measures [28, 29, 30, 31, 32, 33, 34, 35, 
36, 37] 
 
 Length of stay. 
 Cost effectiveness analysis. 
Cost analysis reflecting changes in resources utilisation (length of stay, 
blood transfusion, and complications treatment costs). 
 Complications (Incidence in TKR [41,42,43,44]): 
 
1. Wound infection (0.2-1.7%). This is usually a clinical diagnosis. 
Swelling, redness, hotness, tenderness and high temperature are 
the cardinal signs of infection. This is usually associated by rising 
White blood cell and inflammatory markers and confirmed by 
microbiological test. For the purpose of the study, clinical findings 
are essential to the diagnosis of infection, with or without investi-
gative confirmation. Raised WBC and inflammatory markers are 
common after TKR. Microbiology swabs can be a contamination.  
 
 
2. Deep venous thrombosis (41-85%; proximal 5-22%). DVT is taken 
seriously by the orthopaedic team because its treatment, which is 
anticoagulation, carries significant risk to patients‟ joint replace-
ment such haematoma and infection. The current practice is to 
start patients with suspected DVT on treatment and to get Doppler 
ultrasound as soon as possible. In rare occasions, when the Dop-
pler ultrasound is not conclusive, lower limb venogram is re-
quested. Contrary to the infection, the diagnosis of DVT in our 
study is based on investigation rather than the clinical finding.  
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3. Pulmonary embolism (1.5-10%; fatal 0.1-1.7%). As in DVT, PE is 
taken seriously by the orthopaedic team. Unfortunately, all the ob-
jective tests have clinical or practical limitations. The ventilation–
perfusion lung scan has been the first-line test for more than 20 
years. However, 60% to 70% of lung scans are non-diagnostic. 
Use of helical CT in the diagnosis of PE has not been adequately 
evaluated, particularly in peripheral PE. The safety of withholding 
anticoagulant treatment in patients with negative results on helical 
CT is uncertain. Pulmonary angiography is the gold standard, but 
it is invasive and expensive, may be impractical or unavailable in 
some clinical settings and carries cardiac or pulmonary complica-
tions in 3% to 4% of patients. In our current practice, we almost 
always consulted a physician to make the definite diagnosis and 
for the purpose of our study, we will do the same. If a patient is 
treated for PE by a physician, we will regard him/her have a PE. 
However, we will make note whether this diagnosis was based on 
confirmatory test [22]. 
 
4. Myocardial infarction (0.4%). Chest pain is common and not every 
chest pain is an MI. On the other hand, MI can be silent without 
any pain, particularly in postoperative patients with diabetes melli-
tus. So the diagnosis of MI must be confirmed by rising cardiac 
enzyme (Troponin T) and / or ECG changes in the form of ST ele-
vation, Q-wave and T wave changes. 
 
 
5. Cerebrovascular accident. Difficulties occur in the diagnosis of 
CVA because similar clinical events can be caused by different 
pathological processes. CT scan is now available and is indicated 
virtually in all patients with a stroke. CT scan will usually demon-
strate the site of a lesion and distinguish between a haemorrhage 
and infarction. Ninety percent of all infarcts are detected at 1 
week. It also rules out or show unexpected causes [22,23] 
 
6. Death until discharge (0.5%). 
 
 
Blood transfusion protocol: 
 
Based on the recommendation of British Orthopaedic Association (BOA) [24], 
Blood Transfusion Task Force, and The British Committee for Standards in 
Haematology [26], UK blood transfusion and tissue transplantation services 
[25], our transfusion protocol recommend the following: 
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 Red cell transfusion is not indicated when Haemoglobin concentration is 
more than 10 g/dl. 
 Red cell transfusion id indicated when Haemoglobin concentration is < 
7 g/dl. Red cell transfusion should be given in relation to the rate of red 
cell loss. In otherwise stable patient, 2 units of red cell should be trans-
fused and then the clinical situation and Haemoglobin concentration 
should be reassessed. 
 The correct strategy for transfusing patients with haemoglobin between 
7 and 10 is less clear. Clinicians often transfuse although the available 
evidence suggest this is not justified. BOA recommends that sympto-
matic patients should be transfused. 
 In patients who tolerate anaemia poorly, example, patients over 65 
years or those with cardiovascular diseases or respiratory diseases, con-
sider adopting a higher threshold level for blood transfusion ( when 
Haemoglobin concentration is 8 g/dl). 
 
The Haemoglobin level will be checked the next day after the transfusion and 
the same protocol is applied if the Haemoglobin level is low. 
 
Data analysis: 
All data will be stored on a hospital computer in accordance with the data pro-
tection act. It will be accessible to researchers and the Research Governance 
Committee. Data analysis will be done on an intention to treat basis. Continuous 
outcomes will be analysed by two sample t-tests (blood loss, volume trans-
fused, EuroQol, Oxford knee score, length of stay and overall cost). For skewed 
data, the validity of estimates will be checked by using bootstrap techniques 
[18]. Categorical outcomes will be analysed by Fisher exact (blood transfusion 
required, haemoglobin & Haematocrit and complications). All tests will be two-
tailed and considered statistically significant at the 5% level. 
 
 
Safety Profile: 
 
Definitions 
 
Adverse Reaction (ARs): Means any untoward and unintended response in a 
participant to the Tranexamic acid as stated in the Summary of Product Charac-
teristics (SmPC). 
 
The followings are recognised reactions to the Tranexamic acid [38]: 
 
1. Nausea 
2. Dizziness 
3. Vomiting 
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4. Diarrhoea 
5. Allergic skin reaction (uncommon) 
6. Rare cases of thromboembolism events and impaired colour vision 
have been reported with use of tranexamic acid. 
 
Adverse Event (AEs): Any untoward medical occurrence in a participant to 
whom the study drug has been administered. These include the complications 
of TKR as well as ARs mentioned above. The followings have been reported as 
potential complications [39, 40, 41, 42, 43, 44]: 
 
1. Nausea and Vomiting. 
2. Dizziness. 
3. Pain (acute and chronic). 
4. Bleeding. 
5. Stiffness. 
6. Neurovascular injuries. 
7. Deep venous thrombosis. 
8. Chest infection. 
9. Pulmonary embolism. 
10. Myocardial infarction. 
11. Cerebrovascular accidents. 
12. Infection. 
13. Loosening of the prosthesis. 
14. Death. 
 
 
Serious Adverse Event (SAE) or Serious Adverse Reaction (SAR): Means any 
of the above AEs or ARs respectively that:  
 
1. Results in death. 
2. Is life threatening. 
3. Results in in-patients hospitalisation. 
4. Results in a persistent or significant disability / incapacity. 
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5. Important medical events that may not result in death, be life threaten-
ing, or require hospitalisation may be considered serious adverse drug 
events when , based on appropriate medical judgement, they may jeop-
ardise the patient and may require medical or surgical intervention to 
prevent one of the outcome listed in this definition. Examples of such 
medical events include acute renal failure, allergic broncho spasm re-
quiring intensive treatment or blood dyscrasias. 
 
Suspected Serious Adverse Reaction (SSAR): means one of the above men-
tioned adverse reactions of the Tranexamic acid that is classed in nature as se-
rious. 
 
Suspected Unexpected Serious Adverse Reaction (SUSAR): means an adverse 
reaction that is classed in nature as serious and which is not consistent with the 
information about the Tranexamic acid. 
 
Adverse Events / Reactions Monitoring: 
 
The occurrence of serious and non serious AEs and ARs in patients on both 
trial arms will be sought while they are in hospital or at each subsequent hospi-
tal visit. Patients will be asked about hospitalisations, consultations with other 
medical practitioners, disabilities or incapacity or whether any other adverse 
events have occurred.  
 
A section in the data collection sheet has been designed to record SAEs as de-
fined above and in the complications section 
 
 SAEs will be assessed and recorded in the patient‟s medical notes including 
the start dates (if known) of the onset of the event as well as the date the event 
stopped or changed, treatment and outcome; if applicable. 
 
 
 
 
Adverse Events / Reactions Reporting: 
 
 Non serious adverse events will not be reported. These are quite com-
mon and mostly self limiting in the first few days after surgery.  
 
 Serious adverse events  
Each SAE must be reported to the Principal and Chief Investigators 
within 24 hours and evaluated for seriousness, expectedness and sever-
ity by them. 
If there is a significant increase in the incidence of the above SAEs 
above the reported incidence, the local trust R&D department (the spon-
sor) will be informed and consulted. The causality of SAE must be evalu-
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ated by the data monitoring committee as below and if causality of these 
SAEs is linked to the Tranexamic acid, it will be reported to the MHRA, 
REC within 7 days if the event was fatal or life threatening or 15 days if 
the event was not fatal or life threatening. 
 
 In accordance with the EU directive (article 16 & 17) the principal investi-
gator will report SUSARs to the chief investigator and the local trust R&D 
department (the sponsor) within 24 hours of becoming aware of the 
event. The chief investigator and the sponsor will report SUSARs to the 
MHRA, REC within the required reporting timelines. 
 
We will provide the following information when reporting an SAE: 
 
1. Protocol identification (Centre number and patient unique identification 
number). 
2. Subject identification (Patient initials, date of birth, sex). 
3. The description of the SAE, intervention and the outcome. 
4. Relevant medical background. 
5. Any other available information that is requested by the MHRA, REC or 
the local R&D department. 
 
Data monitoring committee and interim analysis: 
 
Data monitoring committee has been convened and it includes Professor James 
Mason and Professor Hungin from School of Health, University of Durham. 
They are not actively involved in the research project. Data will be reviewed by 
them when 75 patients have recruited to assess safety profile or earlier if safety 
concern rises. The trial will be stopped if there is a statistically significant excess 
of complications such as DVT or fatal pulmonary embolism in the Tranexamic 
acid group in comparison to the placebo.  Example calculations indicated this 
would be achieved by an increase in expected and expected baseline of 3 DVT 
up to 10, or fatal PE from 1 up to 7. 
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Appendix 3.2 Patient’s information sheet 
 
 
 
PATIENT INFORMATION SHEET  
 
 
Randomised Controlled Trial of the Use of Topical of Tranexamic Acid in 
Primary Total Knee Replacement. 
 
 
Dear Sir/ Madam, 
 
You are being invited to take part in the above research study. Before you de-
cide if you want to take part, it is important for you to understand why the re-
search is being done and what it will involve. Please take time to read the fol-
lowing information carefully and discuss it with others if you wish. Ask us if there 
is anything that is not clear or if you would like more information. It is totally vol-
untary and up to you to decide whether or not to take part.  
 
If you do consider taking part, you will be given this information sheet to read. 
On admission (in about 3-6 weeks), if you decide to take part, you will meet an-
other member of our research team who will answer any questions you might 
have and obtain your consent to take part in the trial. If you decide to take part 
you are still free to withdraw at any time and without giving a reason. A decision 
to withdraw at any time, or a decision not to take part, will not affect the stan-
dard of care you receive.  
 
Thank you for reading this. 
 
1. What is the purpose of the study? 
 
Losing blood after TKR is common and may affect how quickly you recover from 
your operation. Patients with heart or lung diseases may have poor tolerance 
for even smaller amount of blood loss. Blood transfusion has always been a 
standard treatment to replace blood loss if it causes symptoms such as fatigue, 
palpitation, shortness of breath.  
 
Previous studies showed that 20-70% of patients who had undergone TKR 
needed blood transfusion. Most patients tolerate blood transfusions very well. 
But, like any medical procedure, there are a few risks involved. Majority are mi-
nor risks with no significant consequences such as fever, chills, nausea, head-
ache, allergic reaction and fluid overload. The risk of transmission of infectious 
diseases through transfusion is minimal, because of the effective blood screen-
ing strategies. Although, extremely rare, death has been reported after blood 
transfusion. Hence, it is important to find new ways to reduce the amount of 
blood loss and subsequent blood transfusion. 
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This study is designed to find out whether Tranexamic acid can reduce blood 
loss after Total Knee Replacement. Tranexamic acid is not a new drug and is 
an approved treatment for many common conditions that involve bleeding. It 
has been successfully used to stop bleeding after heart surgery, dental opera-
tion, removal of tonsils, prostate surgery, heavy menstrual bleeding, eye injuries 
and in patients with Haemophilia. We hope that the study drug (Tranexamic 
acid) will help clotting and so lessen the amount of blood lost and reduce the 
need for a blood transfusion. 
 
To be able to assess the effect of Tranexamic acid on blood loss after total knee 
replacement, we need to make comparisons between those who are given the 
drug or those who are not.  
In this study, one group will receive Tranexamic acid (called the study group) 
and a second group will receive Placebo (a dummy solution which looks like 
Tranexamic acid but contains no active ingredient). This group will be called the 
control group. 
 
2. What will happen to me? 
 
If you agree to enter this study, you will be placed in one of the two groups. 
Which group you will go into will be chosen at random like a spin of a coin. You 
will have a 50% chance of receiving placebo and a 50% chance of receiving 
Tranexamic acid. Neither you nor the investigator will know which group you are 
in. 
  
On admission, you will be asked to sign a consent form and complete a couple 
of questionnaire about the quality of your life and your knee before the opera-
tion. Each questionnaire takes about 10 minutes to complete. About three 
months after your operation, you will be asked to complete similar questionnaire 
about the quality of your life and your knee after the operation. This can be 
completed in the outpatient clinic or at home. 
 
Your operation will be performed in the standard manner with no changes from 
the routine practice in our hospital, but at the end of your operation and before 
the wound is closed a solution will be sprayed into your knee. This solution may 
contain the active ingredient (Tranexamic acid) or a placebo. This is the only 
difference in your treatment and otherwise you will receive standard postopera-
tive treatment for those undergoing total knee replacement surgeries. 
 
On the ward and as per routine practice, we measure the drain blood loss; we 
check and record your Haemoglobin and any blood transfusion you may re-
ceive. There is no extra intervention or restriction apart from routine practice. 
When you are discharged, you will be followed as per routine in our joint re-
placement clinic.   
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3. Why have I been chosen? 
As you are about to have total knee replacement in our department, we would 
like to invite you to consider taking part in this study. We need to recruit 150 pa-
tients who are having a Total Knee Replacement, over a period of 24 months.  
 
4. What do I have to do? 
 
Your participation in the study is voluntary. You may refuse to participate or if 
you decide to participate, you may withdraw at any time and you do not need to 
give a reason. Whatever you choose to do will not affect your treatment in any-
way. We might still use the data generated from your participation before you 
withdraw but we will not ask you for any further information related to the study 
after your withdrawal. 
  
5. What are the side effects of Tranexamic acid? 
 
Tranexamic acid is NOT a new drug and it has been widely used and at the fol-
lowing side effects has been reported with the use of Tranexamic acid: nausea, 
vomiting, diarrhoea and disturbance in colour vision, these are usually tempo-
rary and much less likely to happen after one dose applied directly into the 
wound. 
There is a theoretical increased risk in developing deep vein thrombosis and 
pulmonary embolism. However, some similar studies to this one where Tranex-
amic acid was injected into a vein, have not found an increase in this risk. 
Moreover, one study showed that applying Tranexamic acid directly to the 
wound does not lead to absorption in the blood.  
The operation normally takes about 90 minutes. If you enter into the trial, the 
time will be 5 minutes longer to allow the solution to be sprayed in your knee. 
 
6. What are the possible benefits of taking part? 
 
We do not know for certain whether local Tranexamic acid will help you. There 
is increasing evidence that Tranexamic acid can reduce blood loss and the 
need for blood transfusion significantly after intravenous use. It is anticipated 
that topical application may have a more profound effect in reducing blood loss 
and even lower side effects; however, this remains to be demonstrated by this 
study. 
 
7. What if something goes wrong? 
 
This trial will be carried out under the strict supervision of fully qualified doctors, 
nurses and other health professionals. It is run in accordance with European 
legislation. External and internal independent experts, the Research & Devel-
opment Department of the hospital and the local Ethics Committee had re-
viewed the study and approved it. In events of harm, the treating team will take 
all the necessary measures to treat and deal with any side effects. 
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If you are harmed due to someone‟s negligence, then you may have grounds 
for a legal action and compensation as per usual practice. Regardless of this, if 
you wish to complain, or have any concerns about any aspect of the way you 
have been approached or treated during the course of this study, the National 
Health Service complaints mechanisms are available to you. 
 
8. Will my taking part in this study be kept confidential? 
 
If you consent to take part in the research any of your medical records may be 
inspected by our research team for purposes of analysing the results. They may 
also be looked at by people from regulatory authorities to check that the study is 
being carried out correctly. Your name, however, will not be disclosed outside 
the hospital. Although this study is not conducted by your GP, your GP will be 
notified of your participation in the trial.  
 
9. What will happen to the results of the research study? 
 
At the end of the study, we will look at the results and compare the two groups 
of patients to see whether Tranexamic acid has reduced blood loss in the 
treated group. If it does, we will try to implement this in our clinical practice. We 
may publish the study in the medical journals to benefit other people. If we do 
so, you will not be identified in any report/publication. At the end of the trial, we 
will send you a summary of the trial outcome written in layperson‟s language. 
 
 
 
10. Who is organising and funding the research? 
 
This study is organised by The Directorate of Trauma and Orthopaedics. Your 
doctor will not be paid for including you in this study. 
 
11. Contacts for Further Information 
 
Mr S Alshryda, Mr P Sharda, Mr A Singh 
Department of Trauma and Orthopaedics, University Hospital of North Tees and 
Hartlepool 
Hardwick Road, Stockton,TS19 8PE 
Tele 0844 8118222 / Fax 01642 624089 
 
Let me take this opportunity to thank you for reading this information sheet. 
1 for patient; 1 for researcher; 1 to be kept with hospital notes 
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Appendix 3.3 Consent form 
 
184 
 
3.4 General practitioner notification letter 
 
 
 
Date  
 
 
 
Mr Sattar Alshryda 
SpR in Trauma and Orthopaedics 
Department of Trauma and Orthopaedic 
 
Telephone 0844 8118222 
E-mail sattar26@doctors.org.uk 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Re: The use of local Tranexamic acid in primary cemented Total Knee replacement. 
 
 
 
Dear Dr…………….., 
 
Your patient Mr/Mrs …………………………………has been admitted under the care of 
Mr……………………………..to have a total knee replacement surgery. S/he agreed to take part in our 
research project of the use of topical Tranexamic acid given intrarticularly at the end of the operation.  
 
She would be followed in clinic in 6 weeks time as per our routine practice. For any further 
information, please, do not hesitate to contact me at the above address or phone number. 
 
 
Yours truly, 
 
 
 
 
Mr Sattar Alshryda MB ChB, MRCSEd, MRCS. 
SpR in trauma and orthopaedics. 
 
 
 
Patt iientt   Labell   
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3.5 Data collection sheets 
 
 
Data Collection Sheet of Tranexamic Acid in Total Knee Replacement 
 
      
 
 
 
 
 
                 Pre-operative blood result date: 
WBC  Urea  
Hb  Creat  
PLT  INR  
Hct  PT  
MCV  PTT  
MEMO:  □Patient information sheet   □Consented  □GP informed  □ Anaesthetist informed  □  Randomised                    
Operation Details 
Date:  Tourniquet time:  Type of Anaesthesia: 
Surgeon :  Operative blood loss (Suction +Swabs):  Type of Warming: 
 
□ Post-op bloods requested  
Date:     Notes- please, write the DVT prophylaxis down) 
WBC      
Hb      
Hct      
Urea      
Creat      
INR      
Drain       
BT      
      
 Pre-op Post-op    
Oxford Knee Score      
EQ-5D      
EQ-VAS      
ROM      
 
 
 
 
 
 
 
 
 
 
Complications Yes- Mode of diagnosis No  Notes 
Wound infection 
 
   
Deep venous thrombosis 
 
  
Pulmonary embolism 
 
  
Myocardial infarction 
 
  
Cerebral vascular accident 
 
  
Death 
 
  
 
 
For any inquiries, please, do contact: S Alshryda / P Sharda / B Stothart/ M Vaghela through the switchboard. 
Randomisation code: 
Consultant: 
Weight: 
Height: 
Sex: 
PMH & Medications 
 
Patient label 
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Appendix 3.6 Trial checklist 
INCLUSION AND EXCLUSION CRITERIA YES NO 
Undergoing unilateral primary cemented total knee replacement (not for trauma or 
tumour) 
  
   
Allergic to Tranexamic acid.   
Bleeding tendency (e.g. Haemophilic and platelets disorders).   
Warfarin, treatment dose of LMWH or conventional heparin   
History of DVT and pulmonary embolism.   
Renal failure with creatinine > 250 micromole/l   
Female subjects of child bearing potential must have a negative pregnancy test.   
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3.7 Pharmacy and theatre protocol 
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3.8 Blood transfusion policy 
 Hb Level Action 
Hb ≤ 7 g/dl  
Healthy patient who is under 65 year old. 
Blood transfusion is indicated.  
In otherwise stable patient, 2 
units of red cell should be trans-
fused, then reassess. 
Hb ≤ 8 g/dl  
Patients over 65 years or those with cardio-
vascular diseases or respiratory diseases. 
Hb between 7 and 10 g/dl  Blood transfusion is indicated if 
patient has symptoms such as 
fatigue, palpitation, short of 
breath.  
Hb ≥ 10 g/dl. Blood transfusion is not indi-
cated. 
The Haemoglobin level should be checked the next day after 
the transfusion and the same protocol is applied if the Hae-
moglobin level is low. 
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Appendix 3.9 The EuroQol Questionnaire 
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Appendix 3.10 The Oxford knee score 
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3.11 Power calculation 
 
Power vs Number per group with P1=0.30 P2=0.10
A=0.05 N2=Number per group 2-Side
P
o
w
e
r
Number per group
0.2
0.4
0.6
0.8
1.0
10 30 50 70 90 110
 
 
Power analysis based on the difference between the current rates of transfusion 
(30%) and expected rate of transfusion (10%), Alpha 0.05. 
 
 
Power vs N1 with M1=1191.0 M2=595.0 S1=669.0
S2=669.0 Alpha=0.05 N2=N1 2-Sided Z
P
o
w
e
r
N1
0.2
0.4
0.6
0.8
1.0
0 10 20 30 40 50  
Number per group 
 
Power analysis based on the difference between the current mean drain blood loss 
(1191 ml) and the mean drain blood loss (669 ml), Alpha 0.05. 
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3.12 Interim analyses 
Summary Statements 
Sample sizes of 75 and 75 achieve 80% power to detect a difference of 0.20 
between the group proportions of 0.10 and 0.30 at a significance level (alpha) of 
0.05 using a two-sided z-test. These results assume that 2 sequential tests are 
made using the O'Brien-Fleming spending function to determine the test 
boundaries. 
 
Details when Spending = O'Brien-Fleming, N1 = 75, N2 =75, P1 = 0.10, P2 = 0.30 
Look Time Lower 
Boundary 
Upper 
Boundary 
Nominal 
Alpha 
Inc 
Alpha 
Total 
Alpha 
Inc 
Power 
Total 
Power 
1 0.50 -2.96259 2.96259 0.003051 0.003051 0.003051 0.212573 0.212573 
2 1.00 -1.96857 1.96857 0.049002 0.046949 0.050000 0.650954 0.863528 
  
O'Brien-Fleming Boundaries with Alpha = 0.05
Upper
Lower
Z
 V
a
lu
e
Look
-0.5
-1.0
-1.5
-2.0
-2.5
-3.0
0.0
0.5
1.0
1.5
2.0
2.5
3.0
1.4 1.9 2.4
 
The following is a hypothetical scenario to stop the trial prematurely because of 
significant reduction in blood transfusion rate. The trial would be stopped if 19 
out of 37 patients received a blood transfusion in the placebo group versus 5 
out of 38 in the TXA group. This would be statistically significant with a P-value 
of 0.000393. 
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Transfused * treatment Cross tabulation 
Count 
 
treatment 
Total placebo           TXA 
Transfused Yes 19 5 24 
No 18 33 51 
Total 37 38 75 
 
Chi-Square Tests 
 
Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Point Prob-
ability 
Pearson Chi-Square 12.567a 1 .00039 .00049 .00039  
Continuity Correctionb 10.873 1 .00098    
Likelihood Ratio 13.172 1 .00028 .00049 .00039  
Fisher's Exact Test    .00049 .00039  
Linear-by-Linear Asso-
ciation 
12.400c 1 .00043 .00049 .00039 .00034 
N of Valid Cases 75      
 
Summary Statements 
Sample sizes of 250 and 250 achieve 79% power to detect a difference of 0.10 
between the group proportions of 0.15 and 0.25 at a significance level (alpha) of 
0.05 using a two-sided z-test. These results assume that 3 sequential tests (83 
patients) are made using the O'Brien-Fleming spending function to determine 
the test boundaries. 
 
Details when Spending = O'Brien-Fleming, N1 = 250, N2 =250, P1 = 0.15, P2 = 0.25 
Look Time Lower 
Boundary 
Upper 
Boundary 
Nominal 
Alpha 
Inc 
Alpha 
Total 
Alpha 
Inc 
Power 
Total 
Power 
1 0.33 -3.71030 3.71030 0.000207 0.000207 0.000207 0.018016 0.018016 
2 0.67 -2.51142 2.51142 0.012025 0.011890 0.012097 0.391672 0.409688 
3 1.00 -1.99302 1.99302 0.046259 0.037903 0.050000 0.383429 0.793117 
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O'Brien-Fleming Boundaries with Alpha = 0.05
Upper
Lower
Z
 V
a
lu
e
Look
-1
-2
-3
-4
0
1
2
3
4
0.5 1.0 1.5 2.0 2.5 3.0
 
The following is a hypothetical scenario to stop the trial prematurely because of 
the increase risk of DVT. 
 
 
treatment 
Total placebo         TXA 
DVT Yes 5 21 26 
No 32 17 49 
Total 37 38 75 
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Chi-Square Tests 
 
Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Point Prob-
ability 
Pearson Chi-Square 14.427a 1 .00015 .00021 .00014  
Continuity Correctionb 12.643 1 .00038    
Likelihood Ratio 15.240 1 .00009 .00021 .00014  
Fisher's Exact Test    .00021 .00014  
Linear-by-Linear Asso-
ciation 
14.235c 1 .00016 .00021 .00014 .00012 
N of Valid Cases 75      
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Appendix 4.1 Research and development approval letter 
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Appendix 4.2 National Research Ethic Service/ Newcastle and North Tyneside 2 Committee approval  
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Appendix 4.3 Local Research Ethics Committee approval 
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Appendix 4.4 Medicine and health products regulatory authority 
(MHRA) approval  
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4.5 Characteristics of the study population  
 
Age 
Tests of Normality 
 
Groups 
Kolmogorov-Smirnova Shapiro-Wilk 
 Statistic df Sig. Statistic df Sig. 
years Placebo .097 78 .069 .971 78 .072 
Tranexamic acid .078 79 .200* .972 79 .074 
a. Lilliefors Significance Correction 
*. This is a lower bound of the true significance. 
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Group Statistics 
 Groups N Mean Std. Deviation Std. Error Mean 
years Placebo 78 67.13 10.259 1.162 
Tranexamic acid 79 65.53 9.627 1.083 
 
 
Independent Samples Test 
  Levene's Test for Equality of 
Variances t-test for Equality of Means 
  
  
95% Confidence Interval of 
the Difference 
  
F Sig. t df Sig. (2-tailed) 
Mean Differ-
ence 
Std. Error 
Difference Lower Upper 
years Equal variances as-
sumed 
.044 .835 1.006 155 .316 1.597 1.588 -1.540 4.733 
Equal variances not 
assumed 
  1.005 154.103 .316 1.597 1.588 -1.541 4.734 
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Gender 
 Cases 
 Valid Missing Total 
 N Percent N Percent N Percent 
Group * gen-
der 
157 100.0% 0 .0% 157 100.0% 
 
 
Group * gender Crosstabulation 
Count 
  sex 
Total   Male Female 
Groups Placebo 44 34 78 
Tranexamic acid 30 49 79 
Total 74 83 157 
 
Chi-Square Tests 
 
Value df 
Asymp. Sig. (2-
sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Pearson Chi-Square 5.353a 1 .021   
Continuity Correctionb 4.639 1 .031   
Likelihood Ratio 5.384 1 .020   
Fisher's Exact Test    .025 .015 
Linear-by-Linear Associa-
tion 
5.319 1 .021   
N of Valid Cases 157     
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 36.76. 
b. Computed only for a 2x2 table 
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Body mass index 
 
Groups 
Cases 
 Valid Missing Total 
 N Percent N Percent N Percent 
BMI Placebo 61 78.2% 17 21.8% 78 100.0% 
Tranexamic acid 64 81.0% 15 19.0% 79 100.0% 
 
Tests of Normality 
 
Groups 
Kolmogorov-Smirnova Shapiro-Wilk 
 Statistic df Sig. Statistic df Sig. 
BMI Placebo .119 61 .032 .945 61 .008 
Tranexamic acid .159 64 .000 .934 64 .002 
a. Lilliefors Significance Correction 
 
Mann-Whitney Test 
Ranks 
 Groups N Mean Rank Sum of Ranks 
BMI Placebo 61 57.76 3523.50 
Tranexamic acid 64 67.99 4351.50 
Total 125   
 
Test Statisticsa 
 BMI 
Mann-Whitney U 1632.500 
Wilcoxon W 3523.500 
Z -1.579 
Asymp. Sig. (2-tailed) .114 
a. Grouping Variable: Groups 
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Group Statistics 
 Groups N Mean Std. Deviation Std. Error Mean 
BMI Placebo 61 30.74098 5.034229 .644567 
Tranexamic acid 64 32.53031 6.227141 .778393 
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Independent Samples Test 
  Levene's Test for Equality of 
Variances t-test for Equality of Means 
  
  
95% Confidence Interval of 
the Difference 
  
F Sig. t df Sig. (2-tailed) 
Mean Differ-
ence 
Std. Error 
Difference Lower Upper 
BMI Equal variances as-
sumed 
2.502 .116 -1.762 123 .081 -1.789329 1.015760 -3.799964 .221306 
Equal variances not 
assumed 
  -1.771 119.851 .079 -1.789329 1.010624 -3.790320 .211662 
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BMI_Class * Groups Crosstabulation 
   Groups 
Total 
   
Placebo 
Tranexamic 
acid 
BMI_Class Normal weight Count 6 4 10 
% within Groups 9.8% 6.3% 8.0% 
Overweight Count 28 25 53 
% within Groups 45.9% 39.1% 42.4% 
Obese Count 23 27 50 
% within Groups 37.7% 42.2% 40.0% 
Morbidly obese Count 4 8 12 
% within Groups 6.6% 12.5% 9.6% 
Total Count 61 64 125 
% within Groups 100.0% 100.0% 100.0% 
 
Chi-Square Tests 
 
Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Point Prob-
ability 
Pearson Chi-Square 2.152a 3 .541 .544   
Likelihood Ratio 2.180 3 .536 .544   
Fisher's Exact Test 2.131   .547   
Linear-by-Linear Asso-
ciation 
2.050b 1 .152 .169 .094 .033 
N of Valid Cases 125      
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Medication / NSAID 
 Cases 
 Valid Missing Total 
 N Percent N Percent N Percent 
Groups * NSAID 142 90.4% 15 9.6% 157 100.0% 
 
Groups * NSAID Crosstabulation 
   NSAID 
Total    0 1 
Groups Placebo Count 47 21 68 
% within Groups 69.1% 30.9% 100.0% 
Tranexamic acid Count 49 25 74 
% within Groups 66.2% 33.8% 100.0% 
Total Count 96 46 142 
% within Groups 67.6% 32.4% 100.0% 
 
 
Chi-Square Tests 
 
Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Point Prob-
ability 
Pearson Chi-Square .136a 1 .712 .724 .425  
Continuity Correctionb .036 1 .850    
Likelihood Ratio .136 1 .712 .724 .425  
Fisher's Exact Test    .724 .425  
Linear-by-Linear Asso-
ciation 
.135c 1 .713 .724 .425 .133 
N of Valid Cases 142      
a. 0 cells (.0%) have expected count less than 5. The minimum expected count is 22.03. 
b. Computed only for a 2x2 table 
c. The standardized statistic is .368. 
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Medication / Antiplatelets 
 Cases 
 Valid Missing Total 
 N Percent N Percent N Percent 
Groups * Antiplatelets 142 90.4% 15 9.6% 157 100.0% 
 
Groups * Antiplatelets Crosstabulation 
   Antiplatelets 
Total    None 1 Antiplatelet 2 Antiplatelets 
Groups Placebo Count 44 21 3 68 
% within Groups 64.7% 30.9% 4.4% 100.0% 
Tranexamic acid Count 49 25 0 74 
% within Groups 66.2% 33.8% .0% 100.0% 
Total Count 93 46 3 142 
% within Groups 65.5% 32.4% 2.1% 100.0% 
 
Chi-Square Tests 
 
Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Point Prob-
ability 
Pearson Chi-Square 3.369a 2 .186 .224   
Likelihood Ratio 4.522 2 .104 .193   
Fisher's Exact Test 2.980   .251   
Linear-by-Linear Asso-
ciation 
.450b 1 .502 .526 .305 .102 
N of Valid Cases 142      
a. 2 cells (33.3%) have expected count less than 5. The minimum expected count is 1.44. 
b. The standardized statistic is -.671. 
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Hb and Hct levels 
 
Groups 
Cases 
 Valid Missing Total 
 N Percent N Percent N Percent 
Preop HB Placebo 78 100.0% 0 .0% 78 100.0% 
Postop HB Placebo 78 100.0% 0 .0% 78 100.0% 
Preop HCT Placebo 78 100.0% 0 .0% 78 100.0% 
Postop HcT Placebo 78 100.0% 0 .0% 78 100.0% 
 
Tests of Normality 
 
Groups 
Kolmogorov-Smirnova Shapiro-Wilk 
 Statistic df Sig. Statistic df Sig. 
Preop HB Placebo .045 78 .200* .992 78 .933 
Postop HB Placebo .070 78 .200* .982 78 .321 
Preop HCT Placebo .045 78 .200* .993 78 .938 
Postop HcT Placebo .079 78 .200* .981 78 .293 
a. Lilliefors Significance Correction 
*. This is a lower bound of the true significance. 
 
Group Statistics 
 Groups N Mean Std. Deviation Std. Error Mean 
Preop HB Placebo 78 13.579 1.2770 .1446 
Tranexamic acid 79 13.275 1.2570 .1414 
Postop HB Placebo 78 10.6897 1.34518 .15231 
Tranexamic acid 79 11.5228 1.33320 .15000 
Preop HCT Placebo 78 .39732 .036408 .004122 
Tranexamic acid 79 .39037 .035584 .004003 
Postop HcT Placebo 78 .31254 .038826 .004396 
Tranexamic acid 79 .33938 .038511 .004333 
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Independent Samples Test 
  Levene's Test for Equality 
of Variances t-test for Equality of Means 
  
  
95% Confidence Interval of 
the Difference 
  
F Sig. t df 
Sig. (2-
tailed) 
Mean Differ-
ence 
Std. Error 
Difference Lower Upper 
Preop HB Equal variances as-
sumed 
.004 .951 1.507 155 .134 .3048 .2022 -.0947 .7043 
Equal variances not 
assumed 
  1.507 154.873 .134 .3048 .2023 -.0947 .7043 
Postop HB Equal variances as-
sumed 
.001 .973 -3.897 155 .000 -.83304 .21376 -1.25530 -.41079 
Equal variances not 
assumed 
  -3.897 154.927 .000 -.83304 .21377 -1.25532 -.41076 
Preop HCT Equal variances as-
sumed 
.001 .978 1.210 155 .228 .006953 .005746 -.004397 .018303 
Equal variances not 
assumed 
  1.210 154.802 .228 .006953 .005747 -.004398 .018305 
Postop 
HcT 
Equal variances as-
sumed 
.016 .901 -4.349 155 .000 -.026841 .006172 -.039034 -.014649 
Equal variances not 
assumed 
  -4.349 154.932 .000 -.026841 .006172 -.039034 -.014648 
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Functional scores (OKS and EuroQol) 
 Groups N Mean Std. Deviation Std. Error Mean 
TPreOKS Placebo 60 19.40 7.674 .991 
Tranexamic acid 61 19.34 7.657 .980 
TPostOKS Placebo 45 35.91 8.581 1.279 
Tranexamic acid 53 34.83 9.405 1.292 
PreopIndex Placebo 59 .431254 .3303539 .0430084 
Tranexamic acid 63 .377206 .3066195 .0386304 
VAS_Preop Placebo 54 59.35 18.302 2.491 
Tranexamic acid 58 61.48 21.881 2.873 
PostopIndex Placebo 46 .780565 .2407176 .0354919 
Tranexamic acid 52 .705154 .3110496 .0431348 
VAS_Post Placebo 47 75.57 16.817 2.453 
Tranexamic acid 52 75.19 19.243 2.668 
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Independent Samples Test 
  Levene's Test for Equality of Vari-
ances t-test for Equality of Means 
  
  
95% Confidence Interval of the 
Difference 
  
F Sig. t df Sig. (2-tailed) Mean Difference 
Std. Error Differ-
ence Lower Upper 
TPreOKS Equal variances assumed .057 .812 .040 119 .968 .056 1.394 -2.704 2.816 
Equal variances not assumed   .040 118.958 .968 .056 1.394 -2.704 2.816 
TPostOKS Equal variances assumed .054 .817 .590 96 .557 1.081 1.832 -2.555 4.717 
Equal variances not assumed   .595 95.481 .554 1.081 1.818 -2.528 4.690 
PreopIndex Equal variances assumed .097 .756 .937 120 .351 .0540479 .0576683 -.0601312 .1682270 
Equal variances not assumed   .935 117.682 .352 .0540479 .0578103 -.0604355 .1685313 
VAS_Preop Equal variances assumed 1.634 .204 -.557 110 .579 -2.131 3.827 -9.714 5.453 
Equal variances not assumed   -.560 108.786 .576 -2.131 3.802 -9.667 5.405 
PostopIndex Equal variances assumed 1.675 .199 1.329 96 .187 .0754114 .0567331 -.0372029 .1880256 
Equal variances not assumed   1.350 94.396 .180 .0754114 .0558595 -.0354929 .1863157 
VAS_Post Equal variances assumed 2.351 .128 .105 97 .917 .382 3.649 -6.861 7.625 
Equal variances not assumed   .105 96.898 .916 .382 3.625 -6.812 7.576 
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Tourniquet Time 
 Groups N Mean Std. Deviation Std. Error Mean 
Tourniquet Time Placebo 66 73.08 17.284 2.128 
Tranexamic acid 70 73.84 16.036 1.917 
 
 
Independent Samples Test 
  Levene's Test for Equality 
of Variances t-test for Equality of Means 
  
  
95% Confidence Interval 
of the Difference 
  
F Sig. t df 
Sig. (2-
tailed) 
Mean Differ-
ence 
Std. Error 
Difference Lower Upper 
Tourniquet 
Time 
Equal variances as-
sumed 
.062 .804 -.268 134 .789 -.767 2.857 -6.418 4.884 
Equal variances not 
assumed 
  -.268 131.639 .789 -.767 2.864 -6.432 4.897 
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Type of anaesthesia 
 Cases 
 Valid Missing Total 
 N Percent N Percent N Percent 
Type anaesthesia * Groups 142 90.4% 15 9.6% 157 100.0% 
 
Type anaesthesia * Groups Crosstabulation 
Count 
  Groups 
Total 
  
Placebo 
Tranexamic 
acid 
Type anaesthesia GA 9 4 13 
SA 63 64 127 
GA&SA 0 1 1 
GA&NB 0 1 1 
Total 72 70 142 
 
 
Chi-Square Tests 
 
Value df 
Asymp. Sig. 
(2-sided) 
Exact Sig. (2-
sided) 
Exact Sig. (1-
sided) 
Point Prob-
ability 
Pearson Chi-Square 3.904a 3 .272 .244   
Likelihood Ratio 4.726 3 .193 .244   
Fisher's Exact Test 3.711   .244   
Linear-by-Linear Asso-
ciation 
3.547b 1 .060 .090 .049 .034 
N of Valid Cases 142      
a. 4 cells (50.0%) have expected count less than 5. The minimum expected count is .49. 
b. The standardized statistic is 1.883. 
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6.1 Analysis of patients who did not receive blood transfusion  
 
 Group N Mean Std. Deviation Std. Error Mean 
LOS Placebo 61 4.93 1.999 .256 
Tranexamic acid 76 4.78 2.237 .257 
Drain  Placebo 54 460.35 294.001 40.008 
Tranexamic acid 63 294.29 196.228 24.722 
Postop HB Placebo 65 11.0092 1.18529 .14702 
Tranexamic acid 78 11.5603 1.29928 .14711 
HB_drop Placebo 65 2.84 .954 .118 
Tranexamic acid 78 1.72 .841 .095 
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Independent Samples Test 
 
Levene's Test for Equality of 
Variances t-test for Equality of Means 
F Sig. t df Sig. (2-tailed) 
Mean Differ-
ence 
Std. Error 
Difference 
95% Confidence Interval of 
the Difference 
Lower Upper 
LOS Equal variances as-
sumed 
.038 .846 .431 135 .667 .158 .367 -.567 .884 
Equal variances not 
assumed 
  
.436 133.405 .663 .158 .362 -.559 .875 
Drain  Equal variances as-
sumed 
4.807 .030 3.638 115 .000 166.066 45.651 75.641 256.491 
Equal variances not 
assumed 
  
3.531 89.987 .001 166.066 47.031 72.632 259.501 
Postop HB Equal variances as-
sumed 
.706 .402 -2.627 141 .010 -.55103 .20973 -.96565 -.13640 
Equal variances not 
assumed 
  
-2.649 139.819 .009 -.55103 .20798 -.96222 -.13983 
HB_drop Equal variances as-
sumed 
2.758 .099 7.410 141 .000 1.112 .150 .816 1.409 
Equal variances not 
assumed 
  
7.325 128.837 .000 1.112 .152 .812 1.413 
 
